---
document_datetime: 2023-09-21 17:23:45
document_pages: 69
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/zontivity-h-c-2814-ii-05-epar-epar-assessment-report-variation_en.pdf
document_name: zontivity-h-c-2814-ii-05-epar-epar-assessment-report-variation_en.pdf
version: success
processing_time: 92.4137223
conversion_datetime: 2025-12-27 13:52:13.752509
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 June 2016 EMA/CHMP/500315/2016 Committee for Medicinal Products for Human Use (CHMP)

CHMP extension of indication variation assessment Assessment report Invented name: Zontivity International non-proprietary name: vorapaxar Procedure No. EMEA/H/C/002814/II/0005 Marketing authorisation holder (MAH): Merck Sharp &amp; Dohme Limited Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure.............................................. 5                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5                                                                                                                    |
| 1.2. Steps taken for the assessment of the product ........................................................6                                                                                                                                  |
| 2. Scientific discussion................................................................................ 6                                                                                                                                    |
| 2.1. Introduction ........................................................................................................6                                                                                                                   |
| 2.2. Non-clinical aspects..............................................................................................9                                                                                                                      |
| 2.3. Clinical aspects ....................................................................................................9                                                                                                                   |
| 2.3.1. Problem statement -Rationale for the proposed indication ......................................9                                                                                                                                       |
| 2.4. Clinical Pharmacology......................................................................................... 12                                                                                                                        |
| 2.5. Clinical efficacy .................................................................................................. 12 authorised                                                                                                       |
| 2.5.1. Dose response study(ies) ................................................................................. 12                                                                                                                          |
| 2.5.2. Main study ..................................................................................................... 13                                                                                                                    |
| 2.5.3. Discussion on clinical efficacy............................................................................ 36                                                                                                                         |
| 2.5.4. Conclusions on the clinical efficacy .................................................................... 38                                                                                                                           |
| 2.6. Clinical safety .................................................................................................... 38                                                                                                                  |
| 2.6.1. Discussion on clinical safety.............................................................................. 59                                                                                                                         |
| 2.6.2. Conclusions on clinical safety ............................................................................ 61                                                                                                                         |
| 2.6.3. PSUR cycle ..................................................................................................... 61 longer                                                                                                             |
| 2.7. Risk management plan ....................................................................................... 61                                                                                                                          |
| 2.8. Update of the Product information........................................................................ 63 64 no                                                                                                                       |
| 2.8.1. User consultation ............................................................................................ 64                                                                                                                      |
| 3. Benefit-Risk Balance............................................................................. Risks ....................................................................................................................... 65 product |
| Benefits ................................................................................................................... 64                                                                                                               |
| Effects Table ............................................................................................................ 66                                                                                                                 |
| Benefit-Risk Balance ................................................................................................. 67                                                                                                                     |
| 4. Recommendations................................................................................. 69                                                                                                                                        |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## List of abbreviations

## Abbreviation/Term Definition

| ABI         | ankle/brachial index                                                                                                           |
|-------------|--------------------------------------------------------------------------------------------------------------------------------|
| ACE         | angiotensin converting enzyme                                                                                                  |
| ACS         | acute coronary syndromes                                                                                                       |
| ACT         | activated clotting time                                                                                                        |
| ADP         | adenosine diphosphate                                                                                                          |
| AE          | adverse event                                                                                                                  |
| ACC         | American College of Cardiology                                                                                                 |
| AHA         | American Heart Association                                                                                                     |
| ALI         | acute limb ischemia                                                                                                            |
| AMI         | acute myocardial infarction                                                                                                    |
| aPTT        | accelerated partial thromboplastin time                                                                                        |
| ARB         | angiotensin II receptor blocker                                                                                                |
| ASA         | aspirin authorised                                                                                                             |
| AUC         | area under the curve                                                                                                           |
| BB          | beta blockers                                                                                                                  |
| BCS         | Biopharmaceutics Classification System                                                                                         |
| BMI         | body mass index                                                                                                                |
| B/R         | Benefit-risk                                                                                                                   |
| CABG        | coronary artery bypass grafting                                                                                                |
| CAD         | coronary artery disease                                                                                                        |
|             | acronym for a clinical study in secondary prevention of ischemic versus Aspirin in Patients at Risk of Ischaemic Events longer |
| CAPRIE      | events: Clopidogrel                                                                                                            |
| CEC         | Clinical Events Committee acronym for a clinical study in primary and secondary prevention of ischemic events:                 |
| CHARISMA CI | Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance confidence interval no        |
| CrCl        | creatinine clearance                                                                                                           |
| CSR         | clinical study report                                                                                                          |
| CV          | cardiovascular                                                                                                                 |
| CVD         | cerebrovascular disease                                                                                                        |
| CYP         | refers to cytochrome P450 isoenzymes                                                                                           |
| DAP         | data analysis plan                                                                                                             |
| DAPT        | dual anti-platelet therapy product                                                                                             |
| DDI         | drug-drug Interactions                                                                                                         |
| DSMB        | data and safety monitoring board                                                                                               |
| ECG         | electrocardiogram                                                                                                              |
| eCRF        | electronic case report form ecarin clotting time                                                                               |
| ECT EDC     | electronic data capture                                                                                                        |
| eGFR        | filtration rate                                                                                                                |
|             | estimated glomerular                                                                                                           |
| ESC         | European Society of Cardiology                                                                                                 |
| EU F        | European Union                                                                                                                 |
| GCP         | female good clinical practice                                                                                                  |
| GMR         | geometric mean ratio                                                                                                           |
| GUSTO       | Global Utilization of Streptokinase and Tissue                                                                                 |
|             | Plasminogen Activator for Occluded                                                                                             |
|             | Arteries cooperative group; a classification system for degree of bleeding Medicinal                                           |
| HC ICH      | Health Canada intracranial hemorrhage                                                                                          |
| INR         | international normalized                                                                                                       |
|             | ratio intent to treat-refers to a study data set for statistical analysis                                                      |
| ITT         | Kaplan-Meier                                                                                                                   |
| KM, K-M     | low-density-lipoprotein cholesterol                                                                                            |
| LDL-C M     | male event                                                                                                                     |
| MACE        | major adverse cardiac                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

MI

myocardial infarction

N/A

not applicable

NSTEACS

non-ST segment elevation acute coronary syndrome

NSTEMI

non ST segment elevation myocardial infarction

NNH

number needed to harm (BR analysis)

NNT

number needed to treat (BR analysis)

P

Placebo (used as abbrev in many of the statistical figures)

PAD

peripheral artery(arterial) disease

PAR-1

protease-activated receptor 1 (the \"thrombin receptor\")

PCI

percutaneous coronary intervention

PD

pharmacodynamics

Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in

TT

TQT

UA

UCR

PH proportional hazard PK pharmacokinetics PMF Preliminary Marketing Formulation PT prothrombin time RAAS renin-angiotensin aldosterone system RIR recurrent ischemia with rehospitalization RD risk difference RRR relative risk reduction RR risk reduction Revasc revascularization S SCH 530348 (used in many of the statistical figures) SAE serious adverse event STEMI ST segment elevation myocardial infarction TIA transient ischemic attack TIMI Thrombolysis in Myocardial Infarction Study Group TRA thrombin-receptor antagonist; specifically SCH 530348, as used in this study TRAP thrombin receptor agonist peptide TRA 2ºP-TIMI 50 Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events; the present study TRACER acronym for study under Protocol P04736 (A Multicenter, Randomized, Double-Blind, Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) thrombin time thorough QT unstable angina urgent coronary revascularization Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme Limited submitted to the European Medicines Agency on 1 September 2015 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to include treatment of patients with Peripheral Arterial Disease (PAD) and as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the contact details of local representative in Luxembourg in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 9.1. Moreover, revised RMP version 2.0 was provided as part of the application. The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP). Information on paediatric requirements Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0222/2013 on the agreement of a paediatric investigation plan (PIP). At  the  time  of  submission  of  this  application,  the  PIP  was  not  yet  completed  as  some  measures  were deferred. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the  MAH  did  not  submit  a  critical  report  addressing  the  possible  similarity  with  authorised orphan  medicinal  products  because  there  is  no  authorised  orphan  medicinal  product  for  a  condition related to the proposed indication. Scientific advice Medicinal product no longer authorised

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Greg Markey

Co-Rapporteur:

N/A

| Timetable                                                   | Actual dates                |
|-------------------------------------------------------------|-----------------------------|
| Submission date                                             | 1 September 2015            |
| Start of procedure:                                         | 19 September 2015           |
| CHMP Rapporteur Assessment Report                           | 13 November 2015 authorised |
| PRAC Rapporteur Assessment Report                           | 21 November 2015            |
| PRAC members comments                                       | 25 November 2015            |
| Updated PRAC Rapporteur Assessment Report                   | 26 November 2015            |
| PRAC Outcome                                                | 3 December 2015             |
| CHMP members comments                                       | 7 December 2015             |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report longer | 10 December 2015            |
| Request for supplementary information (RSI)                 | 17 December 2015            |
| CHMP Rapporteur Assessment Report                           | 2 March 2016                |
| PRAC Rapporteur Assessment Report                           | 4 March 2016                |
| PRAC members comments                                       | 9 March 2016                |
| Updated PRAC Rapporteur Assessment Report no                | 10 March 2016               |
| PRAC Outcome                                                | 17 March 2016               |
| CHMP members comments                                       | 17 March 2016               |
| Updated CHMP Rapporteur Assessment Report product           | 23 March 2016               |
| Request for supplementary information (RSI)                 | 1 April 2016                |
| PRAC Rapporteur Assessment Report                           | 30 May 2016                 |
| PRAC members comments                                       | 3 June 2016                 |
| CHMP Rapporteur Assessment Report Medicinal                 | 8 June 2016                 |
| PRAC Outcome                                                | 9 June 2016                 |
| CHMP members comments                                       | 13 June 2016                |
| Updated CHMP Rapporteur Assessment Report                   | 15 June 2016                |
| Opinion                                                     | 23 June 2013                |

## 2. Scientific discussion

## 2.1. Introduction

Zontivity (vorapaxar) is an antiplatelet agent, the first-in-class selective antagonist of the proteaseactivated receptor 1 (PAR-1), the primary thrombin receptor on human platelets, which mediates the

<div style=\"page-break-after: always\"></div>

downstream effects of this critical coagulation factor in haemostasis and thrombosis. As an antagonist of PAR-1, vorapaxar blocks thrombin-mediated platelet aggregation and thereby has the potential to reduce the risk of atherothrombotic complications.

Zontivity received a marketing authorisation (MA) in the EU in January 2015 for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (co-administered with acetylsalicylic acid and, where appropriate, clopidogrel) but without history of stroke or TIA (absolute contraindications). Zontivity was also approved in the US in May 2014 with a broader indication i.e. for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease.

The MAH now seeks an extension of the indications for use of Zontivity in patients with peripheral arterial disease (similar to the US label). The initially proposed wording for section 4.1 of the SmPC is as follows (additional text shown as bold/italics/underlined): Zontivity,  co-administered  with  acetylsalicylic  acid  (ASA)  and /or ,  where  appropriate,  clopidogrel,  is indicated for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD) The posology remains unchanged to one tablet (2.08 mg vorapaxar) once daily. This variation application is based to a large extent on the same dossier as the initial MA application (MAA). There are no additional non-clinical or clinical pharmacology data and no new clinical studies. The application is mainly supported by data from the same pivotal study assessed during the initial MAA i.e. the TRA 2ºP-TIMI 50 (Study P04737; A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Vorapaxar in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events). However, in this application, the focus is on the population of patients with PAD who were included in the pivotal trial, complemented by additional analyses. Background information During the review of the MAA, the MAH requested an amendment of the originally proposed indications (which concerned only patients with a history of myocardial infarction) to include also patients with PAD. This followed the FDA licensing decision to grant a broad indication encompassing PAD patients. The CHMP considered the MAH's request and agreed that the changes to extend the indications should be submitted either as a post-authorisation variation or as separate standalone MAA. This would allow time for a more thorough assessment of the data related to the PAD population which had not been specifically presented and discussed in the original submission. Following the CHMP advice (as well as comments from Rapporteurs during a pre-submission meeting) the MAH is now applying for an extension of the indications through a type II variation. Peripheral Arterial Disease Medicinal product no longer authorised

Atherosclerosis is a polyarterial disease that can manifest as coronary artery disease (CAD), cerebrovascular disease (CVD), and/or PAD.  The risk factors for the development of coronary and peripheral artery atherosclerosis are the same; namely, diabetes mellitus, hyperlipidaemia, hypertension, age, family history and smoking. Also the pathophysiology of atherothrombosis is the same in PAD and CAD; only the diagnostic site differs.

Atherothrombotic stimulation of platelet aggregation is inhibited with aspirin and clopidogrel (or other P2Y12 inhibitors) through different mechanisms, but there is evidence that both mechanisms are associated with varying degrees of preventing MACE in patients with either PAD or CAD. Similarly,

<div style=\"page-break-after: always\"></div>

vorapaxar an inhibitor of the platelet PAR-1 receptor, blocks platelet aggregation induced by thrombin and may reduce MACE in CAD and PAD patients via a common pharmacologic action.

The REACH registry is the most recent large compilation of outcomes in patients with atherothrombosis manifested as CAD, CVD, PAD, or with multiple risk factors.  Among nearly 65,000 patients with one year follow-up, CV death, MI, or stroke rates were 4.52% for patients with CAD, 6.47% for patients with CVD, and 5.35% for patients with PAD. Patients with multiple atheromatous sites had higher event rates. Thus, patients with atherothrombosis have high rates of MACE regardless of original presentation. Disease in any vascular bed increases the risk to a similar degree suggesting that the site of disease is not as important, with respect to future MACE events, as the presence of atherothrombotic disease itself.

The 2011 European Society of Cardiology (ESC) Guideline on the diagnosis and treatment of peripheral artery diseases notes, in relation to PAD epidemiology, that in a recent study in a population aged 60-90 years in Sweden, the prevalence of Lower Extremity Arterial Disease (LEAD) was 18% and that of intermittent claudication was 7%. Typically, one-third of all LEAD patients in the community are symptomatic but the prevalence of critical limb ischaemia is much less. The frequency of LEAD is strongly age related: uncommon before 50 years, rising steeply at older ages. In a recent study in Germany the prevalence of symptomatic and asymptomatic LEAD in men aged 45-49 years was 3.0%, rising to 18.2% in those aged 70-75 years. Corresponding rates for women were 2.7% and 10.8%.

The European Society of Cardiology (ESC) guidelines describe PAD as occurring in the following vascular sites; carotid, vertebral, upper extremity, mesenteric, renal and lower extremity vessels (LEAD or lower extremity arterial disease). For the purpose of this application, the term PAD refers to the LEAD component of peripheral arterial disease as described by the ESC . Most studies of PAD use the criterion of ankle brachial index (ABI) &lt;0.90 as indicative of the presence of disease and this cut point has largely been established based on outcomes of patients with measured ABIs. There is a large increment in risk when ABI is less than 0.90 compared to an ABI of 0.90-1.1. Pain does not always accompany impaired limb perfusion, as defined by an ABI&lt;0.90. Thus, PAD and its accompanying increased risk of CV events and mortality may go undetected. PAD in the presence of other sites of atheromatous disease is associated with further increased risk for MACE, as demonstrated from follow-up of the REACH registry. Critical limb ischemia (CLI), the peripheral equivalent of acute coronary syndrome, represents the most serious manifestation of PAD. Though only 1%-2% of patients will develop CLI, this condition is associated with a high rate of limb amputation and mortality (~25% 1-year outcomes for each). Evidence for the high risk and the unmet medical need in the PAD population was also seen in the TRA2°P TIMI 50 study. All placebo subjects in the trial received background therapy with aspirin and/or clopidogrel. Yet the placebo rates of the primary and secondary composite efficacy endpoints were highest for those patients qualifying for the trial on the basis of established PAD: the 3-year KM rates for the primary endpoint were CAD, 12.1%; CVD, 12.1%; PAD, 13.4% and for the secondary endpoint were CAD, 9.7%; CVD, 11.7%; PAD, 11.9%, indicating an unmet medical need at least as great in patients with PAD as it is in CAD. In general, the residual risk in patients with documented atherothrombotic disease remains high as documented in the REACH registry and in the control group of the TRA 2°P -TIMI 50 trial, despite recommended guideline therapy.  There is a need for further treatment in this vulnerable population, which should not exclude patients with PAD. Peer-reviewed guidelines note the paucity of evidence-based medicine supporting antiplatelet therapy for PAD patients. Guidelines currently support aspirin therapy (75-325mg) to reduce MACE risk in atherosclerotic lower extremity PAD. However, a recent meta-analysis of aspirin therapy for PAD disclosed no benefit [Berger et al. JAMA 2009]. Guidelines mention clopidogrel monotherapy as an alternative to aspirin at 'B' level of evidence citing the CAPRIE trial. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Risk factors for PAD are similar to those in the aetiology of CAD i.e. the typical risk factors for atherosclerotic disease. However, for some peripheral sites the evidence linking certain factors to the development of atherosclerosis is limited. Also, specific risk factors may be more important for the development of the disease at certain sites, but there are few comparative studies. For LEAD the evidence appears to support a stronger link with smoking and diabetes.

The ESC guideline also notes that all patients with LEAD are at increased risk of CVD events and secondary prevention measures are mandatory to improve prognosis. Further to pharmacological approaches aimed at improving exercise capacity in patients with intermittent claudication (such as naftidrofuryl, cilostazol, pentoxifylline and others) as well as antihypertensive and lipid-lowering therapy, where relevant, the Guideline suggests the use of antiplatelets (generally antiplatelet therapy is a Class I recommendation for patients with symptomatic PAD). Mainly this advice concerns low dose aspirin with clopidogrel recommended in case of intolerance. In LEAD patients with co-existing stable CAD, the Guideline advises that clopidogrel may be considered as an alternative to aspirin for long-term antiplatelet therapy (Class IIa recommendation).

Atherothrombosis frequently occurs in multiple vascular beds within the same patient.  The pivotal TRA 2°P  -TIMI  50  trial  enrolled  subjects  with  atherothrombosis  in  the  coronary,  cerebral  and  peripheral arteries based on a hierarchy defined by which vascular bed was affected in the prior 12 months (with randomization  stratified  by  qualifying  condition  at  entry  i.e.  CAD,  CVD,  or  PAD)  and  was  designed  to evaluate the efficacy and safety of vorapaxar in reducing atherothrombotic events in patients receiving standard therapy.

The most recent (2011) ACCF/AHA Guideline on the management of patients with PAD also advises (Class I recommendation) use of antiplatelet therapy to reduce the risk of MI, stroke, and vascular death in individuals with symptomatic LEAD, including those with intermittent claudication or CLI, prior lower extremity revascularization (endovascular or surgical), or prior amputation for lower extremity ischemia (Level of Evidence: A). The Guideline recommends aspirin, typically in daily doses of 75 to 325 mg, as safe and effective therapy to reduce the CV risk in symptomatic LEAD (Level of Evidence: B). Clopidogrel (75 mg per day) is recommended as alternative therapy to aspirin (Level of Evidence: B). For asymptomatic patients with LEAD antiplatelet therapy is also recommended (Class IIa) in case of  an ABI ≤ 0.90 (Level of Evidence: C). For those with ABI of 0.91 to 0.99, the Guideline states that the usefulness of antiplatelet therapy is not well established. The concomitant use of aspirin and clopidogrel is generally not recommended. It should be noted here the clopidogrel is the only antiplatelet agent currently licensed for prevention of atherothrombotic events in patients with established PAD. 2.2. Non-clinical aspects No new clinical data have been submitted in this application, which was considered acceptable by the CHMP. 2.3. Clinical aspects 2.3.1. Problem statement -Rationale for the proposed indication Medicinal product no longer authorised

Subjects with a recent history (&lt; 12 months) of MI were randomized in the CAD stratum regardless of disease presence in the other two vascular beds. Subjects without a recent history of MI (as defined in the CAD stratum), regardless of disease presence of PAD, who had a recent stroke (&lt; 12 months) were

<div style=\"page-break-after: always\"></div>

randomized  in  the  CVD  stratum.  Finally,  subjects  randomized  to  the  PAD  stratum  had  symptomatic peripheral  arterial  disease  (history  of  intermittent  claudication  and  resting  ABI  &lt;0.85,  or  amputation, peripheral bypass, or peripheral angioplasty of the extremities secondary to ischemia) but did not have a history of recent MI or recent stroke. As expected, there was a considerable overlap in between the three strata in the TRA 2°P TIMI 50 population: in the CAD stratum, 1604 subjects had peripheral vascular bed involvement and 585 subjects had a history of stroke.  Likewise, 986 subjects in the PAD stratum had a prior MI (&gt;12 months from randomization) and 304 subjects had a history of stroke (253 subjects &gt; 12 months from randomization).

The  results  of  the  study  in  the Overall  Population were  significantly  in  favour  of  vorapaxar  and  the findings in the specific CAD population were the basis of the initial MAA approval. The MAH notes that the success  or  failure  of  a  trial  should  be  determined  by  the  prespecified  analyses  based  on  its  original, overall  population.  Having  excluded  patients  with  cerebrovascular  disease  (as  established  during  the original MAA, due to safety issues; please see below), the analysis of the remaining cohorts (CAD or PAD) should be considered together as the TRA 2°P - TIMI 50 study was not powered to demonstrate statistical significance in the PAD population or any of the other individual qualifying strata. The pooled results in those two strata (as shown in the efficacy/safety below), complemented with additional analyses in the PAD population can support the expended indication. Based  on  the  common  pathophysiology  associated  with  CAD  and  PAD,  the  substantial  unmet  medical need especially in patients with PAD, and the strength of the benefit - risk assessment in TRA 2°P -TIMI 50, the MAH seeks the new indication based on the pooled data from those patients with a previous MI or PAD with no history of stroke or TIA. This population and its corresponding analyses best maintain the integrity of the original trial. CHMP comments The MAH suggests that patients with atherosclerosis, irrespective of whether it is manifested as CAD, CVD,  or  PAD,  share  a  common  pathophysiology  and  poor  prognosis  and  this  was  the  basis  of  the population selection in the pivotal TRA 2ºP-TIMI 50 trial. They note that during the evaluation of the vorapaxar  application  in  the  US,  the  FDA  expressed  the  view  that,  to  maintain  best  the  scientific integrity of the trial, the only patient group(s) that should be excluded from analysis should be those with a safety concern, in this case patients with previous history of stroke. The remaining patients from either the CAD (recent history of MI) or the PAD stratum could be examined together. In line with this view, the MAH's position for this application is that the primary evidence comes from the  pooled  data  of  the  CAD  (post-MI)  and  PAD  populations.  Although  there  are  additional  analyses focused on the PAD group, as discussed in the clinical part below, these have a secondary role in the presentation of the results. In  this  context,  a  key  issue  in  the  review  of  the  current  application  is  the  validity  of  the  MAH's argument that, based on the common atherosclerotic background, patients with CAD and/or PAD can be considered as a single population and if this is sufficient justification for a pooled analysis of the two TRA  2ºP-TIMI  50  strata.  This  is  an  important  question  since,  as  suggested  by  the  MAH,  the  PAD stratum alone was not powered to establish vorapaxar efficacy and safety. Medicinal product no longer authorised

It is agreed that both CAD and PAD populations often overlap and share underlying risk factors and a high  risk  of  future  events.  However,  the  question  is  whether  the  two  populations  represent  a sufficiently homogeneous group to permit extrapolations from one to the other and to draw conclusions for either of them based on a pooled analysis.

This approach, to examine together patients with different manifestations of atherosclerotic vascular disease, is not unique to TRA 2ºP-TIMI 50. CAPRIE (a randomised trial of clopidogrel versus aspirin in patients at risk of ischaemic events; Lancet 1996) randomised 19,185 patients with a history of recent

<div style=\"page-break-after: always\"></div>

MI  (≤35  days  before  randomisation;  n=6,302),  ischaemic  stroke  (n=6,431)  or  symptomatic  PAD (n=6,452) to aspirin (325 mg) or clopidogrel (75 mg). After a mean follow-up of 1.9 years the overall results  showed  a  statistically  significant  (p=0.043)  relative-risk  reduction  of  8.7%  in  favour  of clopidogrel in the primary endpoint of ischaemic stroke, myocardial infarction or vascular death. The group of patients with PAD showed the greatest benefit with clopidogrel; the average event rate/year in  the  clopidogrel  group  was  3.71%  compared  with  4.86%  in  the  aspirin  group,  a  relative-risk reduction of 23.8% (8.9 to 36.2; p=0.0028). Vascular deaths appeared to have contributed most to the  differences  between  treatments  in  the  PAD  group.  In  contrast  to  PAD,  no  clear  benefit  of clopidogrel  vs  aspirin  was  seen  in  the  MI  population  alone.  Therefore,  in  CAPRIE  there  was  some evidence of heterogeneity between the PAD and MI populations, although following a post-hoc analysis in the subgroup of patients who had both MI and PAD (+stroke) the results showed more consistency across  the  three  patients  groups.  Based  on  this  the  investigators  suggested  that  the  observed heterogeneity does not invalidate the underlying concept of CAPRIE to study all atherosclerotic patients together.

In the initial MAA, the 'Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety  and  Efficacy  of  Vorapaxar  in  Addition  to  Standard  of  Care  in  Subjects  With  a  History  of Atherosclerotic  Disease:  Thrombin  Receptor  Antagonist  in  Secondary  Prevention  of  Atherothrombotic Ischemic Events ( TRA 2°P-TIMI 50 ; Protocol No. P04737)'.

Following CAPRIE, the CHARISMA trial (Bhatt et al. NEJM 2006) again investigated a range of patients with atherosclerotic disease i.e. with documented  CAD,  CVD,  symptomatic  PAD,  or multiple atherothrombotic risk factors.  A  total  of  15,603  patients  were  assigned  to  receive  either  DAPT  with clopidogrel plus aspirin (n=7,802) or aspirin alone (n=7,801). After a median of 28 months of followup, the rate of the primary event (MI, stroke, or death from cardiovascular causes) was not statistically different between treatments (relative risk, 0.93; 95%CI, 0.83 to 1.05; P=0.22) while bleedings were more  common  with  dual  therapy.  In  a  subsequent  analysis  of  CHARISMA  (Cacoub  et  al.  European Heart Journal 2009) including only the PAD population, the investigators reported that in general the overall rate of CV death (as well as deaths from any cause), MI, or stroke was significantly higher in patients  with  PAD  than  the  rest.  Yet,  in  line  with  the  overall  CHARISMA  results  there  were  no significant differences between DAPT with clopidogrel plus aspirin compared to aspirin alone, although the trend was in favour of clopidogrel. The rate of severe bleeding was similar between groups (but in general the data suggested that PAD patients were at higher risk of bleeding than non-PAD patients). The above indicate that indeed the model of studying together patients with different expressions of atherosclerosis has been put to the test before, but the findings (especially of CAPRIE) do not seem to provide much support that this is a clinically and/or methodologically valid concept. The fact also that in  TRA  2ºP-TIMI  50  one  of  the  atherosclerotic  populations,  patients  with  history  of  stroke  (CVD stratum), were found to be at much higher risk of bleeding and ICH and were forced to discontinue from the study casts some doubts on the principle that the common pathophysiological background and risk factors are sufficiently strong determinants of the homogeneity of the disease to allow pooled analyses with consistent findings across the different patients groups. This issue is further discussed in the efficacy and safety sections below. Overview of the clinical data Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Study No   | Methodology                                                                                                | Study Population   | Study Population   | Study Population   | Diagnosis/ Inclusion Criteria                                                                                                           | Dosage/ Duration                                                                                                                                  | Evaluation Criteria                                                                                                                                                                                                                                                                                                                                          | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------------|------------------------------------------------------------------------------------------------------------|--------------------|--------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study No   | Methodology                                                                                                | M                  | F                  | Age Range          | Diagnosis/ Inclusion Criteria                                                                                                           | Dosage/ Duration                                                                                                                                  | Evaluation Criteria                                                                                                                                                                                                                                                                                                                                          | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| P04737     | Multinational, randomized, double-blind, placebo- controlled, fixed- dose, balanced- parallel-groups study | 20123              | 6326               | 21-95              | men/women, aged ≥18y with evidence or a history of atherosclero sis involving the coronary, cerebral, or peripheral vascular systems no | vorapaxar 2.5 mg tablet or placebo tablet to match vorapaxar 2.5 mg tablet; 1 tablet taken orally each day; Duration of treatment: ~3.5-4y longer | Primary efficacy endpoint: time from randomized treatment assignment to the first occurrence of any component of the composite of CV death, MI, stroke, and UCR. The key secondary endpoint of the study was the time from randomized treatment assignment to the first occurrence of any component of the composite of CV death, MI, and stroke. authorised | -The addition of daily dose of 2.5 mg of vorapaxar to standard therapy (including ASA and thienopyridine) reduced the risk of CV death, MI, stroke or UCR among subjects with stable atherosclerosis in the overall population. -Vorapaxar increased the risk of GUSTO moderate or severe bleeding, including intracranial haemorrhage in the overall population while in the proposed label population the rates of ICH and fatal bleeding were similar in both treatment groups. |

GCP The trial was conducted following appropriate Good Clinical Practice (GCP) standards and considerations for  the  ethical  treatment  of  human  subjects  that  were  in  place  at  the  time  the  trials  were  performed. Three site closures occurred during the trial due to GCP compliance issues and are detailed in the TRA 2°P-TIMI 50 CSR. No GCP issues were identified during the review of TRA 2ºP-TIMI 50 at the time of the initial MAA. 2.4. Clinical Pharmacology No new clinical  pharmacology  data  have  been  submitted  with  this  variation.  The  pharmacokinetic  and pharmacodynamic profile of vorapaxar was established during the initial MAA. 2.5. Clinical efficacy Medicinal product no longer authorised

## 2.5.1. Dose response study(ies)

No new dose response studies have been submitted.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Main study

## Methods

The TRA 2°P-TIMI 50 trial was extensively discussed during the initial MAA; therefore, only the aspects of the study that are relevant to the current application are presented in detail in this report.

In  brief,  TRA  2°P-TIMI  50  was  a  multicenter,  randomized,  double-blind,  placebo-controlled,  balancedparallel-groups trial that included subjects with evidence or a history of atherosclerosis as follows:

a) CAD as indicated by a history of presumed spontaneous myocardial infarction (MI) ≥2 weeks but ≤ 12 months or b) ischaemic (presumed thrombotic) CVD as indicated by a history of ischemic stroke ≥2 weeks but ≤12 months or c) PAD as indicated by a history of intermittent claudication and · a resting ankle/brachial index (ABI) of &lt;0.85, or · amputation, peripheral bypass, or peripheral angioplasty of the extremities secondary to ischemia Treatments Upon enrolment, subjects were to receive the randomized allocated treatment with vorapaxar or placebo in  a  1:1  ratio.  All  doses  were  to  be  taken  by  the  subject  orally,  once  daily,  with  or  without  food,  as follows: · one tablet of vorapaxar 2.5 mg, or · one tablet of matching placebo Investigators  were  encouraged  to  follow  applicable  clinical  guidelines  for  subjects  with  established atherosclerosis,  including  antiplatelet  therapy  (eg,  aspirin,  thienopyridine),  lipid-modification  therapy, cardiac remodelling therapy, and antianginal therapies. If aspirin was used, it was recommended that it be administered in the range of 75 to 325 mg daily. Following randomized treatment assignment, subjects were to return after 30 days, 4, 8, and 12 months, and every 6 months thereafter for scheduled evaluations until the end of the study; that is, when a prespecified defined number of subjects had efficacy endpoint events and every subject had the opportunity to participate in the study for at least 1 year. Outcomes/endpoints The primary efficacy endpoint of the study was the time from randomized treatment assignment to the first  occurrence  of  any  component  of  the  composite  of  cardiovascular  death,  MI,  stroke,  and  urgent coronary revascularization. The key secondary endpoint of the study was the time from randomized treatment assignment to the first occurrence  of  any  component  of  the  composite  of  cardiovascular  death,  MI,  and  stroke.  Additional secondary efficacy endpoints and exploratory endpoints comprising various combinations of components and individual components were addressed. Medicinal product no longer authorised

Secondary safety endpoints were based on measures of bleeding, including composite of moderate and severe bleeding events according to GUSTO classification, and clinically significant bleeding, defined as TIMI  major  or  TIMI  minor  bleeding,  or  bleeding  that  requires  unplanned  medical  treatment,  surgical treatment, or laboratory evaluation.

## Sample size

<div style=\"page-break-after: always\"></div>

The initial plan was to recruit 19,500 subjects, but following a blinded sample size re-estimation in March 2009, up to 25,000 subjects were to be recruited at approximately 1000 centres in North America, Latin America, Eastern and Western Europe, Israel, South Africa, Asia/Pacific, and Australia/New Zealand; 1032 study  sites  in  32  countries.  This  sample  size  was  required  to  provide  adequate  power  to  test  the hypothesis of a 15% relative risk reduction with vorapaxar relative to placebo, each added to the existing standard  of  care,  for  occurrence  of  the  primary  and  key  secondary  composite  efficacy  endpoints,  plus adjust for potential dropouts during the study.

## Randomisation

Randomized treatment assignment was stratified by qualifying condition at entry - CAD, CVD, or PAD and planned use of a thienopyridine (none versus already being taken or to be added). Blinding Treatment assignment was blinded for subjects, investigators and staff who evaluated subjects and their responses  or  made  decisions  about  subject  care,  and  Sponsor  personnel  who  had  direct  contact  with subject records or were involved with study contact or data review. Unblinding during the study was to occur only in the event of an emergency or adverse event for which it was necessary to know the study treatment to determine an appropriate course of therapy for the subject. Statistical methods An 'Intent-to-Treat' (ITT) population was used for analyses and evaluations of efficacy, whereas an 'As Treated' population was used for analyses and evaluations of safety. Analyses of the primary efficacy endpoint and key secondary endpoint were accomplished via the Cox proportional hazards model with covariates of treatment and stratification factors. Subjects who did not have any endpoint event before the last visit or subjects who were lost to follow-up and had no event, were censored at the time of last available information (last study visit). If a subject had a fatal event that  was  not  part  of  a  specific  endpoint  for  analysis,  the  subject  was  censored  at  the  time  of  death. Treatment  differences  were  tested  at  alpha=0.049  to  account  for  one  interim  analysis.  P-values  and estimates  of  the  hazard  ratios  and  95%  confidence  intervals  were  provided.  Similar  analyses  were performed  for  other  secondary  and  exploratory  efficacy  endpoints  at  alpha=0.05.  There  was  a  single primary  efficacy  endpoint  (composite  of  cardiovascular  death,  MI,  stroke,  or  UCR)  and  one  primary comparison  (placebo  vs  vorapaxar)  defined  in the primary  hypothesis. Therefore, no  additional adjustment for multiplicity was needed for the primary hypothesis other than the endpoint (composite of cardiovascular death, MI, or stroke) in this study. The key secondary hypothesis was to be tested only if the  primary  analysis  was  statistically  significant.  Therefore,  no  additional  multiplicity  adjustment  was needed for the key secondary efficacy endpoint other than the adjustment for protocol-specified interim efficacy analysis. The efficacy analyses were categorized into 3 groups based on the level of pre-specification of the analyses Medicinal product no longer authorised

Group 1: Analyses were pre-specified in the study Data Analysis Plan (DAP), and were covered under a multiplicity adjustment procedure:

- The primary efficacy endpoint: composite of CV death, MI, stroke or UCR.
- The key secondary efficacy endpoint: the composite of CV death, MI or stroke.

Other secondary efficacy endpoints included the evaluation of the occurrence of the following composites or individual components as indicated:

1. all-cause death, MI, stroke, and urgent coronary revascularization

2. cardiovascular death and MI

<div style=\"page-break-after: always\"></div>

3. cardiovascular death, MI, stroke, urgent coronary revascularization, or urgent hospitalization for vascular cause of ischemic nature

4. all-cause death, MI, stroke, any revascularization (including amputation for ischaemic limb)
5. cardiovascular death, MI, stroke, any revascularization (including amputation for ischaemic limb), or urgent hospitalization for vascular cause of ischaemic nature
6. the individual components of the composite primary efficacy endpoint
- a. cardiovascular death
- b. MI
- c. stroke

d. urgent coronary revascularization 7. all-cause death Group 2: Analyses were pre-specified in the study DAP, and were not covered under a multiplicity adjustment procedure. Significance levels associated with these analyses were to be interpreted in this context including potential elevation of both type I and type II error rates. a) The primary and key secondary endpoints (as defined above among the following subpopulations of subjects: · CAD/PAD: subjects who received randomised treatment and whose qualifying condition was either CAD or PAD, regardless of stroke history. · No Stroke History (NSH): subjects who received randomised treatment and did NOT have a documented prior history of stroke prior to randomisation. · CAD: subjects who received randomised treatment assignment and whose qualifying condition was CAD, analysed in (a) all of these subjects, regardless of stroke history, and (b) those subjects without documented prior history of stroke prior to randomisation. b) Exploratory efficacy endpoints include the first occurrence of any component of the following composites: · All-cause death, MI, and stroke in subjects undergoing PCI during the study · All-cause death, MI, and stroke in subjects undergoing CABG during the study · CV death, MI, stroke, and UCR in association with use of thienopyridine · CV death, MI, stroke, and UCR in subjects taking aspirin but not thienopyridine · CV death, MI and stroke in subjects taking aspirin but not thienopyridine c) The primary and key secondary endpoints within category of the following subgroups: · Sex, age: &lt;65 vs ≥65 and &lt; 75 vs. ≥75, race: Caucasian, vs non-Caucasian · Geographic Regions: North America, Latin America, Europe I, Europe II, Asia, Australia/New Zealand. · Body weight: &lt; median (81 kg) vs. ≥median · Stratification factor of atherosclerosis history at time of enrolment: CAD, CVD, PAD · Planned use of thienopyridine, aspirin use, history of diabetes, renal insufficiency, tobacco use, · Prior stroke, prior MI, prior ACS (MI or hospitalization for unstable angina), lipid medication, statin therapy Medicinal product no longer authorised

<!-- image -->

Group 3: Analyses that were NOT pre-specified in the study DAP, and NOT covered under a multiplicity adjustment  procedure  were  considered  exploratory  and  post  hoc  in  nature.  Inferential  results  (e.g  pvalues) based on these analyses were interpreted with caution as these analyses were subject to biases and  confounding  associated  with  post-hoc  analyses  including  potentially  elevated  false  discovery  rates and potential inflation of both the type I and type II error rates. The p values presented in this group were not adjusted  p-values  and  were  used  only  to  support  hypothesis-generating  purposes.  Examples include subgroups including but not limited to subgroup by body weight, exposure to PPI, exposure to H2A, systemic exposure to CYP34P inducer and subgroups based on time from MI or stroke qualifying

<div style=\"page-break-after: always\"></div>

events to randomization.

Pre-specified bleeding endpoints were analysed via the Cox proportional hazards model with covariates of treatment and stratification factors for time-to-event analyses. Pearson's Chi-squared test and analysis of variance models, as appropriate, were used for other variable measures.

## CHMP comments

The TRA 2ºP-TIMI 50 methodology has previously been reviewed and considered adequate.

The statistical methods presented above are those for the initial submission. In particular, references to the DAP and analysis groups apply to the original application only. The methods were considered adequate in the original submission. It is assumed that the analysis methods for the new submission and  newly  defined  population  are  the  same  and  therefore  adequate.  As  discussed  throughout  this document, the patient population on which this application is based was defined post hoc. Results ·  Conduct of the study and participant flow A  total  of  26,449  received  randomized  treatment  assignment:  13,224  placebo  and  13,225  vorapaxar (Intent  to  Treat  population).  There  were  20,123  men  (76%)  and  6,326  (24%)  women  aged  21  to  95 years. The ITT population comprised: -17,779 subjects with CAD, -4,883 with CVD, and -3,787 with PAD as the qualifying condition. The patients' disposition in the whole TRA 2ºP-TIMI 50 is shown in the diagram below. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure E.1. Subject Disposition

<!-- image -->

Following  the  recommendation of  the  DSMB  and  prior  to  database  lock,  the  Executive  Committee  and Sponsor pre-specified populations that excluded the group identified by the DSMB. While not part of the pre-specified  populations  of  interest,  the  Sponsor  in  conjunction  with  the  Executive  Committee  also decided that a history of TIA should be granted the same level of consideration as stroke for it is clinically difficult to distinguish between history of TIA or stroke. This led to the further restriction of the population to subjects with no history of stroke or TIA.

In January 2011 (approximately 3.5 years after initiation of the trial) the DSMB recommended that all subjects  with  a  stroke  either  prior  to  or  during  the  study  discontinue  study  medication  while  the remaining  subjects  continue  the  study  drug  as  planned.  This  was  due  to  an  increased  number  of intracranial haemorrhages (ICH) reported in subjects with a prior history of stroke. A communication was sent to all study sites to inform about discontinuing subjects with a prior history of stroke, conduct followup  visits  and  inform  subjects.  Patients  with  MI  and  PAD  who  also  had  a  stroke  were  to  discontinue treatment but continue their follow-up visits. The initial plan for the primary efficacy analysis in the overall population involved data from subjects in all three strata, based on their qualifying atherosclerotic disease presentation, in their entirety. Medicinal product no longer authorised

During the initial MAA the findings in the following subpopulations of TRA 2ºP-TIMI 50 were submitted and reviewed (Note: the numbers reflect the ITT population):

<div style=\"page-break-after: always\"></div>

- -'Overall population' (n =26,449) - subjects, regardless of the qualifying condition, who received randomized treatment assignment.
- -'NSH  population' (n  =  20,699)  -  subjects  with  no  stroke  history  (NSH)  -  regardless  of  the qualifying condition, who received randomized treatment assignment.
- -'CAD (Post MI) and no history of stroke' (n = 17,191) - subjects whose qualifying condition was CAD and did not have a documented history of stroke prior to randomization.

as well as the post-hoc defined:

-'Proposed Label Population' (n = 16,897) - subjects whose qualifying condition was CAD (post MI) who did not have documented history of stroke or TIA prior to randomization. The results in this population were the basis of the currently approved indication. In support of this variation application, the MAH has now submitted the results for a new post-hoc cohort, an expanded version of the previous 'Proposed Label Population', termed: -'Intended Label Population' (n = 20,170) - subjects whose qualifying condition was CAD or PAD with no history of stroke or TIA prior to randomization. In  addition,  the  MAH  has  also  provided  the  results  in  the  following  groups  that  include  only  patients diagnosed with PAD: -PAD stratum and no history of stroke or TIA (n = 3,273) -  subjects with no history of stroke or TIA whose qualifying condition was PAD at entry; -Clinical PAD Population (n = 3,945) -Subjects with: · Subjects with no history of stroke or TIA whose qualifying condition was PAD at entry or · Subjects with baseline ABI ≤0.90 and Fontaine category &gt;1; or · Subjects with a history of peripheral arterial revascularization The rationale for this Clinical PAD group is that many subjects fulfilled the diagnostic criteria for PAD but, based on the hierarchical definition, were assigned to the CAD stratum (because they had a recent MI &lt; 12  months  prior  to  enrolling);  thus  they  were  excluded  from  the  PAD  stratum.  For  this  population  a clinically relevant and well-accepted definition of PAD was used. These criteria may miss some patients with  PAD  because  even  though  they  satisfy  ABI  criteria,  they  did  not  include  symptoms  and  might therefore be undiagnosed. The population for these sensitivity analyses fit with accepted definitions of PAD, and more likely represent patients with clinically relevant PAD. -Aspirin-Only PAD Population (n = 2,087): · Subjects with no history of stroke or TIA whose qualifying condition was PAD at entry and · Had aspirin use at baseline with no planned use of a thienopyridine Medicinal product no longer authorised

This sample was analyzed to be consistent with typical background treatment in Europe.

## CHMP comments

It  needs  to  be  noted  again  here  that  the  MAH  considers  the 'Intended Label Population' as  the primary  population  for  this  application  with  the  results  in  the  other  groups  mainly  presented  as supporting evidence.

This is based, according to the MAH, on the original objective and design of TRA 2ºP-TIMI 50 aiming at the atherosclerotic population as a whole. Having excluded patients with CVD (due to safety issues),

<div style=\"page-break-after: always\"></div>

the analysis of the remaining cohorts (CAD or PAD) should be considered together, as the TRA 2°P TIMI 50 study was not powered to demonstrate statistical significance in the PAD population or any of the other individual qualifying strata.

The 'Intended  Label Population' mainly  comprises  patients  with  CAD  and  prior  MI  and  only approximately 16%-19% patients with evidence of PAD (as defined by the PAD stratum or Clinical PAD population criteria). Therefore, the findings in the 'Intended Label Population' still reflect primarily the post-MI population that was reviewed in the initial MAA.

Certainly, it is  essential to  evaluate  also  the  efficacy  and  safety  of  vorapaxar  in  the  PAD  population separately; therefore, the data in the PAD stratum are also presented here and discussed in detail with more information on the Clinical PAD and Aspirin-only PAD groups shown where relevant. Of note, Unless otherwise stated, all TRA 2ºP-TIMI 50 populations mentioned in the remaining sections of  this  report  concern  patients  'with  no  history  of  stroke  or  TIA'  (not  repeated  for  the  sake  of simplicity); for example, ' PAD stratum' refers to patients in PAD stratum and no history or stroke of TIA . Also the terms 'CAD stratum', 'post-MI patients', 'patients with recent MI' all referring to TRA 2ºP-TIMI 50 CAD stratum (Post MI)  and no history of stroke or TIA , are used interchangeably. ·  Baseline data -Intended Label Population In the Intended Label Population , subjects were predominantly white (89%), male (78%), with a median age  of  60  years;  9%  were  over  75 years  old.  Median  body  weight  was  82  kg.  Overall,  the  use  of concomitant medications was similar between the two treatment groups. There was near universal use of aspirin  (97%), 71%  of  subjects  were  treated  with  clopidogrel  and  70%  were  treated  with  dual antiplatelet therapy.  The  two  treatment  groups  were  well  balanced  in  terms  of  relevant  medical history. Overall, 65% of the subjects had hypertension, 85% had hyperlipidaemia, and 24% had diabetes mellitus. Approximately 82% of subjects with hyperlipidaemia were being treated with lipid medications, of those 93% were receiving statins. Antihypertensive agents were also commonly used: 80% of subjects were taking a beta blocker, 63% an ACE inhibitor or combination, and 14% an ARB or combination. Table  E.1 . TRA  2ºP-TIMI 50 Baseline  Demographics, Disease Characteristics, and Concomitant Medications in Subjects With No History of Stroke or TIA Whose Qualifying Condition was CAD or PAD Characteristic Age (y) Mean (SD) Median Age (n (%)) &lt;65 y 65-&lt;75 y ≥ 75 y Sex (n (%)) Female Male Medicinal product no longer authorised

| Characteristic         | Placebo (N=10090)   | Vorapaxar (N=10080)   | Total (N=20170   |
|------------------------|---------------------|-----------------------|------------------|
| Age (y)                |                     |                       |                  |
| Mean (SD)              | 59.7 (10.66)        | 59.9 (10.73)          | 59.8 (10.70)     |
| Median                 | 60.0                | 60.0                  | 60.0             |
| Age (n (%)) Medicinal  |                     |                       |                  |
| <65 y                  | 6787(67.3)          | 6649 (66.0)           | 13436 (66.6)     |
| 65-<75 y               | 2378(23.6)          | 2502 (24.8)           | 4880 (24.2)      |
| ≥ 75 y                 | 925 (9.2)           | 929 (9.2)             | 1854 (9.2)       |
| Sex (n (%))            |                     |                       |                  |
| Female                 | 2165 (21.5)         | 2204 (21.9)           | 4369 (21.7)      |
| Male                   | 7925 (78.5)         | 7876 (78.1)           | 15801 (78.3)     |
| Race (n (%))           |                     |                       |                  |
| White                  | 8924 (88.4)         | 8939 (88.7)           | 17863 (88.6)     |
| Non-white              | 1163 (11.5)         | 1134 (11.3)           | 2297 (11.4)      |
| Asian                  | 353 (3.5)           | 332 (3.3)             | 685 (3.4)        |
| Black/African American | 238 (2.4)           | 231 (2.3)             | 469 (2.3)        |
| Weight (kg)            | (n=10071)           | (n=10067)             | (n=20138)        |
| Mean (SD)              | 83.96 (17.312)      | 83.39 (16.857)        | 83.68 (17.088)   |
| Median                 | 82.10               | 82.00                 | 82.00            |
| Weight (n(%))          |                     |                       |                  |
| <60 kg                 | 580 (5.7)           | 597 (5.9)             | 1177 (5.8)       |
| ≥60 kg                 | 9491 (94.1)         | 9470 (93.9)           | 18961 (94.0)     |

<div style=\"page-break-after: always\"></div>

| Characteristic                                                                                            | Placebo (N=10090)                    | Vorapaxar (N=10080)                           | Total (N=20170                               |
|-----------------------------------------------------------------------------------------------------------|--------------------------------------|-----------------------------------------------|----------------------------------------------|
| Calculated Body Mass Index (kg/m2)a                                                                       | (n=10065)                            | (n=10057)                                     | (n=20122)                                    |
| Mean (SD)                                                                                                 | 28.51 (5.028)                        | 28.37 (4.871)                                 | 28.44 (4.951)                                |
| Median                                                                                                    | 27.80                                | 27.80                                         | 27.80                                        |
| Systolic Blood Pressure (mm Hg)                                                                           | (n=10063)                            | (n=10060)                                     | (n=20123)                                    |
| Mean (SD)                                                                                                 | 131.8 (19.07)                        | 132.0 (19.37)                                 | 131.9 (19.22)                                |
| Median                                                                                                    | 130.0                                | 130.0                                         | 130.0                                        |
| Diastolic Blood Pressure (mm Hg)                                                                          | (n=10062)                            | (n=10057)                                     | (n=20119)                                    |
| Mean (SD)                                                                                                 | 77.6 (10.71)                         | 77.5 (10.71)                                  | 77.5 (10.71)                                 |
| Median                                                                                                    | 78.0                                 | 78.0                                          | 78.0                                         |
| Ankle/Brachial Index                                                                                      | (n=9818)                             | (n=9830)                                      | (n=19648)                                    |
| Mean (SD)                                                                                                 | 1.027 (0.2248)                       | 1.029 (0.2225)                                | 1.028 (0.2236)                               |
| Median                                                                                                    | 1.040                                | 1.050                                         | 1.040                                        |
| Hypertension                                                                                              | 6564 (65.1)                          | 6520 (64.7)                                   | 13084 (64.9)                                 |
| History of Cigarette Smoking                                                                              | 7411 (73.4)                          | 7348(72.9)                                    | 14759(73.2)                                  |
| Hyperlipidaemia                                                                                           | 8573 (85.0)                          | 8554 (84.9)                                   | 17127 (84.9)                                 |
| Diabetes Mellitus                                                                                         | 2377 (23.6)                          | 2385 (23.7)                                   | 4762 (23.6)                                  |
| Prior Peripheral Arterial Disease                                                                         | 2049 (20.3)                          | 1980(19.6)                                    | 4029 (20.0)                                  |
| Claudication                                                                                              | 2230 (22.1)                          | 2187 (21.7)                                   | 4417 (21.9)                                  |
| Heart Failure                                                                                             | 873 (8.7)                            | 856 (8.5)                                     | 1729 (8.6)                                   |
| Prior PCI                                                                                                 | 7153 (70.9)                          | 7125 (70.7)                                   | 14278 (70.8)                                 |
| Prior CABG                                                                                                | 1471 (14.6)                          | 1471 (14.6)                                   |                                              |
| Prior Percutaneous Carotid Intervention                                                                   | 55 (0.5)                             | 59 (0.6)                                      | 2942 (14.6) 114 (0.6) authorised             |
| Prior Carotid Endarterectomy                                                                              | 134 (1.3)                            | 160 (1.6)                                     | 294 (1.5)                                    |
| Peripheral Arterial Revascularization                                                                     | 1199 (11.9)                          | 1171 (11.6)                                   | 2370 (11.8)                                  |
| Prior Amputation Related to Limb Ischemia                                                                 |                                      | 93 (0.9)                                      |                                              |
| Estimated eGFR at Baseline                                                                                |                                      |                                               | 176 (0.9)                                    |
|                                                                                                           | 83 (0.8)                             |                                               | 2859 (14.2)                                  |
| <60 mL/min . 1.73m 2 ≥60 mL/min • 1.73m 2                                                                 | 1383 (13.7) 8591 (85.1)              | 1476 (14.6) 8482 (84.1) 122 (1.2)             | 17073 (84.6)                                 |
| Not Able to Calculate                                                                                     | 116 (1.1)                            |                                               | 238 (1.2)                                    |
| Functional status                                                                                         | longer                               |                                               |                                              |
| NYHA Functional Classification I (no limitation of activities) II (slight, mild limitation of activities) | (n=10068) 8678 (86.2) 1307 (13.0) no | (n=10055) 8654 (86.1) 1303 (13.0) 89 (0.9)    | (n=20123) 17332 (86.1) 2610 (13.0) 165 (0.8) |
| III (marked limitation of activities)                                                                     | 76 (0.8) 7 (0.1)                     | 9 (0.1)                                       |                                              |
| IV (symptoms with any activity, or at rest)                                                               | (n=10009)                            |                                               | 16 (0.1)                                     |
| Fontaine Classification                                                                                   |                                      | (n=9991)                                      | (n=20000)                                    |
| I (asymptomatic)                                                                                          | 8355 (83.5)                          | 8343 (83.5)                                   | 16698 (83.5)                                 |
| IIa (intermittent claudication walking >200                                                               | 998 (10.0)                           | 1000 (10.0)                                   | 1998 (10.0)                                  |
| m) IIb (intermittent claudication walking <200 m) product                                                 | 597 (6.0)                            | 589 (5.9) 39 (0.4)                            | 1186 (5.9) 85 (0.4)                          |
| III (pain at rest or at night)                                                                            | 46 (0.5)                             | 20 (0.2)                                      |                                              |
| IV (ulceration, necrosis, or gangrene)                                                                    | 13 (0.1)                             |                                               |                                              |
| Concomitant medication                                                                                    |                                      |                                               |                                              |
|                                                                                                           |                                      |                                               | 33 (0.2)                                     |
| Any Antiplatelet Agent (including aspirin) Any Aspirin                                                    | 10005 (99.2) 9756 (96.7)             | 10013 (99.3) 9746 (96.7) 7088 (70.3) 72 (0.7) | 20018 (99.2) 19502 (96.7)                    |
| Any Clopidogrel Any Ticlopidine                                                                           | 7137 (70.7) 64 (0.6)                 |                                               | 14225 (70.5) 136 (0.7)                       |
| Any Prasugrel                                                                                             | 17 (0.2) 7215 (71.5)                 | 21 (0.2) 7177                                 | 38 (0.2) 14392 (71.4)                        |
| Any Thienopyridine                                                                                        |                                      | (71.2) 11 (0.1)                               | 20 (0.1)                                     |
| Any Dipyridamole                                                                                          | 9 (0.1)                              |                                               |                                              |
| Any Cilostazol                                                                                            | 220 (2.2)                            | 192 (1.9)                                     | 412 (2.0)                                    |
| Any Antiplatelet Agent Other Than Aspirin Medicinal                                                       | 32 (0.3)                             | 35 (0.3)                                      | 67 (0.3)                                     |
| or Clopidogrel                                                                                            |                                      |                                               |                                              |
| Aspirin Only                                                                                              | 2642 (26.2)                          | 2704 (26.8)                                   | 5346 (26.5) 13903                            |
| Aspirin Plus a Thieopyridine                                                                              | 6983 (69.2) 7114 (70.5)              | 6920 (68.7) 7042 (69.9)                       | (68.9) 14156                                 |
| Aspirin Plus Any Other Antiplatelet Agent Any Oral Anticoagulant                                          |                                      | 11 (0.1)                                      | (70.2) 18 (0.1)                              |
|                                                                                                           | 7 (0.1)                              |                                               | 15 (0.1)                                     |
| Warfarin                                                                                                  | 6 (0.1)                              | 9 (0.1)                                       |                                              |
| Any Beta-adrenergic Antagonist (excludes ophthalmic preps)                                                | 8065 (79.9)                          | 8019 (79.6)                                   | 16084 (79.7)                                 |
| Any Angiotensin Converting Enzyme Inhibitor                                                               |                                      | 6326 (62.8)                                   | 12693                                        |
| or Combination                                                                                            | 6367 (63.1)                          |                                               | (62.9)                                       |
| Any Angiotensin II Receptor Antagonist or                                                                 | 1484 (14.7)                          | 1371 (13.6)                                   | 2855 (14.2)                                  |
| Combination                                                                                               |                                      |                                               | 18787                                        |
| Any Statin                                                                                                | 9458 (93.7)                          | 9329 (92.5)                                   | (93.1)                                       |

<div style=\"page-break-after: always\"></div>

| Characteristic                                                                                                                                                                                                                                                                                                                | Placebo (N=10090)                                                                                                                                                                                                                                                                                                             | Vorapaxar (N=10080)                                                                                                                                                                                                                                                                                                           | Total (N=20170                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Any Proton Pump Inhibitor                                                                                                                                                                                                                                                                                                     | 2542 (25.2)                                                                                                                                                                                                                                                                                                                   | 2521 (25.0)                                                                                                                                                                                                                                                                                                                   | 5063 (25.1)                                                                                                                                                                                                                                                                                                                   |
| Any H2-Receptor Antagonist                                                                                                                                                                                                                                                                                                    | 480 (4.8)                                                                                                                                                                                                                                                                                                                     | 457 (4.5)                                                                                                                                                                                                                                                                                                                     | 937 (4.6)                                                                                                                                                                                                                                                                                                                     |
| Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione Subjects were not taking aspirin or Clopidogrel | Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione Subjects were not taking aspirin or Clopidogrel | Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione Subjects were not taking aspirin or Clopidogrel | Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione Subjects were not taking aspirin or Clopidogrel |

## CHMP comments

In  general  the  TRA  2ºP-TIMI  50  patient  characteristics  are  consistent  with  what  is  expected  in  a population  with  atherosclerotic  disease  and  multiple  risk  factors.  The  groups  were  well  balanced  in terms of demographics, coexistent conditions and background therapies. Almost all patients were on aspirin  and  the  majority  were  also  receiving  clopidogrel  (i.e.  double  antiplatelet  therapy)  but  there were  very  few  patients  on  other  antiplatelet  agents  like  prasugrel  or  ticagrelor.  This  is  a  limitation identified in the previous round and currently reflected in the approved SmPC. Of course, this population mainly reflects post-MI patients who represent the majority in this group. The baseline characteristics in patients with PAD ( PAD stratum ) are described below. -PAD stratum The baseline data in the PAD stratum with no history of stroke or TIA are shown below. Table  E.2. TRA  2ºP-TIMI 50 Baseline Demographics, Disease Characteristics, and Concomitant Medications Subjects With No History of Stroke or TIA whose Qualifying Condition was PAD at Entry and Prior to Randomization Medicinal product no longer authorised

| product                             | Placebo (n=1651)   | Vorapaxar (n=1622)   | TOTAL (n=3273)   |
|-------------------------------------|--------------------|----------------------|------------------|
| Age (years)                         |                    |                      |                  |
| Mean (SD)                           | 66.0 (9.39)        | 65.8 (9.44)          | 65.9 (9.41)      |
| Median                              | 66.0               | 66.0                 | 66.0             |
| Age (n(%))                          |                    |                      |                  |
| <65                                 | 735(44.5)          | 689(42.5)            | 1424(43.5)       |
| 65 - <75                            | 597(36.2)          | 638(39.3)            | 1235(37.7)       |
| >=75                                | 319(19.3)          | 295(18.2)            | 614(18.8)        |
| Sex (n(%))                          |                    |                      |                  |
| Female                              | 489(29.6)          | 481(29.7)            | 970(29.6)        |
| Male                                | 1162(70.4)         | 1141(70.3)           | 2303(70.4)       |
| Race (n(%))                         |                    |                      |                  |
| White                               | 1509(91.4)         | 1458(89.9)           | 2967(90.7)       |
| Non-White                           | 142 (8.6)          | 163(10.0)            | 305 (9.3)        |
| Asian                               | 13 (0.8)           | 11 (0.7)             | 24 (0.7)         |
| Black or African American Medicinal | 61 (3.7)           | 59 (3.6)             | 120 (3.7)        |
| Weight (kg)                         | (n=1646)           | (n=1619)             | (n=3265)         |
| Mean (SD)                           | 80.32 (16.921)     | 80.30 (16.818)       | 80.31 (16.867)   |
| Median                              | 78.45              | 78.90                | 78.70            |
| Weight (n(%)                        |                    |                      |                  |
| < 60 kg                             | 151 (9.1)          | 165(10.2)            | 316 (9.7)        |
| >=60 kg                             | 1495(90.6)         | 1454(89.6)           | 2949(90.1)       |
| Missing                             | 5 (0.3)            | 3 (0.2)              | 8 (0.2)          |
| Calculated Body Mass Index (kg/m²)a | (n=1646)           | (n=1616)             | (n=3262)         |
| Mean (SD)                           | 27.94 (5.229)      | 27.82 (4.958)        | 27.88 (5.096)    |
| Median                              | 27.30              | 27.40                | 27.30            |
| Systolic Blood Pressure (mm Hg)     | (n=1648)           | (n=1620)             | (n=3268)         |
| Mean (SD)                           | 139.8 (19.26)      | 140.8 (20.13)        | 140.3 (19.70)    |
| Median                              | 140.0              | 140.0                | 140.0            |
| Diastolic Blood Pressure (mm Hg)    | (n=1647)           | (n=1618)             | (n=3265)         |
| Mean (SD)                           | 76.8 (10.59)       | 77.1 (10.97)         | 76.9 (10.78)     |
| Median                              | 78.0               | 78.0                 | 78.0             |
| Ankle/Brachial Index                | (n=1595)           | (n=1548)             | (n=3143)         |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                               | Placebo (n=1651)                                                                                                                                                                                                                                                              | Vorapaxar (n=1622)                                                                                                                                                                                                                                                            | TOTAL (n=3273)                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mean (SD)                                                                                                                                                                                                                                                                     | 0.765 (0.2268)                                                                                                                                                                                                                                                                | 0.767 (0.2269)                                                                                                                                                                                                                                                                | 0.766 (0.2268)                                                                                                                                                                                                                                                                |
| Median                                                                                                                                                                                                                                                                        | 0.770                                                                                                                                                                                                                                                                         | 0.760                                                                                                                                                                                                                                                                         | 0.760                                                                                                                                                                                                                                                                         |
| Missing                                                                                                                                                                                                                                                                       | 56                                                                                                                                                                                                                                                                            | 74                                                                                                                                                                                                                                                                            | 130                                                                                                                                                                                                                                                                           |
| Hypertension                                                                                                                                                                                                                                                                  | 1353(82.0)                                                                                                                                                                                                                                                                    | 1344(82.9)                                                                                                                                                                                                                                                                    | 2697(82.4)                                                                                                                                                                                                                                                                    |
| Hyperlipidaemia                                                                                                                                                                                                                                                               | 1457(88.2)                                                                                                                                                                                                                                                                    | 1403(86.5)                                                                                                                                                                                                                                                                    | 2860(87.4)                                                                                                                                                                                                                                                                    |
| Diabetes Mellitus                                                                                                                                                                                                                                                             | 563(34.1)                                                                                                                                                                                                                                                                     | 576(35.5)                                                                                                                                                                                                                                                                     | 1139(34.8)                                                                                                                                                                                                                                                                    |
| Prior Peripheral Arterial Disease                                                                                                                                                                                                                                             | 1610(97.5)                                                                                                                                                                                                                                                                    | 1572(96.9)                                                                                                                                                                                                                                                                    | 3182(97.2)                                                                                                                                                                                                                                                                    |
| Claudication                                                                                                                                                                                                                                                                  | 1638(99.2)                                                                                                                                                                                                                                                                    | 1618(99.8)                                                                                                                                                                                                                                                                    | 3256(99.5)                                                                                                                                                                                                                                                                    |
| Heart Failure                                                                                                                                                                                                                                                                 | 157 (9.5)                                                                                                                                                                                                                                                                     | 157 (9.7)                                                                                                                                                                                                                                                                     | 314 (9.6)                                                                                                                                                                                                                                                                     |
| Prior PCI                                                                                                                                                                                                                                                                     | 441(26.7)                                                                                                                                                                                                                                                                     | 414(25.5)                                                                                                                                                                                                                                                                     | 855(26.1)                                                                                                                                                                                                                                                                     |
| Prior CABG                                                                                                                                                                                                                                                                    | 388(23.5)                                                                                                                                                                                                                                                                     | 370(22.8)                                                                                                                                                                                                                                                                     | 758(23.2)                                                                                                                                                                                                                                                                     |
| Prior Percutaneous Carotid Intervention                                                                                                                                                                                                                                       | 30 (1.8)                                                                                                                                                                                                                                                                      | 44 (2.7)                                                                                                                                                                                                                                                                      | 74 (2.3)                                                                                                                                                                                                                                                                      |
| Prior Carotid Endarterectomy                                                                                                                                                                                                                                                  | 97 (5.9)                                                                                                                                                                                                                                                                      | 126 (7.8)                                                                                                                                                                                                                                                                     | 223 (6.8)                                                                                                                                                                                                                                                                     |
| Peripheral Arterial Revascularization                                                                                                                                                                                                                                         | 1024(62.0)                                                                                                                                                                                                                                                                    | 1022(63.0)                                                                                                                                                                                                                                                                    | 2046(62.5)                                                                                                                                                                                                                                                                    |
| Prior Amputation for Limb Ischemia                                                                                                                                                                                                                                            | 63 (3.8)                                                                                                                                                                                                                                                                      | 79 (4.9)                                                                                                                                                                                                                                                                      | 142 (4.3)                                                                                                                                                                                                                                                                     |
| Estimated eGFR at Baseline                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                               |
| <60 mL/min . 1.73m 2                                                                                                                                                                                                                                                          | 457(27.7)                                                                                                                                                                                                                                                                     | 427(26.3)                                                                                                                                                                                                                                                                     | 884(27.0)                                                                                                                                                                                                                                                                     |
| ≥60 mL/min . 1.73m 2                                                                                                                                                                                                                                                          | 1180(71.5)                                                                                                                                                                                                                                                                    | 1172(72.3)                                                                                                                                                                                                                                                                    | 2352(71.9)                                                                                                                                                                                                                                                                    |
| Not Able to Calculate                                                                                                                                                                                                                                                         | 14 (0.8)                                                                                                                                                                                                                                                                      | 23 (1.4) 37 (1.1) authorised                                                                                                                                                                                                                                                  | 23 (1.4) 37 (1.1) authorised                                                                                                                                                                                                                                                  |
| Functional status                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                               |
| NYHA Functional Classification                                                                                                                                                                                                                                                | (n=1648)                                                                                                                                                                                                                                                                      | (n=1620)                                                                                                                                                                                                                                                                      | (n=3268)                                                                                                                                                                                                                                                                      |
| I (no limitation of activities)                                                                                                                                                                                                                                               | 1380(83.7)                                                                                                                                                                                                                                                                    | 1339(82.7)                                                                                                                                                                                                                                                                    | 2719(83.2)                                                                                                                                                                                                                                                                    |
| II (slight, mild limitation of activities)                                                                                                                                                                                                                                    | 165(10.0)                                                                                                                                                                                                                                                                     | 166(10.2)                                                                                                                                                                                                                                                                     | 331(10.1)                                                                                                                                                                                                                                                                     |
| III (marked limitation of activities)                                                                                                                                                                                                                                         | 87 (5.3)                                                                                                                                                                                                                                                                      | 95 (5.9)                                                                                                                                                                                                                                                                      | 182 (5.6)                                                                                                                                                                                                                                                                     |
| IV (symptoms with any activity, or at rest)                                                                                                                                                                                                                                   | 15 (0.9)                                                                                                                                                                                                                                                                      | 19 (1.2)                                                                                                                                                                                                                                                                      | 34 (1.0)                                                                                                                                                                                                                                                                      |
| Fontaine Classification                                                                                                                                                                                                                                                       | (n=1645) longer                                                                                                                                                                                                                                                               | (n=1615)                                                                                                                                                                                                                                                                      | (n=3260)                                                                                                                                                                                                                                                                      |
| I (asymptomatic)                                                                                                                                                                                                                                                              | 442(26.9)                                                                                                                                                                                                                                                                     | 405(25.1)                                                                                                                                                                                                                                                                     | 847(26.0)                                                                                                                                                                                                                                                                     |
| IIa (intermittent claudication walking >200 m)                                                                                                                                                                                                                                | 672(40.9)                                                                                                                                                                                                                                                                     | 674(41.7)                                                                                                                                                                                                                                                                     | 1346(41.3)                                                                                                                                                                                                                                                                    |
| IIb (intermittent claudication walking <200 m)                                                                                                                                                                                                                                | 485(29.5)                                                                                                                                                                                                                                                                     | 485(30.0)                                                                                                                                                                                                                                                                     | 970(29.8)                                                                                                                                                                                                                                                                     |
| III (pain at rest or at night)                                                                                                                                                                                                                                                | 35 (2.1)                                                                                                                                                                                                                                                                      | 32 (2.0)                                                                                                                                                                                                                                                                      | 67 (2.1)                                                                                                                                                                                                                                                                      |
| IV (ulceration, necrosis, or gangrene)                                                                                                                                                                                                                                        | 11 (0.7)                                                                                                                                                                                                                                                                      | 19 (1.2)                                                                                                                                                                                                                                                                      | 30 (0.9)                                                                                                                                                                                                                                                                      |
| Concomitant medication                                                                                                                                                                                                                                                        | no                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                               |
| Any Antiplatelet Agent (including aspirin)                                                                                                                                                                                                                                    | 1607 (97.3)                                                                                                                                                                                                                                                                   | 1576 (97.2)                                                                                                                                                                                                                                                                   | 3183 (97.3)                                                                                                                                                                                                                                                                   |
| Any Aspirin                                                                                                                                                                                                                                                                   | 1458 (88.3)                                                                                                                                                                                                                                                                   | 1431 (88.2)                                                                                                                                                                                                                                                                   | 2889 (88.3)                                                                                                                                                                                                                                                                   |
| Any Clopidogrel                                                                                                                                                                                                                                                               | 565 (34.2)                                                                                                                                                                                                                                                                    | 550 (33.9)                                                                                                                                                                                                                                                                    | 1115 (34.1)                                                                                                                                                                                                                                                                   |
| Any Ticlopidine                                                                                                                                                                                                                                                               | 20 (1.2)                                                                                                                                                                                                                                                                      | 24 (1.5)                                                                                                                                                                                                                                                                      | 44 (1.3)                                                                                                                                                                                                                                                                      |
| Any Prasugrel                                                                                                                                                                                                                                                                 | 0                                                                                                                                                                                                                                                                             | 0                                                                                                                                                                                                                                                                             | 0                                                                                                                                                                                                                                                                             |
| Any Thienopyridine                                                                                                                                                                                                                                                            | 584 (35.4)                                                                                                                                                                                                                                                                    | 573 (35.3)                                                                                                                                                                                                                                                                    | 1157 (35.3)                                                                                                                                                                                                                                                                   |
| Any Dipyridamole                                                                                                                                                                                                                                                              | 7 (0.4)                                                                                                                                                                                                                                                                       | 3 (0.2)                                                                                                                                                                                                                                                                       | 10 (0.3)                                                                                                                                                                                                                                                                      |
| Any Cilostazol                                                                                                                                                                                                                                                                | 191 (11.6)                                                                                                                                                                                                                                                                    | 176 (10.9)                                                                                                                                                                                                                                                                    | 367 (11.2)                                                                                                                                                                                                                                                                    |
| Any Antiplatelet Agent Other Than Aspirin or product                                                                                                                                                                                                                          | 30 (1.8)                                                                                                                                                                                                                                                                      | 27 (1.7)                                                                                                                                                                                                                                                                      | 57 (1.7)                                                                                                                                                                                                                                                                      |
| Clopidogrel                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                               |
| Aspirin Only                                                                                                                                                                                                                                                                  | 888 (53.8)                                                                                                                                                                                                                                                                    | 882 (54.4)                                                                                                                                                                                                                                                                    | 1770 (54.1)                                                                                                                                                                                                                                                                   |
| Aspirin Plus a Thieopyridine                                                                                                                                                                                                                                                  | 452 (27.4)                                                                                                                                                                                                                                                                    | 438 (27.0)                                                                                                                                                                                                                                                                    | 890 (27.2)                                                                                                                                                                                                                                                                    |
| Aspirin Plus Any Other Antiplatelet Agent                                                                                                                                                                                                                                     | 570 (34.5)                                                                                                                                                                                                                                                                    | 549 (33.8)                                                                                                                                                                                                                                                                    | 1119 (34.2)                                                                                                                                                                                                                                                                   |
| Any Oral Anticoagulant                                                                                                                                                                                                                                                        | 3 (0.2)                                                                                                                                                                                                                                                                       | 4 (0.2)                                                                                                                                                                                                                                                                       | 7 (0.2)                                                                                                                                                                                                                                                                       |
| Warfarin                                                                                                                                                                                                                                                                      | 3 (0.2)                                                                                                                                                                                                                                                                       | 4 (0.2)                                                                                                                                                                                                                                                                       | 7 (0.2)                                                                                                                                                                                                                                                                       |
| Any Beta-adrenergic Antagonist (excludes ophthalmic preps)                                                                                                                                                                                                                    | 856 (51.8)                                                                                                                                                                                                                                                                    | 825 (50.9)                                                                                                                                                                                                                                                                    | 1681 (51.4)                                                                                                                                                                                                                                                                   |
| Any Angiotensin Converting Enzyme Inhibitor or Combination                                                                                                                                                                                                                    | 781 (47.3)                                                                                                                                                                                                                                                                    | 740 (45.6)                                                                                                                                                                                                                                                                    | 1521 (46.5)                                                                                                                                                                                                                                                                   |
| Any Angiotensin II Receptor Antagonist or Combination Medicinal                                                                                                                                                                                                               | 379 (23.0)                                                                                                                                                                                                                                                                    | 369 (22.7)                                                                                                                                                                                                                                                                    | 748 (22.9)                                                                                                                                                                                                                                                                    |
| Any Statin                                                                                                                                                                                                                                                                    | 1372 (83.1)                                                                                                                                                                                                                                                                   | 1298 (80.0)                                                                                                                                                                                                                                                                   | 2670 (81.6)                                                                                                                                                                                                                                                                   |
| Any Proton Pump Inhibitor                                                                                                                                                                                                                                                     | 374 (22.7)                                                                                                                                                                                                                                                                    | 338 (20.8)                                                                                                                                                                                                                                                                    | 712 (21.8)                                                                                                                                                                                                                                                                    |
| Any H2-Receptor Antagonist                                                                                                                                                                                                                                                    | 59 (3.6)                                                                                                                                                                                                                                                                      | 59 (3.6)                                                                                                                                                                                                                                                                      | 118 (3.6)                                                                                                                                                                                                                                                                     |
| Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione | Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione | Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione | Any Thienopyridine includes Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor Any Other Antiplatelet includes any Thienopyridine, Dipyridamole, Cilostazol, Glycoprotein IIb/IIIa Inhibitor Any Oral Anticoagulant includes Warfarin, Phenoprocoumon, Acenocoumarol, Fluindione |

## CHMP comments

<div style=\"page-break-after: always\"></div>

There are some interesting observations when the baseline characteristics of the PAD population are compared  with  their  CAD  counterparts.  Compared  to  the  previously  considered  'Proposed  Label Population'  comprising  only  CAD  patients  with  no  history  of  stroke  or  TIA,  the  PAD  population  was older (PAD: median 66yrs vs CAD: median 58 yrs), there was a higher percentage of diabetic patients (PAD:  average  34.8%  vs  CAD:  average  21.4%),  as  well  as  a  higher  rate  of  renal  impairment  as suggested by the percentage of patients with eGFR &lt;60 mL/min . 1.73m 2 .

As expected, more PAD patients had a history of peripheral revascularisation procedures, but far less coronary  revascularisations  than  their  CAD  counterparts.  Also  in  terms  of  background  therapy, although in the CAD population the use of aspirin was almost universal, in PAD a significant proportion of  patients  were  receiving  clopidogrel  instead  of  aspirin  as  a  sole  antiplatelet.  Also  DAPT  in  CAD patients was common (more than 75%) but only half of that (around 34%) in PAD patients.

|                                   | Placebo (n=10090)        | Placebo (n=10090)   | Placebo (n=10090)   | Vorapaxar (n=10080)      | Vorapaxar (n=10080)   | Vorapaxar (n=10080)   |                           |            |
|-----------------------------------|--------------------------|---------------------|---------------------|--------------------------|-----------------------|-----------------------|---------------------------|------------|
| Medicinal                         | Subjects with Events (%) | KM % a              | Event Rate f        | Subjects with Events (%) | KM% a                 | Event rate f          | Hazard Ratio (95% CI) b,c | P- Value c |
| Primary Efficacy Endpoint d       | 1073 (10.6%)             | 11.8%               | 4.4%                | 896 (8.9%)               | 10.1%                 | 3.6%                  | 0.83 (0.76-0.90)          | <0.001     |
| CV Death                          | 154 (1.5%)               |                     |                     | 129 (1.3%)               |                       |                       |                           |            |
| MI                                | 531 (5.3%)               |                     |                     | 450 (4.5%)               |                       |                       |                           |            |
| Stroke                            | 123 (1.2%)               |                     |                     | 91 (0.9%)                |                       |                       |                           |            |
| Ischemic                          | 100 (1.0%)               |                     |                     | 60 (0.6%)                |                       |                       |                           |            |
| Haemorrhagic e                    | 16 (0.2%)                |                     |                     | 22 (0.2%)                |                       |                       |                           |            |
| Uncertain                         | 7 (0.1%)                 |                     |                     | 9 (0.1%)                 |                       |                       |                           |            |
| UCR                               | 265 (2.6%)               |                     |                     | 226 (2.2%)               |                       |                       |                           |            |
| Key Secondary Efficacy Endpoint d | 851 (8.4%)               | 9.5%                | 3.4%                | 688 (6.8%)               | 7.9%                  | 2.8%                  | 0.80 (0.73-0.89)          | <0.001     |
| CV Death                          | 160 (1.6%)               |                     |                     | 132 (1.3%)               |                       |                       |                           |            |
| MI                                | 562 (5.6%)               |                     |                     | 464 (4.6%)               |                       |                       |                           |            |
| Stroke                            | 129 (1.3%)               |                     |                     | 92 (0.9%)                |                       |                       |                           |            |
| Ischemic                          | 104 (1.0%)               |                     |                     | 61 (0.6%)                |                       |                       |                           |            |
| Haemorrhagic e                    | 17 (0.2%)                |                     |                     | 22 (0.2%)                |                       |                       |                           |            |
| Uncertain                         | 8 (0.1%)                 |                     |                     | 9 (0.1%)                 |                       |                       |                           |            |

In  general,  treatment  groups  within  the  PAD  stratum  were  again  well  balanced  in  terms  of demographics, risk factors, functional status and therapies. ·  Outcomes and estimation Primary and Key Secondary Endpoints -Intended Label Population In the Intended Label Population there was a 17% reduction in the primary efficacy endpoint (HR 0.83; 95% CI 0.76-0.90; p &lt;0.001) and a 20 % reduction in the composite key secondary endpoint (HR 0.80; 95% CI 0.73 - 0.89; p &lt;0.001). The rates of all components of the composite endpoints (first event in the  case  of  multiple  events)  were  reduced  by  vorapaxar  compared  with  placebo.    The  individual component of the composite endpoint that most contributed to the difference  between  vorapaxar  and placebo was the reduction in MI (Table E.3). Table E.3. TRA 2ºP-TIMI 50 Primary and Key Secondary Efficacy Endpoints and Contributing Components With  Stroke  Sub-Categories  Included,  in  Subjects  With  No  History  of  Stroke  or  TIA  Whose  Qualifying Condition was CAD or PAD (Event Accrual Period:  Randomization to Last Visit) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Placebo (n=10090)        | Placebo (n=10090)   | Placebo (n=10090)   | Vorapaxar (n=10080)      | Vorapaxar (n=10080)   | Vorapaxar (n=10080)   |                           |            |
|--------------------------|---------------------|---------------------|--------------------------|-----------------------|-----------------------|---------------------------|------------|
| Subjects with Events (%) | KM % a              | Event Rate f        | Subjects with Events (%) | KM% a                 | Event rate f          | Hazard Ratio (95% CI) b,c | P- Value c |

<!-- image -->

f. Annualized Event Rate is expressed as number of patients with events per 100 patient-years of exposure Note: UCR=recurrent ischemia leading to urgent coronary revascularization; MI=myocardial infarction; CV death=Cardiovascular death Figure E.2 . TRA 2 ° P - TIMI 50 Kaplan-Meier Estimate of Time to the First Occurrence of CEC-Adjudicated Primary Efficacy Endpoint: in Subjects With No History of Stroke or TIA Whose Qualifying Condition Was CAD or PAD (Event Accrual Period: Randomization to Last Visit) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure E.3 . TRA 2 ° P - TIMI 50 Kaplan-Meier Estimate of Time to the First Occurrence of CEC-Adjudicated Secondary Efficacy Endpoint: in Subjects With No History of Stroke or TIA Whose Qualifying Condition Was CAD or PAD (Event Accrual Period: Randomization to Last Visit)

|                                             | Placebo (n=1651)         | Placebo (n=1651)   | Placebo (n=1651)   | Vorapaxar (n=1622)       | Vorapaxar (n=1622)   | Vorapaxar (n=1622)   |                           |            |
|---------------------------------------------|--------------------------|--------------------|--------------------|--------------------------|----------------------|----------------------|---------------------------|------------|
|                                             | Subjects with Events (%) | KM % a             | Event Rate f       | Subjects with Events (%) | KM% a                | Event rate f         | Hazard Ratio (95% CI) b,c | P- Value c |
| Primary Efficacy Endpoint d                 | 206 (12.5%)              | 12.8%              | 4.6%               | 177(10.9%)               | 11.1%                | 4.0%                 | 0.87 (0.71-1.06)          | 0.167      |
| CV Death                                    | 58 (3.5% )               |                    |                    | 47(2.9%)                 |                      |                      |                           |            |
| MI                                          | 80 (4.8% )               |                    |                    | 76 (4.7%)                |                      |                      |                           |            |
| Stroke                                      | 39 (2.4% )               |                    |                    | 31 (1.9%)                |                      |                      |                           |            |
| Ischemic                                    | 31 (1.9% )               |                    |                    | 22 (1.4%)                |                      |                      |                           |            |
| Haemorrhagic e                              | 5 (0.3% )                |                    |                    | 6 (0.4%)                 |                      |                      |                           |            |
| Uncertain                                   | 3 (0.2% )                |                    |                    | 3 (0.2%)                 |                      |                      |                           |            |
| UCR                                         | 29 (1.8% )               |                    |                    | 23(1.4%)                 |                      |                      |                           |            |
| Key Secondary Efficacy Endpoint d Medicinal | 180 (10.9%)              | 11.1%              | 4.0%               | 156 (9.6%)               | 9.8%                 | 3.5%                 | 0.88 (0.71-1.09)          | 0.229      |
| CV Death                                    | 59 (3.6% )               |                    |                    | 48 (3.0% )               |                      |                      |                           |            |
| MI                                          | 81 (4.9% )               |                    |                    | 77 (4.7% )               |                      |                      |                           |            |
| Stroke                                      | 40 (2.4% )               |                    |                    | 31 (1.9% )               |                      |                      |                           |            |
| Ischemic                                    | 32 (1.9% )               |                    |                    | 22 (1.4% )               |                      |                      |                           |            |
| Haemorrhagic e                              | 5 (0.3% )                |                    |                    | 6 (0.4% )                |                      |                      |                           |            |
| Uncertain                                   | 3 (0.2% )                |                    |                    | 3 (0.2% )                |                      |                      |                           |            |

-PAD stratum In the PAD stratum with no history of stroke or TIA, there was a 13% reduction in the primary efficacy endpoint (HR 0.87; 95% CI 0.71 - 1.06) and a 12% reduction in the composite key secondary endpoint (HR 0.88; 95% CI 0.71 - 1.09) (Table E.4). Table E.4. TRA 2 ° P - TIMI 50 Primary and Key Secondary Composite Efficacy Endpoints and Contributing Components in Subjects With No History of Stroke or TIA Whose Qualifying Condition was PAD: ITT Event Accrual Period: Randomization to Last Visit Medicinal product no longer authorised

a.  Kaplan-Meier estimate at 1080 days

b.  Hazard Ratio is vorapaxar group versus placebo group

c.  Hazard Ratio and P-value were calculated based on Cox PH model with covariates treatment and stratification factors  (qualifying atherosclerotic disease and planned thienopyridine use)

d.  Each patient was counted only once (first component event) in the component summary that contributed to the primary or key secondary efficacy endpoint

e.   Haemorrhagic stroke includes primary intracerebral haemorrhage, non-haemorrhagic infarction with haemorrhagic conversion, and subarachnoid haemorrhage.

f. Annualized Event Rate is expressed as number of patients with events per 100 patient-years of exposure

Note: UCR=recurrent ischemia leading to urgent coronary revascularization; MI=myocardial infarction; CV death=Cardiovascular death

<div style=\"page-break-after: always\"></div>

Figure E.4 . TRA 2 ° P - TIMI 50 Kaplan-Meier Estimate of Time to the First Occurrence of Primary Efficacy Endpoint: in Subjects With No History of Stroke or TIA Whose Qualifying Condition Was PAD: ITT Event Accrual Period: Randomization to Last Visit

<!-- image -->

<!-- image -->

The  results  in  the Clinical  PAD and Aspirin-Only  PAD populations  were  also  consistent  with  the PAD stratum .

Figure E.5 . TRA 2 ° P - TIMI 50 Kaplan-Meier Estimate of Time to the First Occurrence of Key Secondary Efficacy Endpoint in Subjects with No History of Stroke or TIA Whose Qualifying Condition Was PAD: ITT Event Accrual Period: Randomization to Last Visit -Clinical PAD and Aspirin-Only PAD populations Medicinal product no longer authorised

Table  E.5. TRA 2°P - TIMI 50 Primary and Key Secondary Efficacy Endpoints in PAD Event Accrual -Randomization to Last Visit- ITT

| Subjects With Events (%)   | KM% a   | Subjects With Events (%)   | KM% a   | Hazard Ratio (95% CI) b,c   | p-Value c   |
|----------------------------|---------|----------------------------|---------|-----------------------------|-------------|

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Clinical PAD Population d     | Placebo (n=2006)   | Placebo (n=2006)   | Vorapaxar (n=1939)   | Vorapaxar (n=1939)   |                   |       |
|-------------------------------|--------------------|--------------------|----------------------|----------------------|-------------------|-------|
| CV death/MI/stroke/UCR†       | 282                | 14.6%              | 232                  | 12.5%                | 0.84 (0.71- 1.00) | 0.052 |
| CV death/MI/stroke‡           | 240                | 12.4%              | 200                  | 10.7%                | 0.86 (0.71- 1.03) | 0.105 |
| Aspirin Only PAD Population e | Placebo ( n=1053)  | Placebo ( n=1053)  | Vorapaxar ( n=1034)  | Vorapaxar ( n=1034)  |                   |       |
| CV death/MI/stroke/UCR†       | 119                | 11.6%              | 94                   | 9.3%                 | 0.79 (0.60- 1.04) | 0.088 |
| CV death/MI/stroke‡           | 106                | 10.3%              | 87                   | 8.6%                 | 0.82 (0.62- 1.09) | 0.180 |

a. Kaplan-Meier estimate at 1080 days b. Hazard Ratio is vorapaxar group versus placebo group c. Hazard Ratio is calculated based on Cox PH model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use), with the exception for those subgroup variables related to the stratification factors. For subgroup variable of stratification factor, qualifying atherosclerotic disease (or planned thienopyridine use), hazard ratio is calculated from Cox PH model with covariates treatment and the other stratification factor, planned thienopyridine use (or qualifying atherosclerotic disease) d. Subjects With No History of Stroke or TIA Who Were NOT in the CVD Stratum AND Whose Qualifying Condition Was PAD OR (had ABI&lt;= 0.9 with Symptoms~) OR History of Peripheral Arterial Revascularization Symptoms [Fontaine Stage II, III, or IV]) e. Subjects with no history of stroke or TIA whose qualifying condition was PAD who were on aspirin at baseline, and did not plan thienopyridine use during the study † Primary Endpoint ‡ Secondary Endpoint CHMP comments In  the Intended  Label  Population the  results  showed  a  significant  reduction  in  primary  and  key secondary efficacy endpoints by 17% and 20%, respectively compared to placebo with all components (CV deaths, MI, stroke and UCR) contributing almost to the same extent. These findings are similar to those in the previously considered 'Proposed Label Population' (see table below) comprising only CAD patients  with  no  history  of  stroke  ort  TIA,  who  also  represent  the  majority  of  the Intended  Label Population. Medicinal product no longer authorised

TRA 2oP - TIMI 50 Primary and Key Secondary Efficacy Endpoints and Contributing Components With Stroke SubCategories  Included,  in  Subjects  With  No  History  of  Stroke  or  TIA  Whose  Qualifying  Condition  was  CAD  (Event Accrual Period: Randomization to Last Visit) [ 'Proposed Label Population' ]

<div style=\"page-break-after: always\"></div>

|                                               | Placebo (n = 8439)       | Placebo (n = 8439)   | Vorapaxar (n = 8458)     | Vorapaxar (n = 8458)   |                                        |          |
|-----------------------------------------------|--------------------------|----------------------|--------------------------|------------------------|----------------------------------------|----------|
| Endpoint and Contributing Component           | Subjects With Events (%) | KM%                  | Subjects With Events (%) | KM%                    | Hazard Ratio (95% Confidence Interval) | P Valueb |
| Primary EficacyEndpoint                       | 867 (10.3%)              | 11.4%                | 719 (8.5%)               | 9.8%                   | 0.82 (0.74-0.90)                       | <0.001   |
| CV Death                                      | 96 (1.1%)                |                      | 82 (1.0%)                |                        |                                        |          |
| MI                                            | 451 (5.3%)               |                      | 374 (4.4%)               |                        |                                        |          |
| Stroke                                        | 84 (1.0%)                |                      | 60 (0.7%)                |                        |                                        |          |
| Ischemic(Non-Hemorrhagic Cerebral Infarction) | 69 (0.8%)                |                      | 38 (0.4%)                |                        |                                        |          |
| Hemorrhagic Stroke                            | 11 (0.1%)                |                      | 16 (0.2%)                |                        |                                        |          |

In the PAD stratum a similar trend in favour of vorapaxar is also seen in the primary and secondary endpoints but without reaching statistical significance. The same applies also to the Clinical PAD and Aspirin-Only PAD populations . Clearly, the key efficacy results appear very consistent across the different populations, but there are also  some  interesting  qualitative  differences.  Compared  to  the  CAD  population  (as  captured  in  the 'Proposed Label Population', shown in the table above) the rate of CV deaths among PAD patients was almost three times as high and the rate of strokes almost twice as high, while MIs and UCR were less common. Interestingly, while in the CAD population the results were mainly driven by a reduction in MIs,  in  the  PAD  group  it  is  a  reduction  in  CV  mortality  that  appears  to  contribute  more  to  the differences between vorapaxar and placebo. ·  Ancillary analyses Efficacy in Subgroups A wide range of demographic, concurrent baseline medications and other baseline characteristics were examined for their effect on outcome in the different populations. The results in specific subgroups for the primary endpoint are shown in Figures E.6a/b for the Intended Label Population and E.7a/b for the PAD stratum . Medicinal product no longer authorised

## -Intended Label Population

Figure E.6a/b. TRA  2 ° P  -  TIMI  50  Plot  of  Hazard  Ratio  and  95%  CI  for  Primary  Efficacy  Endpoint  in Subjects with No History of Stroke or TIA Whose Qualifying Condition Was CAD or PAD by Subgroup: ITT Population (Randomization to Last Visit)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 0.25 0.5 1 2 Placebo (P) Better SCH530348 (S) Better &gt;=300 mg Renal Insufficiency eGFR &lt;60 ml/min/1.73 m*m eGFR &gt;= 60 ml/min/1.73 m*m History of Diabetes Mellitus Yes No History of Prior Stroke No History of Prior MI Yes No History of Prior ACS Yes No Taking Any Lipid Medication Yes No Taking a Statin at Baseline Yes No 2620 2859 17073 4762 15407 20170 17760 2409 18183 1985 19090 1080 18787 1383 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## -PAD stratum

Figure  E.7a/b. TRA  2 ° P  -  TIMI  50    Plot  of  Hazard  Ratio  (95%  CI)  for  Primary  Efficacy  Endpoint  in Subjects With No History of Stroke or TIA Whose Qualifying Condition was PAD: ITT  Population Event Accrual Period Randomization to Last Visit

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

As  described  above,  vorapaxar  was  associated  with  a  reduction  in  occurrence  of  MIs  from  time  of randomization. This is a landmark analysis (i.e., events occurring after the first ACS event which serves as the 'landmark') of the primary and key secondary endpoints in subjects with ACS during the study for the Intended Label Population .  Such analyses allow for direct examination of subsequent event rates in subjects experiencing an ACS event while on study medication.

CHMP comments In  both  the Intended  Label  Population and PAD  stratum the  treatment  effect  of  vorapaxar  was generally consistent across most subgroups including sex, age, different risk factors and concomitant therapies at baseline including aspirin, thienopyridine and statins. A  subgroup  identified  during  the  initial  MAA  review,  with  uncertain  efficacy  findings  which  are confirmed in the current analyses, were patients weighing &lt;60kg. Due also to some safety concerns, it was considered appropriate to include a warning in the SmPC advising use with caution in patients with a body weight &lt;60 kg. The current subgroup analyses do not provide any significant new information. In  addition  to  the  above,  the  MAH  has  provided  a  number  of  additional  efficacy  analyses  exploring different  aspects  of  the  key  endpoints  in  the Intended Label Population , some of  which  are  shown below: Efficacy Endpoints in Subjects Following an ACS Event Medicinal product no longer authorised

There were 114 more first ACS events in the placebo group than in the vorapaxar group.  The results indicate that in those subjects who had an ACS event during the TRA 2°P - TIMI 50 study, vorapaxar was associated with 16% reduction in the primary endpoint and 20% reduction in the key secondary endpoint in  those  patients  from  the  time  of  the  ACS  event  to  the  end  of  the  study  [Table  E.6].  Therefore, vorapaxar reduced first ACS events and also reduced the rate of the primary and secondary endpoints in subjects following an ACS event.

<div style=\"page-break-after: always\"></div>

Table E.6. TRA  2 ° P  -  TIMI  50  [Landmark  Analysis]  Primary  and  Key  Secondary  Efficacy  Endpoints  in Subjects  with  ACS  During  the  Study  Whose  CEC  Adjudicated  Efficacy  Events  During  the  Study  Met Coronary Ischemic Criteria: ITT Population Subjects with No History of Stroke or TIA Whose Qualifying Condition Was CAD or PAD Event Accrual Period: First ACS to Last Visit

|                              | Placebo ( n=913)         | Vorapaxar (n=799)        |                           |           |
|------------------------------|--------------------------|--------------------------|---------------------------|-----------|
|                              | Subjects with Events (%) | Subjects with Events (%) | Hazard Ratio (95% CI) a,b | P-Value b |
| Since ACS                    |                          |                          |                           |           |
| CV Death / MI / Stroke / UCR | 245 (26.8%)              | 179 (22.4%)              | 0.84 (0.69 - 1.01)        | 0.069     |
| CV Death / MI / Stroke       | 199 (21.8%)              | 139 (17.4%)              | 0.80 (0.64 - 0.99)        | 0.040     |

|                                 | Placebo (n=10090) no   | Vorapaxar n=10080)   | Hazard Ratio (95% CI) a,b   | P- Value b   |
|---------------------------------|------------------------|----------------------|-----------------------------|--------------|
| Primary Efficacy Endpoint       |                        |                      |                             |              |
| Total Events                    | 1420                   | 1174                 | 0.83(0.76-0.89)             | <0.001       |
| Subjects with only one Event    | 832                    | 706                  |                             |              |
| Subjects with two Events        | 181                    | 138                  |                             |              |
| Subjects with >= 3 Events       | 60                     | 52                   |                             |              |
| Key Secondary Efficacy Endpoint | product                |                      |                             |              |
| Total Events                    | 1090                   | 894                  | 0.82 (0.75-0.89)            | <0.001       |
| Subjects with only one Event    | 684                    | 544                  |                             |              |
| Subjects with two Events        | 125                    | 106                  |                             |              |
| Subjects with >= 3 Events       | 42                     | 38                   |                             |              |

CV death = Cardiovascular death

Multiple Occurrences of Adjudicated Endpoints Table  E.7  below  shows  total  events  (including  first  and  recurrent  events)  for  both  primary  and  key secondary  composite  endpoints  compared  to  the  subjects  in  the  placebo  group  in  the  Intended  Label Population. Vorapaxar was associated with a significant reduction in total events defined in the primary efficacy endpoint (HR 0.83; 95% CI 0.76-0.89).  A similar result was observed for the reduction of total events defined in the secondary efficacy endpoint. Table E.7. TRA 2 ° P - TIMI 50 Analysis of Multiple Occurrences of Adjudicated Primary and Secondary Composite  Endpoint  Component  Events  in  CAD  or  PAD  Subjects  with  no  History  of  Stroke  or  TIA  ITT Population Event Accrual Period: Randomization to Last Visit a. Hazard Ratio is vorapaxar group versus placebo group b. Hazard Ratio and P-value were calculated based on Andersen-Gill model with covariates treatment and stratification factor (qualifying atherosclerotic disease and planned thienopyridine use). Note: UCR = recurrent ischemia leading to urgent coronary revascularization; MI = myocardial infarction; Multiple Occurrences of MI in Efficacy Endpoints Table  E.8  below  shows  total  MI  events  (first  and  subsequent)  in  the Intended  Label  Population with vorapaxar versus placebo (HR 0.83; 95% CI 0.75-0.93). These results suggest that vorapaxar in addition to standard of care, reduced the total number of MI events in the Intended Label Population. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table E.8. TRA 2 ° P - TIMI 50 Analysis of Multiple Occurrences of MI in Efficacy Endpoints in Subjects with  No  History  of  Stroke  or  TIA  Whose  Qualifying  Condition  Was  CAD  or  PAD:  ITT  Population  Event Accrual Period: Randomization to Last Visit

|                                                                                                                                                                                                                                                                                            | Placebo (n=10090)                                                                                                                                                                                                                                                                          | Vorapaxar n=10080)                                                                                                                                                                                                                                                                         | Hazard Ratio (95% CI) a,b                                                                                                                                                                                                                                                                  | P- Value b                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Efficacy Endpoint - MI                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                            |
| Total Events                                                                                                                                                                                                                                                                               | 699                                                                                                                                                                                                                                                                                        | 585                                                                                                                                                                                                                                                                                        | 0.83 (0.75 - 0.93)                                                                                                                                                                                                                                                                         | 0.001                                                                                                                                                                                                                                                                                      |
| Subjects with only one Event                                                                                                                                                                                                                                                               | 482                                                                                                                                                                                                                                                                                        | 398                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                            |
| Subjects with two Events                                                                                                                                                                                                                                                                   | 61                                                                                                                                                                                                                                                                                         | 46                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                            |
| Subjects with >= 3 Events                                                                                                                                                                                                                                                                  | 26                                                                                                                                                                                                                                                                                         | 26                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                            |
| a. Hazard Ratio is vorapaxar group versus placebo group b. Hazard Ratio and P-value were calculated based on Andersen-Gill model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use) Note: MI = myocardial infarction | a. Hazard Ratio is vorapaxar group versus placebo group b. Hazard Ratio and P-value were calculated based on Andersen-Gill model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use) Note: MI = myocardial infarction | a. Hazard Ratio is vorapaxar group versus placebo group b. Hazard Ratio and P-value were calculated based on Andersen-Gill model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use) Note: MI = myocardial infarction | a. Hazard Ratio is vorapaxar group versus placebo group b. Hazard Ratio and P-value were calculated based on Andersen-Gill model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use) Note: MI = myocardial infarction | a. Hazard Ratio is vorapaxar group versus placebo group b. Hazard Ratio and P-value were calculated based on Andersen-Gill model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use) Note: MI = myocardial infarction |

| Title : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Vorapaxar (SCH 530348) in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2ºP-TIMI 50) longer   | Title : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Vorapaxar (SCH 530348) in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2ºP-TIMI 50) longer                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                   | Protocol No. P04737                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                                                                                                                                             | A multicenter, international, randomized, double-blind, placebo-controlled, balanced-parallel-groups, events-driven investigation of orally administered vorapaxar in the secondary prevention of ischemic events in patients with a history of atherosclerotic disease no                                                                                                                                                                                                       |
| Hypothesis                                                                                                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Primary objective                                                                                                                                                                                                                                                                                                                                  | The primary objective was to evaluate the hypothesis that vorapaxar added to standard of care will reduce the incidence of atherothrombotic ischemic events relative to standard of care alone, as measured by the composite of cardiovascular (CV) death, myocardial infarction (MI), stroke, and urgent coronary revascularization (UCR) in subjects with established coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral artery disease (PAD) product |
| Treatments groups                                                                                                                                                                                                                                                                                                                                  | 26,449 patients received randomized treatment: 13,224 placebo and 13,225 vorapaxar (Intent to Treat population; ITT) Subjects were enrolled in one of three strata: 17,779 subjects with CAD; 4,883 with CVD; 3,787 with PAD                                                                                                                                                                                                                                                     |

a. Hazard Ratio is vorapaxar group versus placebo group b. Hazard Ratio and P-value were calculated based on Andersen-Gill model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use) ·  Summary of main efficacy results The  following  table  summarises  the  efficacy  results  from  the  main  study  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections). Table E.9 . Summary of efficacy for trial TRA 2 ° P - TIMI 50 Title : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy  of  Vorapaxar  (SCH  530348) in  Addition  to Standard  of  Care  in  Subjects  With  a  History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2ºP-TIMI 50) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                                       | Following DSMB advice all subjects with a stroke either prior to or during the study discontinued study medication (due to an increased number of intracranial haemorrhages (ICH) reported in subjects with a prior history of stroke). Subjects with MI and PAD who had a stroke also discontinued treatment but continued their follow-up visits. Patients also with a history of TIA should were not included in the analyses as it is clinically difficult to distinguish between history of TIA or stroke. This led to the further restriction of the population to subjects with no history of stroke or TIA Data from subjects in the remaining two strata (CAD and PAD) were reviewed in the following populations of interest: • 'Intended Label Population ' (n=20,170): subjects whose qualifying condition was CAD or PAD with no history of stroke or TIA. • PAD stratum and no history of stroke or TIA (n=3,273): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry • 'Clinical PAD Population' (n=3,945): subjects with no history of stroke or TIA with PAD; or baseline ABI ≤0.90 and Fontaine category >1; or history of peripheral arterial revascularization • 'Aspirin-Only PAD Population' (n=2,087): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry and had aspirin at baseline with no planned use of a thienopyridine Note: results below are presented for the ' Intended Label Population ' and authorised   | Following DSMB advice all subjects with a stroke either prior to or during the study discontinued study medication (due to an increased number of intracranial haemorrhages (ICH) reported in subjects with a prior history of stroke). Subjects with MI and PAD who had a stroke also discontinued treatment but continued their follow-up visits. Patients also with a history of TIA should were not included in the analyses as it is clinically difficult to distinguish between history of TIA or stroke. This led to the further restriction of the population to subjects with no history of stroke or TIA Data from subjects in the remaining two strata (CAD and PAD) were reviewed in the following populations of interest: • 'Intended Label Population ' (n=20,170): subjects whose qualifying condition was CAD or PAD with no history of stroke or TIA. • PAD stratum and no history of stroke or TIA (n=3,273): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry • 'Clinical PAD Population' (n=3,945): subjects with no history of stroke or TIA with PAD; or baseline ABI ≤0.90 and Fontaine category >1; or history of peripheral arterial revascularization • 'Aspirin-Only PAD Population' (n=2,087): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry and had aspirin at baseline with no planned use of a thienopyridine Note: results below are presented for the ' Intended Label Population ' and authorised   | Following DSMB advice all subjects with a stroke either prior to or during the study discontinued study medication (due to an increased number of intracranial haemorrhages (ICH) reported in subjects with a prior history of stroke). Subjects with MI and PAD who had a stroke also discontinued treatment but continued their follow-up visits. Patients also with a history of TIA should were not included in the analyses as it is clinically difficult to distinguish between history of TIA or stroke. This led to the further restriction of the population to subjects with no history of stroke or TIA Data from subjects in the remaining two strata (CAD and PAD) were reviewed in the following populations of interest: • 'Intended Label Population ' (n=20,170): subjects whose qualifying condition was CAD or PAD with no history of stroke or TIA. • PAD stratum and no history of stroke or TIA (n=3,273): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry • 'Clinical PAD Population' (n=3,945): subjects with no history of stroke or TIA with PAD; or baseline ABI ≤0.90 and Fontaine category >1; or history of peripheral arterial revascularization • 'Aspirin-Only PAD Population' (n=2,087): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry and had aspirin at baseline with no planned use of a thienopyridine Note: results below are presented for the ' Intended Label Population ' and authorised   | Following DSMB advice all subjects with a stroke either prior to or during the study discontinued study medication (due to an increased number of intracranial haemorrhages (ICH) reported in subjects with a prior history of stroke). Subjects with MI and PAD who had a stroke also discontinued treatment but continued their follow-up visits. Patients also with a history of TIA should were not included in the analyses as it is clinically difficult to distinguish between history of TIA or stroke. This led to the further restriction of the population to subjects with no history of stroke or TIA Data from subjects in the remaining two strata (CAD and PAD) were reviewed in the following populations of interest: • 'Intended Label Population ' (n=20,170): subjects whose qualifying condition was CAD or PAD with no history of stroke or TIA. • PAD stratum and no history of stroke or TIA (n=3,273): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry • 'Clinical PAD Population' (n=3,945): subjects with no history of stroke or TIA with PAD; or baseline ABI ≤0.90 and Fontaine category >1; or history of peripheral arterial revascularization • 'Aspirin-Only PAD Population' (n=2,087): subjects with no history of stroke or TIA whose qualifying condition was PAD at entry and had aspirin at baseline with no planned use of a thienopyridine Note: results below are presented for the ' Intended Label Population ' and authorised   |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Duration of the study                                                 | ' PAD stratum and no history Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ' PAD stratum and no history Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | of stroke or TIA' only Median (participation in the study): 905 days for placebo; 906 days for vorapaxar not applicable longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | of stroke or TIA' only Median (participation in the study): 905 days for placebo; 906 days for vorapaxar not applicable longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                             | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Composite of CV death, MI, stroke or UCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Composite of CV death, MI, stroke or UCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Composite of CV death, MI, stroke or UCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                             | Key Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Composite of CV death, MI or stroke                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Composite of CV death, MI or stroke                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Composite of CV death, MI or stroke                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                                             | Other Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | - Different composite endpoints with combinations of all- cause death, MI, stroke, and urgent coronary revascularization, any revascularization. - The individual components of the composite primary efficacy endpoint: a. cardiovascular death, b. MI, c. stroke, d. UCR, - All-cause death no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | - Different composite endpoints with combinations of all- cause death, MI, stroke, and urgent coronary revascularization, any revascularization. - The individual components of the composite primary efficacy endpoint: a. cardiovascular death, b. MI, c. stroke, d. UCR, - All-cause death no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | - Different composite endpoints with combinations of all- cause death, MI, stroke, and urgent coronary revascularization, any revascularization. - The individual components of the composite primary efficacy endpoint: a. cardiovascular death, b. MI, c. stroke, d. UCR, - All-cause death no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Database lock 09 January 2012                                         | Database lock 09 January 2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Database lock 09 January 2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Database lock 09 January 2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Database lock 09 January 2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Results and Analysis product                                          | Results and Analysis product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description Primary Analysis                                 | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Analysis description Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Analysis population and time point description Descriptive statistics | Intent to treat; Randomization to Last Visit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Intent to treat; Randomization to Last Visit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Intent to treat; Randomization to Last Visit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Intent to treat; Randomization to Last Visit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| and estimate variability Medicinal                                    | Intended Label Population Stroke 123                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 91                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (0.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                                       | Placebo Vorapaxar                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo Vorapaxar                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo Vorapaxar                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo Vorapaxar                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                       | Number of subject (n=10090) (n=10080) Primary Efficacy Endpoint 1073 (10.6%); 11.8% 896 (8.9%);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Number of subject (n=10090) (n=10080) Primary Efficacy Endpoint 1073 (10.6%); 11.8% 896 (8.9%);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Number of subject (n=10090) (n=10080) Primary Efficacy Endpoint 1073 (10.6%); 11.8% 896 (8.9%);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Number of subject (n=10090) (n=10080) Primary Efficacy Endpoint 1073 (10.6%); 11.8% 896 (8.9%);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                       | (Events %; KM%*) 10.1% CV Death MI 154 (1.5%) 531 (5.3%) 129 (1.3%) 450 (4.5%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (Events %; KM%*) 10.1% CV Death MI 154 (1.5%) 531 (5.3%) 129 (1.3%) 450 (4.5%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (Events %; KM%*) 10.1% CV Death MI 154 (1.5%) 531 (5.3%) 129 (1.3%) 450 (4.5%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (Events %; KM%*) 10.1% CV Death MI 154 (1.5%) 531 (5.3%) 129 (1.3%) 450 (4.5%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                       | Number of subject (n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Number of subject (n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | =1651)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (n =1622)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                       | Primary Efficacy Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Primary Efficacy Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 206 (12.5%); 12.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 177 (10.9%);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                       | Key Secondary Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Key Secondary Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 851 (8.4%); 9.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 688 (6.8%);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 226 (2.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                       | UCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | UCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                       | (Events %; KM%*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (Events %; KM%*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 265 (2.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                       | 7.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 7.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 7.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 7.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                       | PAD Stratum and no history of stroke or TIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | PAD Stratum and no history of stroke or TIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | PAD Stratum and no history of stroke or TIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | PAD Stratum and no history of stroke or TIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                       | (Events %; KM%*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (Events %; KM%*)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                | CV Death MI Stroke UCR                  | CV Death MI Stroke UCR                      | 58 (3.5%) 80 (4.8%) 39 (2.4%) 29 (1.8%)     | 58 (3.5%) 80 (4.8%) 39 (2.4%) 29 (1.8%)     | 47 (2.9%) 76 (4.7%) 31 (1.9%) 23 (1.4%)     |
|--------------------------------|-----------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                | Key Secondary Endpoint (Events %; KM%*) | Key Secondary Endpoint (Events %; KM%*)     | 180 (10.9%); 11.1%                          | 180 (10.9%); 11.1%                          | 156 (9.6% ); 9.8%                           |
| Effect estimate per comparison |                                         | Intended Label Population                   | Intended Label Population                   | Intended Label Population                   | Intended Label Population                   |
| Effect estimate per comparison |                                         | Hazard Ratio (95% CI)                       | Hazard Ratio (95% CI)                       | 0.83 (0.76 - 0.90)                          | 0.83 (0.76 - 0.90)                          |
| Effect estimate per comparison |                                         | P-value                                     | P-value                                     | <0.001                                      | <0.001                                      |
| Effect estimate per comparison |                                         | PAD Stratum and no history of stroke or TIA | PAD Stratum and no history of stroke or TIA | PAD Stratum and no history of stroke or TIA | PAD Stratum and no history of stroke or TIA |
| Effect estimate per comparison |                                         | Hazard Ratio (95% CI)                       | Hazard Ratio (95% CI)                       | 0.87 (0.71 - 1.06)                          | 0.87 (0.71 - 1.06)                          |
| Effect estimate per comparison |                                         | P-value                                     | P-value                                     | 0.167                                       | 0.167                                       |
| Effect estimate per comparison | Key Secondary Endpoint                  | Intended Label Population                   | Intended Label Population                   | Intended Label Population                   |                                             |
| Effect estimate per comparison | Key Secondary Endpoint                  | Hazard Ratio (95% CI)                       | Hazard Ratio (95% CI)                       | 0.80 (0.73 - 0.89)                          | 0.80 (0.73 - 0.89)                          |
| Effect estimate per comparison | Key Secondary Endpoint                  | P-value                                     | P-value                                     | <0.001                                      | <0.001                                      |
| Effect estimate per comparison | Key Secondary Endpoint                  | PAD Stratum and no history of stroke or TIA | PAD Stratum and no history of stroke or TIA | PAD Stratum and no history of stroke or TIA | PAD Stratum and no history of stroke or TIA |
| Effect estimate per comparison | Key Secondary Endpoint                  | Hazard Ratio (95% CI)                       | Hazard Ratio (95% CI)                       | 0.88 (0.71 - 1.09)                          | 0.88 (0.71 - 1.09)                          |
| Effect estimate per comparison | Key Secondary Endpoint                  | P-value                                     | P-value                                     | 0.229                                       | 0.229                                       |

*3-year Kaplan-Meier event rate 2.5.3. Discussion on clinical efficacy Design and conduct of clinical studies The current variation application is based entirely on the same pivotal trial TRA 2P - TIMI 50 (P04737) which supported the initial MAA for patients with a history of myocardial infarction. TRA 2P - TIMI 50 was a large trial in 26,449 patients with evidence of atherosclerosis from three categories: cerebral, coronary or  peripheral  disease,  examined  as  three  separate  strata.  After  the  discontinuation  of  patients  with cerebrovascular disease, only patients with established CAD and PAD remained in the study. Patients were randomized to vorapaxar and placebo and were followed-up for more than two years. The primary  objective was  to evaluate the hypothesis that vorapaxar  can  reduce  the  incidence  of atherothrombotic  events  compared  to  standard  of  care  alone,  as  assessed  by  the  composite  of cardiovascular  death,  myocardial  infarction,  stroke,  and  urgent  coronary  revascularization.  The  overall methodology and specific aspects of TRA 2P - TIMI 50 were considered in detail during the initial review and are not repeated again here as there are no new issues or significant new information. In  the  previous  review,  only  the  results  in  the  CAD  stratum  (recent  MI)  were  considered  in  the benefit:risk analysis which resulted in the currently licensed indication. To support the extension of the indication to PAD patients, the MAH has submitted, as pivotal data, the results in the combined CAD and PAD strata i.e. patients presenting with CAD or PAD but with no history of stroke or TIA, the so-called Intended Label Population . Still, the majority of the Intended Label Population are primarily patients with CAD  (~84%)  with  the  PAD  group  representing  a  small  percentage  (~16%)  of  the  pooled  population. Nonetheless, analyses have also been provided separately for the PAD population alone ( PAD stratum ). Efficacy data and additional analyses Medicinal product no longer authorised

A total of 20,170 subjects from the combined CAD/PAD strata were pooled together in the Intended Label Population that mainly included white (88.6%) males (78.3%), most of them &lt; 65 years of age (66.6%) with cardiovascular comorbidities: high prevalence of hypertension (64.9%) and hyperlipidaemia (84.9%) and  a  significant  percentage  of  diabetics  (23.9%).  However,  when  isolating  the  PAD  population  ( PAD stratum ) it appears that compared with their CAD counterparts, PAD patients were older (PAD: median 66yrs vs CAD: median 58 years), they had a higher prevalence of diabetes (PAD: average 34.8% vs CAD: average  21.4%),  as  well  as  a  higher  rate  of  renal  impairment.  Also  in  terms  of  background  therapy, although in the CAD population the use of aspirin was almost universal, in PAD a percentage of patients

<div style=\"page-break-after: always\"></div>

were receiving clopidogrel instead of aspirin as a sole antiplatelet. Also dual antiplatelet therapy in CAD patients was very common (more than 75%) but not so much (around 34%) among PAD patients. Still, across all populations, the treatment groups (vorapaxar and placebo) were well balanced in terms of key characteristics, risk factors and background therapies.

In the Intended Label Population the efficacy results showed a significant effect of active therapy on the primary  efficacy  composite  endpoint  with  a  3-year  KM  event  rate  of  10.1%  in  the  vorapaxar  group compared to 11.8% in the placebo group (HR; 0.83; 95% CI 0.76-0.90, P&lt;0.001) and all components of the  composite  showing  a  decrease  with  vorapaxar  (although  there  was  an  unfavourable  trend  in haemorrhagic strokes).

In the PAD population alone ( PAD stratum )  the  results  were consistent with Intended Label Population showing a 3-year KM event rate of 11.1% in the vorapaxar group compared to 12.8% in the placebo group  but  without  reaching  statistical  significance  (HR;  0.87;  95%  CI  0.71-1.06,  P&lt;0.167).  Still,  all individual  components  showed  again  a  consistent  trend  in  favour  of  vorapaxar.  Of  interest,  when comparing the findings in the PAD group with CAD patients, it appears that in general PAD patients in TRA  2ºP-TIMI  50  were  at  notably  higher  risk  of  CV  death  as  well  as  stroke  (while  MIs  and  urgent revascularisation  were  more  common  in  the  CAD  stratum).  In  the  same  context,  in  the  PAD  group  a reduction in CV mortality was found to have contributed most to the difference between vorapaxar and placebo whereas in the CAD stratum the results were mainly driven by a reduction in MIs. Similar results were also observed in the other two analyses: the Clinical PAD Population which further to patients  in  the  PAD  stratum  examined  also  those  who,  although  classified  in  the  CAD  stratum,  had evidence of PAD; and the Aspirin-Only  PAD  Population which  included  PAD  patients  who  were  only  on aspirin  and  are  thought  to  represent  better  the  'Guideline-recommended'  conditions  (in  terms  of antiplatelet therapy). With  regard  to  subgroups  or  other  analyses  the  results  were  in  general  consistent  with  the  primary findings  and  there  is  no  significant  new  information  over  and  above  what  was  assessed  during  the previous TRA 2P - TIMI 50 review, including the treatment effect in patients weighing &lt;60Kg or efficacy differences  in  relation  to  other  concomitant  therapies.  The  approved  SmPC  already  includes  relevant information which is generally adequate. Overall, the efficacy results across all populations comprising patients with PAD showed a clear consistent trend in favour of vorapaxar. However, only in the Intended Label Population, where post-MI and PAD patients were examined together as a single group the differences between treatments reached statistical significance.  In  the  other  analyses,  when  PAD  patients  were  studied  alone,  there  were  no  significant differences  between  vorapaxar  and  placebo.  This  could  be  explained by  an  insufficient  number  of  PAD patients.  Nonetheless,  the  evidence  in  favour  of  vorapaxar  in  PAD  patients  and  the  significance  of  the vorapaxar treatment effect depends on the validity of the claim that PAD and post-MI patients can be considered  as  one  group,  based  on  the  common  atherosclerotic  background.  As  discussed  above, although some of the arguments are valid, differences between the two populations in terms of the shortand  longer-term  risks,  concomitant  therapies  (including  revascularisation  and  other  interventions)  and natural  history  of  the  disease  cast  some  doubts  on  the  notion  that  this  is  a  sufficiently  homogenous population to permit conclusions for either patient group based on a single pooled analysis. However, in response, the MAH provided some further information and arguments suggesting that PAD patients may benefit to a similar degree as post-MI patients but the smaller population does not permit a more robust analysis.  A  calculation  of  the  treatment-stratum  interaction  significance  levels  for  the  primary  and  key secondary endpoints indicated no significant heterogeneity. Medicinal product no longer authorised

In addition, it is noted that almost all PAD patients included in TRA 2ºP-TIMI 50 were symptomatic. The clinical  guidelines  make  a  relevant  distinction,  recommending  antiplatelet  therapy  first  to  symptomatic patients  (higher  level  of  evidence  in  both  ESC  and  AHA  guidelines).  Also  in  CHARISMA  trial  there  was

<div style=\"page-break-after: always\"></div>

some  indication  that  symptomatic  patients  might  benefit  more  than  asymptomatic.  The  efficacy  of vorapaxar  in  asymptomatic  patients  is  uncertain;  therefore,  vorapaxar  treatment  should  be  limited  to symptomatic PAD patients only.

Further to the efficacy results, there are also some points related to the initially proposed SmPC changes which deserve further consideration. They concern  specific SmPC amendments aiming at incorporating the new wording related to PAD patients into the existing text that currently applies to CAD patients only. This led to alterations to the advice for post-MI patients that cannot be justified by the available data. For example, for section 4.1 it was initially proposed to amend the text to advise 'Zontivity, co-administered with  acetylsalicylic  acid  (ASA)  and/or,  where  appropriate,  clopidogrel,  is  indicated  for  the  reduction  of atherothrombotic events in adult patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD)'. This means in practice that also patients with history of MI can be treated with either aspirin or clopidogrel,  which  goes  against  the  previous  CHMP  decision  for  MI  patients.  No justification was provided to support this change. The need for background aspirin therapy in all post-MI patients, complemented by clopidogrel as appropriate, was established in the previous review. However, in PAD patients concomitant therapy with either aspirin or clopidogrel may be adequate (although most patients were on aspirin) and can possibly be supported by the TRA 2ºP-TIMI 50 results (depending also on safety; see below). Upon CHMP request, the MAH updated the SmPC wording to include information about PAD patients separately, so that the new proposal does not affect the current recommendations for MI patients. 2.5.4. Conclusions on the clinical efficacy The  efficacy  results  showed  a  positive  trend  for  vorapaxar  in  most  endpoints  and  subgroups  in  the primary  and  secondary  analyses  but  did  not  reach  statistical  significance  when  PAD  patients  were examined as a distinct group. However, the TRA 2ºP-TIMI 50 efficacy results showed a clear consistency across  all  endpoints  and  populations,  with  the  findings  in  PAD  patients  showing  a  trend  in  favour  of vorapaxar similar to their CAD counterparts which suggests that PAD patients may benefit from therapy to a similar degree as post-MI patients. The amendment of the indication to include symptomatic patients with PAD is acceptable. 2.6. Clinical safety Introduction The safety of vorapaxar was evaluated in 19,632 subjects receiving the drug in the Phase 3 development program (13,186 subjects in TRA 2°P-TIMI 50 and 6,446 in TRACER trial in ACS patients).  Of the 13,186 subjects exposed in TRA 2°P-TIMI 50, 2,187 received vorapaxar for more than 3 years. Safety evaluations and bleeding analyses in TRA 2°P-TIMI were performed in the As-Treated population (all  subjects  who  received  at  least  one  dose  of  study  medication).    Safety  assessments  included  prespecified  bleeding  endpoints,  reported  individual  bleeding  events,  adverse  events  by  other  categories (serious and treatment related), clinical laboratory evaluations, vital signs, and electrocardiograms. Medicinal product no longer authorised

Bleeding risk was considered the major potential safety concern. All bleeding events reported throughout the trial were adjudicated by the CEC to determine if each event met the criteria for the pre-specified study  bleeding  endpoints  as  defined  as:  (1)  a  composite  of  moderate  or  severe  GUSTO  bleeding  and (2)\"clinically significant bleeding\". GUSTO severe bleeding was defined as fatal, intracranial, or bleeding with  hemodynamic  compromise  requiring  intervention.    GUSTO  moderate  bleeding  was  defined  as bleeding requiring transfusion of whole  blood  or packed  red blood cells  without  hemodynamic compromise. Clinically significant  bleeding  was  defined  as  Thrombolysis in  Myocardial  Infarction  (TIMI) major or minor bleeding or bleeding that required treatment or laboratory evaluation.

<div style=\"page-break-after: always\"></div>

GUSTO severe is the bleeding category most likely  to be  associated  with  irreversible  damage.  GUSTO moderate  bleeding  required  the  presence  of  a  transfusion  without  haemodynamic  instability.  The protocols  did  not  specify  criteria  for  transfusion.  Thus  GUSTO  moderate  bleeding  was  subject  to potentially  varying  standards.    Recent  literature  support  greater  emphasis  on  the  incidence  of  GUSTO severe bleeding as it most accurately portrays the overall long-term risk of an antiplatelet agent.

It was recommended that subjects continue study treatment during the time of surgery (CABG or other). CABG related fatal bleeding is defined as death that occurred within 7 days among subjects with CABG related bleeding. CABG-related bleeding constitutes a provocative test for assessing surgical bleeding with antithrombotic agents.  TIMI CABG major bleeding is the most specific and objective measurement of surgical bleeding risk associated with CABG.

|                                       | Placebo      | Vorapaxar    |
|---------------------------------------|--------------|--------------|
| Variable                              | (n=10049)    | (n=10059)    |
| Participation: Number (%) of Subjects |              |              |
| Any Participation                     | 10049 (99.6) | 10059 (99.8) |
| ≥ 30 Days                             | 9820 (97.3)  | 9800 (97.2)  |
| ≥ 90 Days                             | 9578 (94.9)  | 9535 (94.6)  |
| ≥ 180 Days                            | 9264 (91.8)  | 922 7(91.5)  |
| ≥ 360 Days                            | 8890 (88.1)  | 8851 (87.8)  |
| ≥ 540 Days                            | 8558 (84.8)  | 8479 (84.1)  |
| ≥ 720 Days                            | 7019 (69.6)  | 6884 (68.3)  |
| ≥ 900 Days                            | 4833 (47.9)  | 473 0(46.9)  |

TIMI major CABG-related bleeding was pre-defined and adjudicated, in accordance with the CEC charter as any haemorrhage that met any of the following criteria: · Fatal bleeding (i.e., bleeding that directly results in death), or · Peri-operative intracranial bleeding, or · Re-operation following closure of the sternotomy incision for the purpose of controlling bleeding, or · Transfusion of ≥5 units of whole blood or PRBCs within a 48 hour period, or · Chest tube output &gt;2 L within a 24 hour period. As such, TIMI major CABG-related bleeding is the appropriate categorization for assessment of bleeding events due to CABG. Transfusions and re-operations, as well as the volume of chest tube drainage, was captured in the electronic case report forms to facilitate evaluation of the outcome of the bleeding events. CHMP comments The key aspects of the safety evaluation in TRA 2ºP-TIMI 50 were discussed in detail during the initial MAA review. As previously concluded, the general plan for integrating and presenting the key safety data of the TRA 2°P-TIMI 50 trial is acceptable. Patient exposure From the entire TRA 2°P-TIMI 50 population, in total 13,186 subjects received vorapaxar. In the Overall population (all strata), subjects randomized to vorapaxar received treatment for a median of 823 days with a range up to 1461 days. More than 76% of the subjects were on treatment for at least 2 years (720 days) and the median duration of treatment was 2.5 years (823 days for vorapaxar and 826 days for placebo). In  the Intended  Label  Population ,  10,059  subjects  received  at  least  one  dose  of  active  treatment which accounts for 76% of the overall TRA 2°P-TIMI 50 population exposed to vorapaxar. The duration of treatment and compliance are shown in Tables S.1 and S.2. Table S.1. TRA 2 ° P - TIMI 50:  Duration of Participation in Treatment Number (%) of Subjects With No History of Stroke or TIA Whose Qualifying Conditions Was CAD or PAD:  All Randomized Subjects Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                         | Placebo        | Vorapaxar      |
|-----------------------------------------|----------------|----------------|
| Variable                                | (n=10049)      | (n=10059)      |
| ≥ 1080Days                              | 2144 (21.2)    | 2103 (20.9)    |
| Randomized, Not treated                 | 41 (0.4)       | 21 (0.2)       |
| Summary Statistics (Duration in Days) a |                |                |
| Number of Subjects                      | 10049          | 10059          |
| Mean Participation (days)               | 831.1          | 820.3          |
| Standard Deviation                      | 321.90         | 326.21         |
| Median Participation (days)             | 894.0          | 891.0          |
| 25th to 75th Percentile (days)          | 702.0 - 1071.0 | 694.0 - 1069.0 |
| Minimum Participation (days)            | 1              | 1              |
| Maximum Participation (days)            | 1461           | 1461           |

|                  | Placebo        | Vorapaxar          |
|------------------|----------------|--------------------|
| Any Exposure     | 10049 (100)    | 10059 (100) longer |
| <= 10%           | 4 (<.1)        | 0                  |
| >10 - 20%        | 3 (<.1)        | 2 (<.1)            |
| >20 - 30%        | 5 (<.1)        | 6 (0.1)            |
| >30 - 40%        | 8 (0.1)        | 12 (0.1)           |
| >40 - 50%        | 19 (0.2)       | 28 (0.3)           |
| >50 - 60%        | 30 (0.3)       | 37 (0.4)           |
| >60 - 70%        | 61 (0.6)       | 73 (0.7)           |
| >70 - 80%        | 189 (1.9)      | 217 (2.2)          |
| >80 - 90%        | 632 (6.3)      | 608 (6.0)          |
| > 90%            | 8947 (89.0) no | 8894 (88.4)        |
| Replacement a    | 149 (1.5)      | 181 (1.8)          |
| Undeterminable b | 2 (<.1)        | 1 (<.1)            |

|                                         | Placebo    | Vorapaxar   |
|-----------------------------------------|------------|-------------|
| Variable                                | (n=1651)   | (n=1622)    |
| Participation: Number (%) of Subjects   |            |             |
| Any Participation                       | 1637(99.2) | 1615(99.6)  |
| ≥ 30 Days                               | 1591(96.4) | 1564(96.4)  |
| ≥ 90 Days                               | 1547(93.7) | 1510(93.1)  |
| ≥ 180 Days                              | 1479(89.6) | 1440(88.8)  |
| ≥ 360 Days                              | 1403(85.0) | 1368(84.3)  |
| ≥ 540 Days                              | 1340(81.2) | 1281(79.0)  |
| ≥ 720 Days                              | 1276(77.3) | 1209(74.5)  |
| ≥ 900 Days                              | 1158(70.1) | 1118(68.9)  |
| ≥ 1080Days                              | 561(34.0)  | 538(33.2)   |
| Randomized, Not treated                 | 14 (0.8)   | 7 (0.4)     |
| Summary Statistics (Duration in Days) a |            |             |
| Number of Subjects                      | 1637       | 1615        |
| Mean Participation (days)               | 896.8      | 871.5       |

Note: \"Duration of Participation in Treatment\" is the interval from date of randomized treatment  assignment  to  date  of  last  dose,  without  regard  to  intervening  days  or intervals when a dose was not taken. For subjects with a partial date of last dose, date of last dose is estimated a. Does not include subjects who received randomized treatment assignment but were not treated Table S.2 .  TRA 2 ° P - TIMI 50:  Compliance to Treatment: Number (%) of Subjects of Subjects With No History of Stroke or TIA Whose Qualifying Conditions Was CAD or PAD a.  Extent  of  exposure  for  subjects  who  were  assigned  replacement kit(s) could not be determined. b. When Total Dispensed Quantity &lt; Total Returned Quantity. Patient exposure in terms of duration and compliance in the PAD stratum is shown in Tables S.3 and S.4 below. Table S.3. TRA 2 ° P - TIMI 50:  Duration of Participation in Treatment Number (%) of Subjects With No History of Stroke or TIA Whose Qualifying Conditions Was PAD:  All Randomized Subjects Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                | Placebo        | Vorapaxar      |
|--------------------------------|----------------|----------------|
| Variable                       | (n=1651)       | (n=1622)       |
| Standard Deviation             | 362.88         | 375.07         |
| Median Participation (days)    | 1018.0         | 1002.0         |
| 25th to 75th Percentile (days) | 789.0 - 1134.0 | 715.0 - 1107.0 |
| Minimum Participation (days)   | 1              | 1              |
| Maximum Participation (days)   | 1427           | 1446           |

Note: \"Duration of Participation in Treatment\" is the interval from date of randomized treatment  assignment  to  date  of  last  dose,  without  regard  to  intervening  days  or intervals when a dose was not taken. For subjects with a partial date of last dose, date of last dose is estimated

a. Does not include subjects who received randomized treatment assignment but were not treated

|               | Placebo     | Vorapaxar       |
|---------------|-------------|-----------------|
| Any Exposure  | 1637 (100)  | 1615 (100)      |
| <= 10%        | 2 (0.1)     | 0               |
| >10 - 20 %    | 0           | 0               |
| >20 - 30 %    | 1 (0.1)     | 0               |
| >30 - 40 %    | 2 (0.1)     | 4 (0.2)         |
| >40 - 50 %    | 3 (0.2)     | 7 (0.4)         |
| >50 - 60 %    | 5 (0.3)     | 5 (0.3)         |
| >60 - 70 %    | 9 (0.5)     | 14 (0.9)        |
| >70 - 80 %    | 34 (2.1)    | 37 (2.3)        |
| >80 - 90 %    | 104 (6.4)   | 122 (7.6)       |
| > 90%         | 1452 (88.7) | 1398 (86.6)     |
| Replacement a | 25 (1.5)    | 28 (1.7) longer |

## BLEEDING

Table S.4. TRA 2 ° P - TIMI 50:  Compliance to Treatment: Number (%) of Subjects of Subjects With No History of Stroke or TIA Whose Qualifying Conditions Was PAD Any Exposure &lt;= 10 % &gt;10 - 20 % &gt;20 - 30 % &gt;30 - 40 % &gt;40 - 50 % &gt;50 - 60 % &gt;60 - 70 % &gt;70 - 80 % &gt;80 - 90 % &gt; 90 % Replacement Note:  \"Extent  of  Exposure\"  is  an  estimate  based  on  total  tablets  dispensed  -  total tablets returned, divided by duration of treatment. (interval from date of first dose to date of last dose, without regard to intervening days or intervals when a dose was not taken). For subjects with a partial date of last dose, date of last dose is estimated. a. Extent of exposure for subjects who were assigned replacement kit(s) could not be determined. CHMP comments The overall exposure to vorapaxar, in terms of numbers of patients included in the vorapaxar clinical program and duration of treatment, is sufficient to establish the key aspects of its safety profile and this was done in the previous review. In the PAD stratum the percentage of patients treated for more than 3 years was higher (&gt;30%) than their CAD counterparts while compliance remained generally at high  levels.  Still,  if  this  application  is  approved,  vorapaxar  for  many  PAD  patients  will  be  a  chronic treatment and a point that needs to be considered is to what extent the available data are sufficient to establish its possible long-term safety in this setting. Adverse events Medicinal product no longer authorised

As  bleeding  represents  the  main  safety  issue  with  this  product  and  is  a  key  determinant  of  the benefit:risk, bleeding events are presented first here.

Adjudicated Bleeding Endpoints -Protocol Specified Analysis of Bleeding Endpoints (Randomization to Last Visit)

- -Intended Label Population

<div style=\"page-break-after: always\"></div>

Table  S.5  shows  the  GUSTO,  TIMI,  and  other  adjudicated  bleeding  endpoints  in  the Intended  Label Population (using  protocol  specified  randomization  to  last  visit  analysis).    The  rates  of  GUSTO  severe bleeding were similar in the two groups with the 3 year KM estimates for GUSTO severe or moderate bleeding endpoints being 3.8% in the vorapaxar group and 2.7% in the placebo group (HR 1.45; 95% CI 1.23-1.71;  p&lt;0.001).    This  increase  in  GUSTO  severe  or  moderate  bleeding  over  placebo  was  driven largely  by  an  increase  in  GUSTO  moderate  bleeding.  Annualized  event  rates  for  GUSTO  severe  or moderate bleeding were 1.3 events per 100 subject-years of exposure in the vorapaxar group and 0.9 events  per  100  subject-years  of  exposure  in  the  placebo  group.    The  3  year  KM  event  rate  for  fatal bleeding was 0.3% for both the vorapaxar and placebo groups (HR 0.95; 95% CI 0.51 - 1.78; p=0.872).

For clinically significant bleeding (i.e. TIMI major or minor bleeding, or bleeding that required unplanned treatment or evaluation) the 3 year KM estimate was 15.2% for vorapaxar vs. 11.1% for placebo (HR 1.42; 95% CI 1.31-1.54; p&lt;0.001), or 6.1 events per 100 patient-years compared to 4.2 for placebo. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table  S.5. TRA  2 ° P  -  TIMI  50  Bleeding  Endpoints  in  Subjects  With  No  History  of  Stroke  or  TIA:  AsTreated Population Whose Qualifying Condition was CAD or PAD (Event Accrual Period: Randomization to Last Visit)

|                                   | Placebo (n =10049 )       | Placebo (n =10049 )       | Placebo (n =10049 )       | Vorapaxar (n =10059 )     | Vorapaxar (n =10059 )     | Vorapaxar (n =10059 )     |                               |                           |
|-----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------------|---------------------------|
| Endpoints                         | Subjects With Events (%)  | KM% c                     | Annual. Event Rate d      | Subjects With Events (%)  | KM% c                     | Annual. Event Rate d      | Hazard Ratio a,b (95% CI)     | P- Value b                |
| GUSTO Bleeding Categories         | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories     | GUSTO Bleeding Categories |
| Severe or Moderate e              | 233 (2.3%)                | 2.7%                      | 0.9%                      | 335 (3.3%)                | 3.8%                      | 1.3%                      | 1.45 (1.23 - 1.71)            | <0.001                    |
| Severe                            | 105 (1.0%)                | 1.3%                      | 0.4%                      | 115 (1.1%)                | 1.3%                      | 0.5%                      | 1.09 (0.84 - 1.43)            | 0.503                     |
| Moderate                          | 138 (1.4%)                | 1.6%                      | 0.5%                      | 229 (2.3%)                | 2.6%                      | 0.9%                      | 1.67 (1.35 - 2.07)            | <0.001                    |
| CABG-Related Severe or Moderate   | 10 (0.1%)                 | 0.1%                      | <0.1%                     | 10 (0.1%)                 | 0.1%                      | <0.1%                     | 1.00 (0.42 - 2.41)            | 0.996                     |
| TIMI Bleeding Categories          | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories      | TIMI Bleeding Categories  |
| Major or Minor e                  | 253 (2.5%)                | 2.9%                      | 1.0%                      | 356 (3.5%)                | 4.1%                      | 1.4%                      | 1.42 (1.21 - 1.66)            | <0.001                    |
| Major                             | 183 (1.8%)                | 2.1%                      | 0.7%                      | 219 (2.2%)                | 2.5%                      | 0.9%                      | 1.20 (0.99 - 1.46)            | 0.069                     |
| Minor                             | 80 (0.8%)                 | 0.9%                      | 0.3%                      | 150 (1.5%)                | 1.7%                      | 0.6%                      | 1.88 (1.44 - 2.47)            | <0.001                    |
| Clinically Significant f          | 1016 (10.1%)              | 11.1%                     | 4.2%                      | 1403(13.9%)               | 15.2%                     | 6.1%                      | 1.42 (1.31 - 1.54)            | <0.001                    |
| Non CABG-Related Major or Minor e | 242 (2.4%)                | 2.8%                      | 1.0%                      | 345 (3.4%)                | 3.9%                      | 1.4%                      | 1.43 (1.22 - 1.69) authorised | <0.001                    |
| Major                             | 172 (1.7%)                | 2.0%                      | 0.7%                      | 208 (2.1%)                | 2.4%                      | 0.8%                      | 1.21 (0.99 - 1.48)            | 0.062                     |
| CABG-Related Major                | 11 (0.1%)                 | 0.1%                      | <0.1%                     | 12 (0.1%)                 | 0.1%                      | <0.1%                     | 1.09 (0.48 - 2.48)            | 0.830                     |
| Other Categories                  | Other Categories          | Other Categories          | Other Categories          | Other Categories          | Other Categories          | Other Categories          | Other Categories              | Other Categories          |
| Intracranial Haemorrhage          | 39 (0.4%)                 | 0.5%                      | 0.2%                      | 49 (0.5%)                 | 0.6%                      | 0.2%                      | 1.25 (0.82 - 1.91)            | 0.294                     |
| Fatal ICH                         | 10 (0.1%)                 | 0.1%                      | <0.1%                     | 13 (0.1%)                 | 0.2%                      | 0.1%                      | 1.30 (0.57 - 2.95)            | 0.538                     |
| Fatal Bleeding                    | 20 (0.2%)                 | 0.3%                      | 0.1%                      | 19 (0.2%)                 | 0.3%                      | 0.1%                      | 0.95 (0.51 - 1.78)            | 0.872                     |

|                                 | Placebo (n =1637 )        | Placebo (n =1637 )        | Placebo (n =1637 )        | Vorapaxar (n =1615 )      | Vorapaxar (n =1615 )      | Vorapaxar (n =1615 )      |                           |                           |
|---------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Endpoints                       | Subjects With Events (%)  | KM% c                     | Annual. Event Rate d      | Subjects With Events (%)  | KM% c                     | Annual. Event Rate d      | Hazard Ratio a,b (95% CI) | P- Value b                |
| GUSTO Bleeding Categories       | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories |
| Severe or Moderate e            | 77 (4.7%)                 | 4.9%                      | 1.7%                      | 104(6.4%)                 | 6.8%                      | 2.3%                      | 1.38 (1.03 - 1.85)        | 0.033                     |
| Severe                          | 32 (2.0%)                 | 2.1%                      | 0.7%                      | 30 (1.9%)                 | 2.0%                      | 0.7%                      | 0.94 (0.57 - 1.54)        | 0.799                     |
| Moderate                        | 50 (3.1%)                 | 3.1%                      | 1.1%                      | 77 (4.8%)                 | 5.0%                      | 1.7%                      | 1.58 (1.11 - 2.25)        | 0.012                     |
| CABG-Related Severe or Moderate | 2 (0.1%)                  | 0.1%                      | <0.1%                     | 4 (0.2%)                  | 0.3%                      | <0.1%                     | 2.02 (0.37 - 11.0)        | 0.416                     |
| TIMI Bleeding Categories        | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  |
| Major or Minor e                | 78 (4.8%)                 | 5.0%                      | 1.7%                      | 97 (6.0%)                 | 6.3%                      | 2.2%                      | 1.26 (0.94 - 1.70)        | 0.123                     |
| Major                           | 50 (3.1%)                 | 3.2%                      | 1.1%                      | 58 (3.6%)                 | 3.7%                      | 1.3%                      | 1.17 (0.80 - 1.71)        | 0.407                     |

Note: Only TIMI major is an appropriate categorization in the context of CABG (in the Clinical Endpoints Committee Manual of Operations). a. Hazard Ratio is vorapaxar group vs placebo group b. Hazard Ratio and P-value were calculated based on Cox PH model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use) c. Kaplan-Meier estimate at 1080 days d. Event rate is expressed as number of patients with events per 100 patient-years of exposure e. Subcategories are mutually exclusive; each subject appears only in the highest intensity subcategory observed for that subject f. TIMI Major or Minor bleeding, or bleeding that requires unplanned medical or surgical treatment, or unplanned evaluation via laboratory test Note: 5 subjects included in the overall population were incorrectly stratified to the CVD stratum and had no qualifying condition for the study. -PAD stratum The magnitude of the increased risk of bleeding in the PAD stratum with no history of stroke or TIA was consistent with the Intended Label Population . Table S.6. TRA  2 ° P  -  TIMI  50:    Bleeding  Endpoints  with  Annualized  Event  Rates  in  Subjects  With  No History of Stroke or TIA Whose Qualifying Condition was PAD: As-treated Population Event Accrual Period Randomization to Last Visit Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                   | Placebo (n =1637 )       | Placebo (n =1637 )   | Placebo (n =1637 )   | Vorapaxar (n =1615 )     | Vorapaxar (n =1615 )   | Vorapaxar (n =1615 )   |                           |            |
|-----------------------------------|--------------------------|----------------------|----------------------|--------------------------|------------------------|------------------------|---------------------------|------------|
| Endpoints                         | Subjects With Events (%) | KM% c                | Annual. Event Rate d | Subjects With Events (%) | KM% c                  | Annual. Event Rate d   | Hazard Ratio a,b (95% CI) | P- Value b |
| Minor                             | 33 (2.0%)                | 2.1%                 | 0.7%                 | 45 (2.8%)                | 3.0%                   | 1.0%                   | 1.39 (0.88 - 2.17)        | 0.155      |
| Clinically Significant f          | 231(14.1%)               | 14.6%                | 5.4%                 | 283(17.5%)               | 18.0%                  | 6.9%                   | 1.28 (1.07 - 1.52)        | 0.006      |
| Non CABG-Related Major or Minor e | 75 (4.6%)                | 4.8%                 | 1.7%                 | 94 (5.8%)                | 6.1%                   | 2.1%                   | 1.27 (0.94 - 1.73)        | 0.118      |
| Major                             | 47 (2.9%)                | 3.0%                 | 1.0%                 | 55 (3.4%)                | 3.5%                   | 1.2%                   | 1.18 (0.80 - 1.75)        | 0.396      |
| CABG-Related Major                | 3 (0.2%)                 | 0.2%                 | <0.1%                | 4(0.2% )                 | 0.3%                   | <0.1%                  | 1.35 (0.30 - 6.02)        | 0.696      |
| Other Categories                  |                          |                      |                      |                          |                        |                        |                           |            |
| Intracranial Haemorrhage          | 9 (0.5%)                 | 0.6%                 | 0.2%                 | 11 (0.7%)                | 0.7%                   | 0.2%                   | 1.24 (0.51 - 2.98)        | 0.638      |
| Fatal ICH                         | 2 (0.1%)                 | 0.1%                 | <0.1%                | 3 (0.2%)                 | 0.2%                   | <0.1%                  | 1.52 (0.25 - 9.09)        | 0.647      |
| Fatal Bleeding                    | 6 (0.4%)                 | 0.4%                 | 0.1%                 | 5 (0.3%)                 | 0.4%                   | 0.1%                   | 0.84 (0.26 - 2.77)        | 0.780      |

|                                           | Placebo (n =1992 ) product   | Placebo (n =1992 ) product   | Placebo (n =1992 ) product   | Vorapaxar (n =1931 )      | Vorapaxar (n =1931 )      | Vorapaxar (n =1931 )      |                           |                           |
|-------------------------------------------|------------------------------|------------------------------|------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Endpoints                                 | Subjects With Events (%)     | KM% c                        | Annual. Event Rate d         | Subjects With Events (%)  | KM% c                     | Annual. Event Rate d      | Hazard Ratio a,b (95% CI) | P- Value b                |
| GUSTO Bleeding Categories                 | GUSTO Bleeding Categories    | GUSTO Bleeding Categories    | GUSTO Bleeding Categories    | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories | GUSTO Bleeding Categories |
| Severe or Moderate e                      | 96 (4.8%)                    | 5.2%                         | 1.8%                         | 123(6.4%)                 | 6.8%                      | 2.4%                      | 1.33 (1.02 - 1.74)        | 0.036                     |
| Severe                                    | 40 (2.0%)                    | 2.3%                         | 0.7%                         | 35 (1.8%)                 | 2.0%                      | 0.7%                      | 0.89 (0.56 - 1.40)        | 0.608                     |
| Moderate                                  | 63 (3.2%)                    | 3.3%                         | 1.2%                         | 91 (4.7%)                 | 5.0%                      | 1.7%                      | 1.51 (1.09 - 2.08)        | 0.012                     |
| CABG-Related Severe or Moderate Medicinal | 2 (0.1%)                     | 0.1%                         | <0.1%                        | 5 (0.3%)                  | 0.3%                      | <0.1%                     | 2.58 (0.50-13.28)         | 0.258                     |
| TIMI Bleeding Categories                  | TIMI Bleeding Categories     | TIMI Bleeding Categories     | TIMI Bleeding Categories     | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  | TIMI Bleeding Categories  |
| Major or Minor e                          | 96 (4.8%)                    | 5.2%                         | 1.8%                         | 118(6.1%)                 | 6.5%                      | 2.3%                      | 1.27 (0.97 - 1.67)        | 0.078                     |
| Major                                     | 60 (3.0%)                    | 3.3%                         | 1.1%                         | 68 (3.5%)                 | 3.7%                      | 1.3%                      | 1.17 (0.82 - 1.65)        | 0.386                     |
| Minor                                     | 42 (2.1%)                    | 2.3%                         | 0.8%                         | 56 (2.9%)                 | 3.1%                      | 1.1%                      | 1.38 (0.93 - 2.06)        | 0.112                     |
| Clinically Significant f                  | 279(14.0%)                   | 14.8%                        | 5.5%                         | 343(17.8%)                | 8.5%                      | 7.2%                      | 1.31 (1.12 - 1.54)        | <.001                     |
| Non CABG-Related Major or Minor e         | 93 (4.7%)                    | 5.0%                         | 1.7%                         | 114(5.9%)                 | 6.3%                      | 2.2%                      | 1.27 (0.97 - 1.67)        | 0.087                     |
| Major                                     | 57 (2.9%)                    | 3.1%                         | 1.1%                         | 64 (3.3%)                 | 3.5%                      | 1.2%                      | 1.15 (0.81 - 1.65)        | 0.429                     |
| CABG-Related Major                        | 3 (0.2%)                     | 0.2%                         | <0.1%                        | 5 (0.3%)                  | 0.3%                      | <0.1%                     | 1.71 (0.41 - 7.17)        | 0.460                     |
| Other Categories                          | Other Categories             | Other Categories             | Other Categories             | Other Categories          | Other Categories          | Other Categories          | Other Categories          | Other Categories          |
| Intracranial Haemorrhage                  | 11 (0.6%)                    | 0.6%                         | 0.2%                         | 12 (0.6%)                 | 0.7%                      | 0.2%                      | 1.12 (0.49 - 2.53)        | 0.794                     |
| Fatal ICH                                 | 3 (0.2%)                     | 0.17%                        | <0.1%                        | 3 (0.2%)                  | 0.17%                     | <0.1%                     | 1.02 (0.21 - 5.07)        | 0.978                     |
| Fatal Bleeding                            | 8 (0.4%)                     | 0.5%                         | 0.1%                         | 6 (0.3%)                  | 0.4%                      | 0.1%                      | 0.77 (0.27 - 2.21)        | 0.621                     |

Note: Only TIMI major is an appropriate categorization in the context of CABC (in the Clinical Endpoints Committee Manual of Operations). a. Vorapaxar vs. placebo; a hazard ratio &lt;1 indicates lower hazard associated with vorapaxar relative to placebo. b. Hazard Ratio and p-value were calculated based on Cox proportional hazards model with covariates of treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use). c. Kaplan-Meier estimate at 1080 days. d. Event rate is expressed as number of subjects with events per 100 patient-years of exposure e. Subcategories are mutually exclusive; each subject appears only in the highest intensity subcategory observed for that subject. f. TIMI Major or Minor bleeding, or bleeding that requires unplanned medical or surgical treatment, or unplanned evaluation via laboratory test.. The  results  in  the Clinical  PAD and Aspirin-Only  PAD populations  were  generally  consistent  with  the results in the PAD stratum . -Clinical PAD Table S.7. TRA 2 ° P - TIMI 50:  Bleeding Endpoints in the Clinical PAD Population: As-Treated;   Event Accrual Period: Randomization to Last Visit Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           | Placebo (n =1992 )             | Placebo (n =1992 )   | Vorapaxar (n =1931 )           | Vorapaxar (n =1931 )   |                           |            |
|-----------|--------------------------------|----------------------|--------------------------------|------------------------|---------------------------|------------|
| Endpoints | Subjects With Events (%) KM% c | Annual. Event Rate d | Subjects With Events (%) KM% c | Annual. Event Rate d   | Hazard Ratio a,b (95% CI) | P- Value b |

Note: Only TIMI major is an appropriate categorization in the context of CABC (in the Clinical Endpoints Committee Manual of Operations).

- a. Vorapaxar vs. placebo; a hazard ratio &lt;1 indicates lower hazard associated with vorapaxar relative to placebo.

b. Hazard Ratio and p-value were calculated based on Cox proportional hazards model with covariates of treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use).

c. Kaplan-Meier estimate at 1080 days.

- d. Event rate is expressed as number of subjects with events per 100 patient-years of exposure

|                                   | Placebo (n =1044 )               | Placebo (n =1044 )               | Placebo (n =1044 )               | Vorapaxar (n =1030 )             | Vorapaxar (n =1030 )             | Vorapaxar (n =1030 )             |                                  |                                  |
|-----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Endpoints                         | Subjects With Events (%)         | KM% c                            | Annual. Event Rate d             | Subjects With Events (%)         | KM% c                            | Annual. Event Rate d             | Hazard Ratio a,b (95% CI)        | P- Value b                       |
| GUSTO Bleeding Categories longer  | GUSTO Bleeding Categories longer | GUSTO Bleeding Categories longer | GUSTO Bleeding Categories longer | GUSTO Bleeding Categories longer | GUSTO Bleeding Categories longer | GUSTO Bleeding Categories longer | GUSTO Bleeding Categories longer | GUSTO Bleeding Categories longer |
| Severe or Moderate e              | 41 (3.9%)                        | 4.1%                             | 1.4%                             | 53 (5.1%)                        | 5.5%                             | 1.9%                             | 1.32 (0.88 - 1.98)               | 0.186                            |
| Severe                            | 20 (1.9%)                        | 2.2%                             | 0.7%                             | 20 (1.9%)                        | 2.1%                             | 0.7%                             | 1.01 (0.54 - 1.88)               | 0.977                            |
| Moderate                          | 24 (2.3%)                        | 2.2%                             | 0.8%                             | 36 (3.5%)                        | 3.8%                             | 1.3%                             | 1.53 (0.91 - 2.56)               | 0.108                            |
| CABG-Related Severe or Moderate   | 1 (0.1%)                         | 0.1%                             | <0.1%                            | 1 (0.1%) no                      | 0.1%                             | <0.1%                            | 1.01 (0.06 - 6.12)               | 0.995                            |
| TIMI Bleeding Categories          | TIMI Bleeding Categories         | TIMI Bleeding Categories         | TIMI Bleeding Categories         | TIMI Bleeding Categories         | TIMI Bleeding Categories         | TIMI Bleeding Categories         | TIMI Bleeding Categories         | TIMI Bleeding Categories         |
| Major or Minor e                  | 41 (3.9%)                        | 4.1%                             | 1.4%                             | 47 (4.6%)                        | 4.7%                             | 1.7%                             | 1.16 (0.76 - 1.76)               | 0.485                            |
| Major                             | 28 (2.7%)                        | 2.9%                             | 1.0%                             | 27 (2.6%)                        | 2.7%                             | 0.9%                             | 0.98 (0.58 - 1.66)               | 0.931                            |
| Minor                             | 14 (1.3%)                        | 1.3%                             | 0.5%                             | 21 (2.0%)                        | 2.1%                             | 0.7%                             | 1.52 (0.77 - 2.98)               | 0.228                            |
| Clinically Significant f          | 124(11.9%)                       | 12.3%                            | 4.5%                             | 148(14.4%)                       | 14.9%                            | 5.6%                             | 1.23 (0.97 - 1.56)               | 0.087                            |
| Non CABG-Related Major or Minor e | 39 (3.7%)                        | 3.9%                             | 1.4%                             | 46 (4.5%)                        | 4.6%                             | 1.6%                             | 1.19 (0.78 - 1.83)               | 0.413                            |
| Major                             | 26 (2.5%)                        | 2.7%                             | 0.9%                             | 26 (2.5%)                        | 2.6%                             | 0.9%                             | 1.01 (0.59 - 1.75)               | 0.961                            |
| CABG-Related Major                | 2 (0.2%)                         | 0.2%                             | <0.1%                            | 1 (0.1%)                         | 0.1%                             | <0.1%                            | 0.50 (0.05 - 5.56)               | 0.576                            |
| Other Categories product          | Other Categories product         | Other Categories product         | Other Categories product         | Other Categories product         | Other Categories product         | Other Categories product         | Other Categories product         | Other Categories product         |
| Intracranial Haemorrhage          | 4 (0.4%)                         | 0.4%                             | 0.1%                             | 8 (0.8%)                         | 0.8%                             | 0.3%                             | 2.02 (0.61 - 6.71)               | 0.250                            |
| Fatal ICH                         | 2 (0.2%)                         | 0.19%                            | <0.1%                            | 1 (0.1%)                         | 0.10%                            | <0.1%                            | 0.51 (0.05 - 5.59)               | 0.579                            |
| Fatal Bleeding                    | 6 (0.6%)                         | 0.7%                             | 0.2%                             | 3 (0.3%)                         | 0.3%                             | 0.1%                             | 0.51 (0.13 - 2.02)               | 0.335                            |

e. Subcategories are mutually exclusive; each subject appears only in the highest intensity subcategory observed for that subject. f. TIMI Major or Minor bleeding, or bleeding that requires unplanned medical or surgical treatment, or unplanned evaluation via laboratory test. -Aspirin-Only PAD Population Table  S.8. TRA  2 ° P  -  TIMI  50:    Bleeding  Endpoints:  in  Aspirin-Only  PAD  Population~  Event  Accrual Period: As-Treated: Randomization to Last Visit Note: Only TIMI major is an appropriate categorization in the context of CABC (in the Clinical Endpoints Committee Manual of Operations). a. Vorapaxar vs. placebo; a hazard ratio &lt;1 indicates lower hazard associated with vorapaxar relative to placebo. b. Hazard Ratio and p-value were calculated based on Cox proportional hazards model with covariates of treatment and stratification factors (qualifying atherosclerotic disease and planned thienopyridine use). c. Kaplan-Meier estimate at 1080 days. d. Event rate is expressed as number of subjects with events per 100 patient-years of exposure e. Subcategories are mutually exclusive; each subject appears only in the highest intensity subcategory observed for that subject. Medicinal product no longer authorised

## CHMP comments

The  risk  of  bleeding  remains  the  most  important  concern  with  vorapaxar.  Bleeding  events  were  more common in patients treated with vorapaxar than placebo across all populations and analyses, with the rates in the Intended Label Population very similar to the ones previously reported in post-MI patients only (see table below).

<div style=\"page-break-after: always\"></div>

TRA 2ºP-TIMI 50 Bleeding Endpoints with Annualized Event Rates in Subjects with No History of Stroke or TIA Whose Qualifying Condition was CAD: Event Accrual Period Randomization to Last Visit

| authorised   | authorised   | authorised   | authorised   | authorised   | authorised   | authorised   | authorised   | authorised   |
|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|

Overall, the above suggests that PAD patients are generally at higher risk of bleeding but the additional risk  associated  with  vorapaxar  treatment  is  consistent  to  that  seen  in  post-MI  patients.  Background antiplatelet  treatment  with  aspirin  and/or  clopidogrel  also  plays  a  role  (see  also  subgroups  below).  In response  to  previous  CHMP  request,  the  MAH  has  provided  further  information  to  clarify  this  point. Although data about PAD patients receiving vorapaxar on top aspirin alone or clopidogrel alone appear consistent  with  the  overall  rates  (with  the  caveat  of  the  small  number  of  reports  in  patients  receiving vorapaxar with clopidogrel), there is a general trend about more bleedings in patients taking vorapaxar concomitantly  with  both  aspirin  and  clopidogrel.  This  raised  concerns  about  the  safety  of  long  term therapy with vorapaxar as add-on to both aspirin and clopidogrel. It is uncertain whether the expected benefits can outweigh the increased risks in this setting. Therefore, the SmPC has been updated to reflect this point and advise that vorapaxar should be taken only with aspirin or clopidogrel alone.  This issue is

An  interesting  finding,  when  PAD  patients  are  examined  alone  (in  the PAD  stratum , Clinical  PAD and Aspirin-Only PAD populations), is an overall much higher risk of bleeding (almost double rates in both GUSTO moderate and severe and TIMI major or  minor)  compared  to  their  CAD  counterparts.  In  PAD patients receiving aspirin alone the overall rates were somewhat lower in both treatment groups but still generally higher than in the CAD population. The  higher  rate  of  bleedings  in  PAD  concerns  both  vorapaxar  and  placebo  groups  suggesting  a characteristic independent of treatment. This observation of a general higher bleeding risk in PAD patients is consistent with the results of the CHARISMA trial (see comments in section 2.1 above) which showed that PAD were more prone to bleeding compared to the remaining atherosclerotic populations examined in the trial. Despite the higher overall rates of bleeding in PAD, the relative risk with vorapaxar versus placebo was similar across strata. Severe bleedings were uncommon with only few reports of ICH and fatal bleeding. For these severe cases the rates were similar between vorapaxar and placebo. Yet GUSTO moderate and TIMI clinical significant bleedings were significantly more common with vorapaxar. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

further discussed below.

## Subgroups

## -Intended Label Population

In  the Intended  Label  Population there  was  an  increase  in  bleeding  risk  associated  with  vorapaxar treatment  compared  with  placebo  treatment  across  the  subgroups  examined.    The  magnitude  of  the effect of vorapaxar on the bleeding endpoints relative to placebo was consistent across the majority of subgroups.  Many of these are shown in Figures S.1a/b. Such analyses must be interpreted cautiously, as differences can reflect the play of chance among a large number of analyses.

<!-- image -->

Figure S.1a/b. TRA 2 ° P - TIMI 50: Plot of hazard Ratio (95% CI) and Event Rate for GUSTO Severe or Moderate Bleeding by Subgroups in Subjects with No History of Stroke or TIA Whose Qualifying Condition Was CAD or PAD: As-treated Population Event Accrual Period: Randomization to Last Visit Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

CHMP comments Generally,  subgroup  analyses  with  regard  to  bleeding  risk  in  the Intended  Label  Population did  not show any clear evidence of a clinically significant interaction, including the effect of factors like age, sex, renal status or background therapy. However, in the whole TRA 2ºP-TIMI 50 the risk of bleeding was higher among older patients and those with weight less 60kgr. Relevant warnings (as well as for, patients with renal and hepatic impairment) are included in the SmPC. In  response  to  CHMP  questions,  the  MAH  has  also  provided  similar  subgroup  analyses  for  the PAD stratum .  Generally,  the  findings  appear  very  consistent  with  the  subgroup  analyses  in  the  overall Intended Label Populatio n and again there is no clear sign of a significant interaction with a particular demographic or clinical factor where the number of events is large enough to permit comparisons. The only deviation that was observed was with 'Geographic Region' with US patients with PAD not having an overall much higher rate of bleedings than non-US patients but also the risk with vorapaxar was  greater  compared  to  their  non-US  counterparts.  The  MAH  has  provided  further  information  to clarify this point. In general, although the possible reason(s) for this discrepancy remain unclear there are no major concerns about the overall results and the validity of the conclusions. . In  terms  of  concomitant antiplatelets  these data  do  not  provide  any  new  information  but,  as  noted above, the concerns of bleeding risk when vorapaxar is given together with aspirin+clopidogrel remain Medicinal product no longer authorised

## Other analyses

In  addition  to  the  above,  the  MAH  has  provided  a  number  of  further  analyses  on  bleeding  events examining  the  association  with  different  factors  such  as  bleedings  following  an  ACS  event,  bleeding associated with CABG or other major surgery as well as information about management of bleeding.

For the Intended Label Population comprising mainly post-MI patients the data offer little additional information  over  and  above  the  evidence  assessed  during  the  initial  MAA.  Therefore,  the  relevant

<div style=\"page-break-after: always\"></div>

tables are not presented again here. In the PAD stratum although in general the number of events is small, the results (further data submitted by the MAH in response to CHMP question in the first round) do not suggest an increased risk of major bleeding with vorapaxar in patients undergoing surgery or other  invasive  procedures.  Relevant  advice  about  surgery  is  already  included  in  the  SmPC  and  no changes are needed.

For  the  remaining  analyses  on  bleeding  events,  especially  some  more  information  about  the management  of  bleeding  which  can  be  a  measure  of  the  seriousness  of  the  events    is  presented (particularly for the PAD stratum ) below.

| Number of Subjects with Any GUSTO Moderate/Severe Bleeding Median (25th to 75th Percentile) product   | Placebo (n= 77)    | Vorapaxar (n= 104)   |
|-------------------------------------------------------------------------------------------------------|--------------------|----------------------|
| Duration of the First GUSTO Moderate/Severe Bleeding (Days)                                           |                    |                      |
| Number of Subjects                                                                                    | 73 2.0 (1.0 - 5.0) | 97 4.0 (2.0 - 6.0)   |
| Action/Outcome, Number (%) of Subjects a                                                              |                    |                      |
| None                                                                                                  | 6 (7.8)            | 7 (6.7)              |
| Additional/Discontinuation/Change in Medications                                                      | 28 (36.4)          | 33 (31.7)            |
| Therapeutic Procedures                                                                                | 35 (45.5)          | 36 (34.6)            |
| Hospitalization                                                                                       | 47 (61.0)          | 64 (61.5)            |
| Study Drug Discontinued                                                                               | 17 (22.1)          | 22 (21.2)            |
| Study Discontinued                                                                                    | 7 (9.1)            | 6 (5.8)              |
| Study Drug Interrupted                                                                                | 16 (20.8)          | 24 (23.1)            |
| Death                                                                                                 | 7 (9.1)            | 7 (6.7)              |

Table S.10. TRA 2 ° P - TIMI 50:  Summary Results for Subjects Who Had a Bleeding Event, that Began (per Investigator) On or After Randomization During the Study, And Received One or More Transfusions that  Began  Within  2  Days  After  Any  Bleeding  Event  For  Subjects  with  CEC-Adjudicated  GUSTO Moderate/Severe Bleeding Events and No History of Stroke or TIA Whose Qualifying Condition Was PAD Number (%) of Subjects Who Received Indicated Transfusate

In the Intended Label Population , there were 338 subjects on vorapaxar and 224 subjects on placebo who  experienced  a  CEC-adjudicated  GUSTO  moderate  or  severe  bleeding  event  with  193  vorapaxar subjects and 145 placebo subjects having a procedure to stop the bleeding. Using  GUSTO moderate/severe  as  the  threshold,  the  most  frequent  bleeding  site  was  gastrointestinal.    The  most common therapeutic procedure was endoscopy (55 subjects in the vorapaxar group and 32 subjects in the placebo group).  The median time from procedure to bleeding resolution was 3.0 days for vorapaxar subjects vs. 3.0 days for placebo treated subjects.  Additionally, of those hospitalized for such bleeding, duration of hospitalization were similar (6 days) for both treatment groups. In the PAD stratum the findings were generally consistent with the Intended Label Population. There were  104  subjects  on  vorapaxar  and  77  subjects  on  placebo  who  experienced  a  GUSTO  moderate  or severe bleeding event with 36 vorapaxar subjects and 35 placebo subjects having a procedure to stop the bleeding. Table  S.9. TRA  2 ° P  -  TIMI  50:    Duration,  Cause,  Action  Outcome  of  GUSTO  Severe  and  GUSTO Moderate Bleeding Events in Subjects No history of Stroke or TIA Whose Qualifying Condition Was PAD: As-Treated Population Number of Subjects with Any GUSTO Moderate/Severe Bleeding Duration of the First GUSTO Moderate/Severe Bleeding (Days) Number of Subjects Median (25th to 75th Percentile) Action/Outcome, Number (%) of Subjects a None Additional/Discontinuation/Change in Medications Therapeutic Procedures Hospitalization Study Drug Discontinued Study Discontinued Study Drug Interrupted Death a. Subject may have had more than one action/outcome for the bleeding event, and can be counted in multiple rows. Medicinal product no longer authorised

|                                          | Placebo n (%)   | Vorapaxar n (%)   |
|------------------------------------------|-----------------|-------------------|
| Number of Subjects with a Bleeding Event | (n= 77)         | (n= 104)          |
| Any Transfusion                          | 60 (77.9)       | 86 (82.7)         |
| Whole Blood Transfusion                  | 13 (16.9)       | 13 (12.5)         |
| Packed Red Blood Cell Transfusion        | 44 (57.1)       | 75 (72.1)         |
| Whole Blood and/or PRBC Transfusion      | 56 (72.7)       | 84 (80.8)         |
| < 3 Units                                | 30 (39.0)       | 51 (49.0)         |

<div style=\"page-break-after: always\"></div>

|                                 | Placebo n (%)   | Vorapaxar n (%)   |
|---------------------------------|-----------------|-------------------|
| 3-5 Units                       | 17 (22.1)       | 25 (24.0)         |
| >5 Units                        | 8 (10.4)        | 6 (5.8)           |
| Missing                         | 1 (1.3)         | 2 (1.9)           |
| Platelet Transfusion            | 8 (10.4)        | 12 (11.5)         |
| Fresh-Frozen Plasma Transfusion | 13 (16.9)       | 10 (9.6)          |
| Cryoprecipitate Transfusion     | 0               | 1 (1.0)           |
| Missing                         | 0               | 1 (1.0)           |

|         | longer   |
|---------|----------|
| no      |          |
| product |          |

In  general  the  findings  in PAD  stratum appear  consistent  with  the Intended  Label  population. Regarding need for transfusion for patients with GUSTO moderate/severe bleedings, the rates appear similar with those previously seen in the post-MI patients (see table below). Summary Results for Subjects Who Had a Bleeding Event, that Began (per Investigator) On or After Randomization During the Study, And Received One or More Transfusions that Began Within 2 Days After  Any  Bleeding  Event  For  Subjects  with  CEC-Adjudicated  GUSTO  Moderate/Severe  Bleeding Events:  Number  (%)  of  Subjects  Who  Received  the  Indicated  Transfusate  for  TRA  2ºP-TIMI  50 overall and Proposed Label Populations Note: Units are as entered in the eCRF, and do not imply a predefined standard volume. Number of units is total for two consecutive calendar days, beginning with first day of transfusion(s). Subsequent transfusions, if any, begin a new 2-day transfusion record. Units represent the single largest 2-day total for the indicated transfusate. Note: Subject may have had more than one type of transfusion and can be counted in multiple rows. PRBC=Packed Red Blood Cells In summary, in line with what was seen in post MI patients, PAD patients on vorapaxar had a higher frequency of GUSTO moderate and severe bleeding events. However, there was no greater need for a therapeutic procedure or hospitalisations in the vorapaxar group. The percentages of patients requiring a transfusion was slightly greater among vorapaxar patients with the majority not needing more than 3-5 units. Medicinal product no longer authorised

## Other bleeding events

The tables below show summaries of bleeding events reported as Treatment Related Treatment Emergent Adverse Events in the Intended Label Population and the PAD stratum .

<div style=\"page-break-after: always\"></div>

## -Intended Label Population

Table S.11. TRA 2 ° P - TIMI 50:  Summary of Treatment Related Treatment Emergent Adverse Events (AEs) - Bleeding Events (0.1% Incidence) During Treatment for Subjects With No History of Stroke or TIA Whose Qualifying Condition Was CAD or PAD Intended Label Population

|                                                           | Placebo (n=10049)   | Placebo (n=10049)   | Vorapaxar (n=10059)   | Vorapaxar (n=10059)   |
|-----------------------------------------------------------|---------------------|---------------------|-----------------------|-----------------------|
| Adverse Events                                            | n                   | (%)                 | n                     | (%)                   |
| SUBJECTS REPORTING ANY ADVERSE EVENT                      | 1198                | (11.9)              | 1833                  | (18.2)                |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                      |                     |                     |                       |                       |
| HAEMORRHAGIC DIATHESIS                                    | 19                  | (0.2)               | 36                    | (0.4)                 |
| EAR AND LABYRINTH DISORDERS                               |                     |                     |                       |                       |
| EAR HAEMORRHAGE                                           | 6                   | (0.1)               | 7                     | (0.1)                 |
| EYE DISORDERS                                             |                     |                     |                       | authorised            |
| CONJUNCTIVAL HAEMORRHAGE                                  | 11                  | (0.1)               | 40                    | (0.4)                 |
| EYE HAEMORRHAGE                                           | 22                  | (0.2)               | 18                    | (0.2)                 |
| GASTROINTESTINAL DISORDERS                                |                     |                     |                       |                       |
| GASTROINTESTINAL HAEMORRHAGE                              | 18                  | (0.2)               | 44                    | (0.4)                 |
| GINGIVAL BLEEDING                                         | 41                  | (0.4)               | 85                    | (0.8)                 |
| HAEMATEMESIS                                              | 11                  | (0.1)               | 14                    | (0.1)                 |
| HAEMATOCHEZIA                                             | 20                  | (0.2)               | 18                    | (0.2)                 |
| HAEMORRHOIDAL HAEMORRHAGE                                 | 36                  | (0.4)               | 44                    | (0.4)                 |
| MELAENA                                                   | 35                  | (0.3)               | 62                    | (0.6)                 |
| MOUTH HAEMORRHAGE                                         | 0                   | 0                   | 7                     | (0.1)                 |
| RECTAL HAEMORRHAGE                                        | 67                  | (0.7)               | 87                    | (0.9)                 |
| UPPER GASTROINTESTINAL HAEMORRHAGE                        | 12                  | (0.1)               | 5                     | (<0.1)                |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS      |                     | longer              |                       |                       |
| CATHETER SITE HAEMATOMA                                   | 11                  | (0.1)               | 9                     | (0.1)                 |
| CATHETER SITE HAEMORRHAGE                                 | 21                  | (0.2)               | 16                    | (0.2)                 |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS            |                     |                     |                       |                       |
| CONTUSION                                                 | 180                 | (1.8)               | 240                   | (2.4)                 |
| LACERATION                                                | 6                   | (0.1)               | 12                    | (0.1)                 |
| OPERATIVE HAEMORRHAGE                                     | 13 no               | (0.1)               | 14                    | (0.1)                 |
| POST PROCEDURAL HAEMORRHAGE                               | 19                  | (0.2)               | 18                    | (0.2)                 |
| SUBCUTANEOUS HAEMATOMA                                    | 4                   | (<0.1)              | 6                     | (0.1)                 |
| WOUND HAEMORRHAGE                                         | 35                  | (0.3)               | 55                    | (0.5)                 |
| INVESTIGATIONS                                            |                     |                     |                       |                       |
| BLOOD URINE PRESENT                                       | 1                   | (<.1)               | 6                     | (0.1)                 |
| OCCULT BLOOD POSITIVE                                     | 9                   | (0.1)               | 12                    | (0.1)                 |
| NERVOUS SYSTEM DISORDERS                                  |                     |                     |                       |                       |
| HAEMORRHAGE INTRACRANIAL                                  | 12                  | (0.1)               | 17                    | (0.2)                 |
| RENAL AND URINARY DISORDERS                               |                     |                     |                       |                       |
| HAEMATURIA                                                | 107                 | (1.1)               | 152                   | (1.5)                 |
| HAEMORRHAGE URINARY TRACT                                 | 3                   | (<0.1)              | 8                     | (0.1)                 |
| REPRODUCTIVE SYSTEM AND BREAST DISORDERS product          |                     |                     |                       |                       |
| GENITAL HAEMORRHAGE                                       | 3                   | (<0.1)              | 6                     | (0.1)                 |
| MENORRHAGIA                                               | 3                   | (<0.1)              | 14                    | (0.1)                 |
| MENSTRUAL DISORDER                                        | 4                   | (<0.1)              | 6                     | (0.1)                 |
| POSTMENOPAUSAL HAEMORRHAGE                                | 3                   | (<0.1)              | 6                     | (0.1)                 |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS Medicinal |                     |                     |                       |                       |
| EPISTAXIS                                                 | 241                 | (2.4)               | 544                   | (5.4)                 |
| HAEMOPTYSIS                                               | 17                  | (0.2)               | 31                    | (0.3)                 |
| PHARYNGEAL HAEMORRHAGE                                    | 8                   | (0.1)               | 12                    | (0.1)                 |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                    |                     |                     |                       |                       |
| ECCHYMOSIS                                                | 33                  | (0.3)               | 48                    | (0.5)                 |
| INCREASED TENDENCY TO BRUISE                              | 154                 | (1.5)               | 247                   | (2.5)                 |
| PETECHIAE                                                 | 5                   | (<0.1)              | 10                    | (0.1)                 |
| SKIN HAEMORRHAGE                                          | 42                  | (0.4)               | 76                    | (0.8)                 |
| VASCULAR DISORDERS                                        |                     |                     |                       |                       |
| HAEMATOMA                                                 | 94                  | (0.9)               | 146                   | (1.5)                 |
| HAEMORRHAGE                                               | 19                  | (0.2)               | 47                    | (0.5)                 |

## -PAD stratum

<div style=\"page-break-after: always\"></div>

Table S.12. TRA 2 ° P - TIMI 50:  Summary of Treatment Related Treatment Emergent Adverse Events Bleeding Events (0.1% Incidence) During Treatment for Subjects With No History of Stroke or TIA Whose Qualifying Condition Was PAD As-Treated Number (%) of Subjects

|                                                          | Placebo (n=1637)   | Placebo (n=1637)   | Vorapaxar (n=1615)   | Vorapaxar (n=1615)   |
|----------------------------------------------------------|--------------------|--------------------|----------------------|----------------------|
| SUBJECTS REPORTING ANY ADVERSE EVENT                     | 177                | (%) (10.8)         | n 276                | (%) (17.1)           |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                     |                    |                    |                      |                      |
| ANAEMIA                                                  | 1                  | (0.1)              | 2                    | (0.1)                |
| HAEMORRHAGIC DIATHESIS                                   | 2                  | (0.1)              | 8                    | (0.5)                |
| SPLENIC HAEMORRHAGE                                      | 1                  | (0.1)              | 0                    |                      |
| SPONTANEOUS HAEMATOMA                                    | 0                  |                    | 2                    | (0.1)                |
| CARDIAC DISORDERS                                        |                    |                    |                      |                      |
| PERICARDIAL EFFUSION                                     | 1                  | (0.1)              | 0                    |                      |
| EAR AND LABYRINTH DISORDERS                              |                    |                    |                      |                      |
| EAR HAEMORRHAGE                                          | 2                  | (0.1)              | 0 authorised         | 0 authorised         |
| EYE DISORDERS                                            |                    |                    |                      |                      |
| CONJUNCTIVAL HAEMORRHAGE                                 | 2                  | (0.1)              | 3                    | (0.2)                |
| EYE HAEMORRHAGE                                          | 2                  | (0.1)              | 1                    | (0.1)                |
| OCULAR VASCULAR DISORDER                                 | 0                  |                    | 1                    | (0.1)                |
| RETINAL HAEMORRHAGE                                      | 1                  | (0.1)              | 2                    | (0.1)                |
| VITREOUS HAEMORRHAGE                                     | 1                  | (0.1)              | 1                    | (0.1)                |
| GASTROINTESTINAL DISORDERS                               |                    |                    |                      |                      |
| ABDOMINAL WALL HAEMORRHAGE                               | 0                  |                    | 1                    | (0.1)                |
| ANAL HAEMORRHAGE                                         | 0                  |                    | 1                    | (0.1)                |
| DIARRHOEA HAEMORRHAGIC                                   | 0                  |                    | 1                    | (0.1)                |
| DUODENAL ULCER                                           | 0                  | longer             | 1                    | (0.1)                |
| EROSIVE OESOPHAGITIS                                     | 0                  |                    | 1                    | (0.1)                |
| FAECES DISCOLOURED                                       | 1                  | (0.1)              | 0                    |                      |
| GASTRIC DISORDER GASTRIC ULCER HAEMORRHAGE               | 1                  | (0.1)              | 0 2                  | (0.1)                |
| GASTROINTESTINAL HAEMORRHAGE                             | 0 6                | (0.4)              | 16                   | (1.0)                |
| GASTROINTESTINAL TELANGIECTASIA                          | 0                  |                    | 1                    | (0.1)                |
| GINGIVAL BLEEDING no                                     | 3                  | (0.2)              | 11                   | (0.7)                |
| HAEMATEMESIS                                             | 2                  | (0.1)              | 4                    | (0.2)                |
| HAEMATOCHEZIA                                            | 5                  | (0.3)              | 4                    | (0.2)                |
| HAEMORRHAGIC EROSIVE GASTRITIS                           | 0                  |                    | 1                    | (0.1)                |
| HAEMORRHOIDAL HAEMORRHAGE                                | 5                  | (0.3)              | 3                    | (0.2)                |
| LARGE INTESTINAL HAEMORRHAGE                             | 0                  |                    | 1                    | (0.1)                |
| LOWER GASTROINTESTINAL HAEMORRHAGE                       | 1                  | (0.1)              | 1                    | (0.1)                |
| MELAENA                                                  | 8                  | (0.5)              | 11                   | (0.7)                |
| RECTAL HAEMORRHAGE                                       | 12                 | (0.7)              | 13                   | (0.8)                |
| UPPER GASTROINTESTINAL HAEMORRHAGE                       | 0                  |                    | 1                    | (0.1)                |
| GENERAL DISORDERS AND ADMINISTRATION SITE product        |                    |                    |                      |                      |
| CONDITIONS CATHETER SITE HAEMATOMA                       | 0                  |                    | 2                    | (0.1)                |
| CATHETER SITE HAEMORRHAGE                                | 2                  | (0.1)              | 4                    | (0.2)                |
| INJECTION SITE HAEMATOMA                                 | 1                  | (0.1)              | 1                    | (0.1)                |
| INJECTION SITE HAEMORRHAGE                               | 1                  | (0.1)              | 0                    |                      |
| ULCER HAEMORRHAGE                                        | 1                  | (0.1)              | 1                    | (0.1)                |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS Medicinal |                    |                    |                      |                      |
| ANAEMIA POSTOPERATIVE                                    | 1                  | (0.1)              | 0                    |                      |
| CONTUSION                                                | 22                 | (1.3)              | 26                   | (1.6)                |
| EXCORIATION                                              | 0                  |                    | 1                    | (0.1)                |
| INJURY                                                   | 0                  |                    | 1                    | (0.1)                |
| LACERATION                                               | 2                  | (0.1)              | 0                    |                      |
| OPERATIVE HAEMORRHAGE                                    | 3                  | (0.2)              | 7                    | (0.4)                |
| PERIORBITAL HAEMATOMA                                    | 1                  | (0.1)              | 0                    |                      |
| POST PROCEDURAL COMPLICATION                             | 1                  | (0.1)              | 0                    |                      |
| POST PROCEDURAL HAEMATOMA                                | 1                  | (0.1)              | 0                    |                      |
| POST PROCEDURAL HAEMORRHAGE                              | 6                  | (0.4)              | 2                    | (0.1)                |
| SUBCUTANEOUS HAEMATOMA                                   | 0                  |                    | 1                    | (0.1)                |
| SUBDURAL HAEMATOMA                                       | 0                  |                    | 1                    | (0.1)                |
| WOUND HAEMORRHAGE                                        | 4                  | (0.2)              | 7                    | (0.4)                |
| INVESTIGATIONS                                           |                    |                    |                      |                      |
| HAEMOGLOBIN DECREASED                                    | 1                  | (0.1)              | 1                    | (0.1)                |
| OCCULT BLOOD                                             | 0                  |                    | 3                    | (0.2)                |
| OCCULT BLOOD POSITIVE                                    | 3                  | (0.2)              | 6                    | (0.4)                |

<div style=\"page-break-after: always\"></div>

|                                                                                             | Placebo (n=1637)   | Placebo (n=1637)        | Vorapaxar (n=1615)   | Vorapaxar (n=1615)      |
|---------------------------------------------------------------------------------------------|--------------------|-------------------------|----------------------|-------------------------|
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)                         |                    |                         |                      |                         |
| LUNG NEOPLASM MALIGNANT                                                                     | 0                  |                         | 1                    | (0.1)                   |
| NERVOUS SYSTEM DISORDERS                                                                    |                    |                         |                      |                         |
| HAEMORRHAGE INTRACRANIAL                                                                    | 2                  | (0.1)                   | 3                    | (0.2)                   |
| RENAL AND URINARY DISORDERS                                                                 |                    |                         |                      |                         |
| HAEMATURIA HAEMORRHAGE URINARY TRACT RENAL CYST HAEMORRHAGE                                 | 18 1 0             | (1.1) (0.1)             | 28 0 1               | (1.7) (0.1)             |
| REPRODUCTIVE SYSTEM AND BREAST DISORDERS                                                    |                    |                         |                      |                         |
| GENITAL HAEMORRHAGE MENORRHAGIA OLIGOMENORRHOEA PROSTATIC HAEMORRHAGE VAGINAL HAEMORRHAGE   | 0 1 0 0 1          | (0.1) (0.1)             | 1 2 1 1 0            | (0.1) (0.1) (0.1) (0.1) |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                             |                    |                         |                      |                         |
| EPISTAXIS HAEMOPTYSIS PHARYNGEAL HAEMORRHAGE PULMONARY HAEMORRHAGE                          | 24 4 0 0           | (1.5) (0.2)             | 71 5 2 1 authorised  | (4.4) (0.3) (0.1) (0.1) |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                      |                    |                         |                      |                         |
| ECCHYMOSIS HAEMORRHAGE SUBCUTANEOUS INCREASED TENDENCY TO BRUISE PETECHIAE SKIN HAEMORRHAGE | 7 1 18 0 8 longer  | (0.4) (0.1) (1.1) (0.5) | 5 0 31 1 14          | (0.3) (1.9) (0.1) (0.9) |
| SURGICAL AND MEDICAL PROCEDURES                                                             |                    |                         |                      |                         |
| SURGERY                                                                                     | 1                  | (0.1)                   | 0                    |                         |
| VASCULAR DISORDERS                                                                          |                    |                         |                      |                         |
| AORTIC ANEURYSM RUPTURE HAEMATOMA                                                           | 1 10               | (0.1) (0.6)             | 0 13                 | (0.8)                   |
| HAEMORRHAGE                                                                                 | 6                  | (0.4)                   | 11                   | (0.7)                   |

Percentage Cutoff is based on Either Treatment Group Overall The  results  in  the PAD  stratum appear  again  consistent  with  the Intended  Label  population with vorapaxar patients having an overall higher frequency of bleedings than placebo.   The most commonly reported event in both populations was epistaxis with more than double incidence with vorapaxar than controls. The differences between groups for other events, including haematuria and GI bleeding AEs, were smaller  but  still  the  rates  were  higher  in  patients  receiving  vorapaxar.  These  AEs  are  already included in the SmPC. There is no need for an update. OTHER ADVERSE EVENTS -Intended Label Population In  the Intended  Label  Population in  TRA  2°P-TIMI  50,  most  of  the  reported  treatment-emergent  nonbleeding AEs occurred at comparable rates in the two treatment groups.  The most frequently reported other  treatment-related  adverse  event  was  anaemia  with  a  higher  frequency  with  vorapaxar  than placebo. Medicinal product no longer authorised

Table  S.13. TRA  2 ° P  -  TIMI  50:    Summary  of  Treatment-Emergent  Adverse  Events  with  Annualized

<div style=\"page-break-after: always\"></div>

Event Rates - Other Adverse Events (2.0% Incidence) During Treatment for Subjects with No History of Stroke  or  TIA  Whose  Qualifying  Condition  Was  CAD  or  PAD:  As-Treated  Population  Number  (%)  of Subjects

|                                                         | Placebo                            | Placebo      | Vorapaxar (n=10059)      | Vorapaxar (n=10059)   |
|---------------------------------------------------------|------------------------------------|--------------|--------------------------|-----------------------|
|                                                         | (n=10049) Subjects with Events (%) | Event Rate a | Subjects with Events (%) | Event Rate a          |
| SUBJECTS REPORTING ANY ADVERSE EVENT                    | 7760(77.2)                         | (89.4)       | 7696(76.5)               | (89.7)                |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                    |                                    |              |                          |                       |
| ANAEMIA                                                 | 235 (2.3)                          | (1.0)        | 304 (3.0)                | (1.4)                 |
| CARDIAC DISORDERS                                       |                                    |              |                          |                       |
| ANGINA PECTORIS                                         | 290 (2.9)                          | (1.3)        | 288 (2.9)                | (1.3)                 |
| ATRIAL FIBRILLATION                                     | 219 (2.2)                          | (1.0)        | 231 (2.3)                | (1.0)                 |
| PALPITATIONS                                            | 195 (1.9)                          | (0.9)        | 197 (2.0)                | (0.9)                 |
| GASTROINTESTINAL DISORDERS                              |                                    |              |                          |                       |
| DIARRHOEA                                               | 301 (3.0)                          | (1.3)        | 284 (2.8)                | (1.3)                 |
| DYSPEPSIA                                               | 213 (2.1)                          | (0.9)        | 213 (2.1)                | (1.0)                 |
| NAUSEA                                                  | 262 (2.6)                          | (1.2)        | 235 (2.3)                | (1.1)                 |
| GENERAL DISORDERS AND ADMINISTRATION SITE               | CONDITIONS                         |              | authorised               |                       |
| CHEST DISCOMFORT                                        | 212 (2.1)                          | (0.9)        | 211 (2.1)                | (0.9)                 |
| CHEST PAIN                                              | 632 (6.3)                          | (2.9)        | 609 (6.1)                | (2.8)                 |
| FATIGUE                                                 | 452 (4.5)                          | (2.0)        | 466 (4.6)                | (2.1)                 |
| NON-CARDIAC CHEST PAIN                                  | 733 (7.3)                          | (3.4)        | 698 (6.9)                | (3.2)                 |
| OEDEMA PERIPHERAL                                       | 344 (3.4)                          | (1.5)        | 331 (3.3)                | (1.5)                 |
| INFECTIONS AND INFESTATIONS                             | longer                             |              |                          |                       |
| BRONCHITIS                                              | 300 (3.0)                          | (1.3)        | 321 (3.2)                | (1.4)                 |
| INFLUENZA                                               | 279 (2.8)                          | (1.2)        | 243 (2.4)                | (1.1)                 |
| NASOPHARYNGITIS                                         | 403 (4.0)                          | (1.8)        | 377 (3.7)                | (1.7)                 |
| PNEUMONIA                                               | 201 (2.0)                          | (0.9)        | 218 (2.2)                | (1.0)                 |
| UPPER RESPIRATORY TRACT INFECTION                       | 251 (2.5)                          | (1.1)        | 261 (2.6)                | (1.2)                 |
| URINARY TRACT INFECTION                                 | 434 (4.3)                          | (1.9)        | 471 (4.7)                | (2.1)                 |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS          |                                    |              |                          |                       |
| FALL                                                    | 296 (2.9) no                       | (1.3)        | 297 (3.0)                | (1.3)                 |
| INVESTIGATIONS                                          |                                    |              |                          |                       |
| ALANINE AMINOTRANSFERASE INCREASED                      | 172 (1.7)                          | (0.8)        | 197 (2.0)                | (0.9)                 |
| BLOOD CREATINE PHOSPHOKINASE INCREASED                  | 311 (3.1)                          | (1.4)        | 301 (3.0)                | (1.4)                 |
| GAMMA- GLUTAMYLTRANSFERASE INCREASED                    | 218 (2.2)                          | (1.0)        | 227 (2.3)                | (1.0)                 |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS product |                                    |              |                          |                       |
| ARTHRALGIA                                              | 347 (3.5)                          | (1.6)        | 340 (3.4)                | (1.5)                 |
| BACK PAIN                                               | 421 (4.2)                          | (1.9)        | 383 (3.8)                | (1.7)                 |
| MUSCLE SPASMS                                           | 241 (2.4)                          | (1.1)        | 228 (2.3)                | (1.0)                 |
| MUSCULOSKELETAL PAIN                                    | 236 (2.3)                          | (1.0)        | 239 (2.4)                | (1.1)                 |
| MYALGIA                                                 | 309 (3.1)                          | (1.4)        | 326 (3.2)                | (1.5)                 |
| PAIN IN EXTREMITY                                       | 435 (4.3)                          | (2.0)        | 400 (4.0)                | (1.8)                 |
| NERVOUS SYSTEM DISORDERS                                |                                    |              |                          |                       |
| DIZZINESS                                               | 546 (5.4)                          | (2.5)        | 541 (5.4)                | (2.5)                 |
| HEADACHE                                                | 416 (4.1)                          | (1.9)        | 379 (3.8)                | (1.7)                 |
| PSYCHIATRIC DISORDERS                                   |                                    |              |                          |                       |
| DEPRESSION                                              | 197 (2.0)                          | (0.9)        | 226 (2.2)                | (1.0)                 |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS         |                                    |              |                          |                       |
| COUGH                                                   | 363 (3.6)                          | (1.6)        | 385 (3.8)                | (1.7)                 |
| DYSPNOEA                                                | 420 (4.2)                          | (1.9)        | 427 (4.2)                | (1.9)                 |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS Medicinal        |                                    |              |                          |                       |
| RASH                                                    | 187 (1.9)                          | (0.8)        | 198 (2.0)                | (0.9)                 |
| VASCULAR DISORDERS                                      |                                    |              |                          |                       |
| HYPERTENSION                                            | 547 (5.4)                          | (2.5)        | 542 (5.4)                | (2.5)                 |
| HYPOTENSION                                             | 197 (2.0)                          | (0.9)        | 181 (1.8)                | (0.8)                 |

Note: Percentage cut-off is based on either treatment group overall

a. Event Rate is expressed as number of patients with events per 100 patient-years of exposure

## -PAD stratum

<div style=\"page-break-after: always\"></div>

Table S.14. TRA 2 ° P - TIMI 50:  Summary of Treatment-Emergent Adverse Events with Annualized Event Rates -Other Adverse Events (2.0% Incidence) During Treatment for Subjects with No History of Stroke or TIA Whose Qualifying Condition Was PAD: As-Treated Population Number (%) of Subjects

|                                                      | Placebo (n=1637)         | Placebo (n=1637)   | Vorapaxar (n=1615)       | Vorapaxar (n=1615)   |
|------------------------------------------------------|--------------------------|--------------------|--------------------------|----------------------|
|                                                      | Subjects with Events (%) | Event Rate a       | Subjects with Events (%) | Event Rate a         |
| SUBJECTS REPORTING ANY ADVERSE EVENT                 | 1295 (79.1)              | (85.7)             | 1268 (78.5)              | (89.2)               |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                 |                          |                    |                          |                      |
| ANAEMIA                                              | 77 (4.7)                 | (2.0)              | 96 (5.9)                 | (2.6)                |
| THROMBOCYTOPENIA                                     | 22 (1.3)                 | (0.5)              | 34 (2.1)                 | (0.9)                |
| CARDIAC DISORDERS                                    |                          |                    |                          |                      |
| ATRIAL FIBRILLATION                                  | 50 (3.1)                 | (1.3)              | 63 (3.9)                 | (1.7)                |
| CARDIAC FAILURE                                      | 45 (2.7)                 | (1.1)              | 36 (2.2)                 | (0.9)                |
| CARDIAC FAILURE CONGESTIVE                           | 22 (1.3)                 | (0.5)              | 37 (2.3)                 | (1.0)                |
| PALPITATIONS                                         | 32 (2.0)                 | (0.8)              | 20 (1.2)                 | (0.5)                |
| GASTROINTESTINAL DISORDERS                           |                          |                    | authorised               |                      |
| CONSTIPATION                                         | 36 (2.2)                 | (0.9)              | 46 (2.8)                 | (1.2)                |
| DIARRHOEA                                            | 67 (4.1)                 | (1.7)              | 67 (4.1)                 | (1.8)                |
| NAUSEA                                               | 55 (3.4)                 | (1.4)              | 46 (2.8)                 | (1.2)                |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS |                          |                    |                          |                      |
| CHEST PAIN                                           | 52 (3.2)                 | (1.3)              | 44 (2.7)                 | (1.2)                |
| FATIGUE                                              | 57 (3.5)                 | (1.5)              | 59 (3.7)                 | (1.6)                |
| NON-CARDIAC CHEST PAIN                               | 56 (3.4)                 | (1.4)              | 61 (3.8)                 | (1.6)                |
| OEDEMA PERIPHERAL                                    | 78 (4.8)                 | (2.0)              | 62 (3.8)                 | (1.6)                |
| INFECTIONS AND INFESTATIONS                          | longer                   |                    |                          |                      |
| BRONCHITIS                                           | 87 (5.3)                 | (2.3)              | 67 (4.1)                 | (1.8)                |
| INFLUENZA                                            | 40 (2.4)                 | (1.0)              | 30 (1.9)                 | (0.8)                |
| NASOPHARYNGITIS                                      | 65 (4.0)                 | (1.7)              | 66 (4.1)                 | (1.8)                |
| PNEUMONIA                                            | 52 (3.2)                 | (1.3)              | 62 (3.8)                 | (1.6)                |
| UPPER RESPIRATORY TRACT INFECTION                    | 44 (2.7)                 | (1.1)              | 63 (3.9)                 | (1.7)                |
| URINARY TRACT INFECTION                              | 93 (5.7)                 | (2.4)              | 108 (6.7)                | (2.9)                |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS no    |                          |                    |                          |                      |
| FALL                                                 | 81 (4.9)                 | (2.1)              | 72 (4.5)                 | (1.9)                |
| INVESTIGATIONS                                       |                          |                    |                          |                      |
| BLOOD CREATINE PHOSPHOKINASE INCREASED product       | 37 (2.3)                 | (0.9)              | 40 (2.5)                 | (1.1)                |
| GAMMA- GLUTAMYLTRANSFERASE INCREASED                 | 37 (2.3)                 | (0.9)              | 38 (2.4)                 | (1.0)                |
| METABOLISM AND NUTRITION DISORDERS                   |                          |                    |                          |                      |
| DIABETES MELLITUS                                    | 31 (1.9)                 | (0.8)              | 34 (2.1)                 | (0.9)                |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS      |                          |                    |                          |                      |
| ARTHRALGIA                                           | 85 (5.2)                 | (2.2)              | 61 (3.8)                 | (1.6)                |
| BACK PAIN                                            | 93 (5.7)                 | (2.4)              | 72 (4.5)                 | (1.9)                |
| MUSCLE SPASMS                                        | 47 (2.9)                 | (1.2)              | 52 (3.2)                 | (1.4)                |
| MUSCULOSKELETAL PAIN                                 | 27 (1.6)                 | (0.7)              | 38 (2.4)                 | (1.0)                |
| OSTEOARTHRITIS                                       | 27 (1.6)                 | (0.7)              | 34 (2.1)                 | (0.9)                |
| PAIN IN EXTREMITY                                    | 104 (6.4)                | (2.7)              | 91 (5.6)                 | (2.5)                |
| NERVOUS SYSTEM DISORDERS                             |                          |                    |                          |                      |
| DIZZINESS                                            | 82 (5.0)                 | (2.1)              | 92 (5.7)                 | (2.5)                |
| HEADACHE                                             | 65 (4.0)                 | (1.7)              | 67 (4.1)                 | (1.8)                |
| SYNCOPE                                              | 38 (2.3)                 | (1.0)              | 35 (2.2)                 | (0.9)                |
| PSYCHIATRIC DISORDERS                                |                          |                    |                          |                      |
| DEPRESSION                                           | 28 (1.7)                 | (0.7)              | 32 (2.0)                 | (0.8)                |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS      |                          |                    |                          |                      |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE Medicinal      | 40 (2.4)                 | (1.0)              | 47 (2.9)                 | (1.2)                |
| COUGH                                                | 46 (2.8)                 | (1.2)              | 54 (3.3)                 | (1.4)                |
| DYSPNOEA                                             | 58 (3.5)                 | (1.5)              | 79 (4.9)                 | (2.1)                |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS               |                          |                    |                          |                      |
| RASH                                                 | 31 (1.9)                 | (0.8)              | 36 (2.2)                 | (0.9)                |
| VASCULAR DISORDERS                                   |                          |                    |                          |                      |
| HYPERTENSION                                         | 91 (5.6)                 | (2.3)              | 105 (6.5)                | (2.8)                |
| HYPOTENSION                                          | 36 (2.2)                 | (0.9)              | 35 (2.2)                 | (0.9)                |
| INTERMITTENT CLAUDICATION                            | 82 (5.0)                 | (2.1)              | 81 (5.0)                 | (2.2)                |

Percentage Cutoff is based on Either Treatment Group Overall.

a. Event Rate is expressed as number of patients with events per 100 patient-years of exposure.

The  analyses  of  non-bleeding  AEs  did  not  provide  any  important  new  information  over  the  data

<div style=\"page-break-after: always\"></div>

previously  assessed.  Anaemia  was  consistently  more  frequent  with  vorapaxar  compared  to  controls and is included in the current SmPC. Otherwise no major differences in the incidence of common AEs were observed between treatment groups across the examined populations. The only exception in the PAD stratum was a higher rate of thrombocytopenia with vorapaxar compared to placebo which was not previously observed in post-MI patients. Further clarification, it can be concluded that at this point there is no sufficient evidence to suggest a causal relationship with vorapaxar therapy to justify the inclusion of this AE in the safety information (section 4.8) of the SmPC.

<!-- image -->

|                                                     | Placebo (n=10090)   | Vorapaxar (n=10080)   |
|-----------------------------------------------------|---------------------|-----------------------|
| Total No. of Deaths                                 | n (%) 445 (4.4) no  | n (%) 409 (4.1)       |
| Total No. Of Deaths On or Before the Last Visit a,b | 415 (4.1)           | 382 (3.8)             |
| Total No. of Deaths After the Last Visit            | 30 (0.3)            | 27 (0.3)              |

|                                                     | Placebo (n=1651)   | Vorapaxar (n=1622)   |
|-----------------------------------------------------|--------------------|----------------------|
| Total No. of Deaths                                 | 167(10.1)          | 156                  |
| Total No. Of Deaths On or Before the Last Visit a,b | 156 (9.4)          | (9.6)                |
|                                                     |                    | 144 (8.9)            |
| Total No. of Deaths After the Last Visit            | 11 (0.7)           | 12 (0.7)             |

Serious adverse events and deaths DEATHS -Intended Label Population Of the 20,170 subjects in the Intended Label Population , 854 (4.2%) died during the study.  Of those, 409 (4.1%) were assigned to vorapaxar and 445 (4.4%) to placebo [Table S.15].  Per protocol, deaths were to be reported up to 30 days after the final visit.  When spontaneous events, including death, were reported even if they occurred later than required per protocol they were not removed from the database. There were fewer deaths from any cause in the vorapaxar treatment group than in the placebo group. Table S.15. T RA 2 ° P - TIMI 50 All Cause Death During the Study in Subjects With No History of Stroke or TIA Whose Qualifying Condition Was CAD or PAD a. Death Date recorded by Adjudicator is used, if different from the one recorded by Investigator. b. For subjects with partial death date, the death date is estimated -PAD stratum Similarly, in the PAD stratum there were overall fewer deaths among the vorapaxar terated patients. Table S.16. T RA 2 ° P - TIMI 50:  All Cause Death During the Study in Subjects With No History of Stroke or TIA Whose Qualifying Condition Was PAD a. Death Date recorded by Adjudicator is used, if different from the one recorded by Investigator. Medicinal product no longer authorised

Across all populations there were fewer deaths among vorapaxar patients than controls. Of interest, the percentage of deaths in the PAD stratum , for both vorapaxar and control groups, is almost three times as high (9.6% and 10.1%, respectively) compared to the mortality previously seen in the postMI patients (3% and 3.3%, respectively) as shown in the table below, which is also reflected in the Intended Label Population .

All-Cause  Death  Recorded  During  the  Study  in  Overall  Population  and  Post-MI  Subjects  without  a

<div style=\"page-break-after: always\"></div>

|                                                | Overall Population   | Overall Population   | Post Ml without a History of StrokeorTIA   | Post Ml without a History of StrokeorTIA   |
|------------------------------------------------|----------------------|----------------------|--------------------------------------------|--------------------------------------------|
|                                                | Placebo              | Vorapaxar            | Placebo                                    | Vorapaxar                                  |
|                                                | (n=13224)            | (n=13225)            | (n=8439)                                   | (n=8458)                                   |
| TOTAL NO. OF DEATHS FROM DEATH or SURVIVALPAGE | 610 (4.6)            | 580 (4.4)            | 278 (3.3)                                  | 253 (3.0)                                  |
| TOTALNO.ofDEATHSONorBEFOREtheLAST              | 565 (4.3)            | 540 (4.1)            | 259 (3.1)                                  | 238 (2.8)                                  |

History of Stroke or TIA: As-Treated Population a,b

| Medicinal                             | Placebo (n=10049)   | Vorapaxar (n=10059)   |
|---------------------------------------|---------------------|-----------------------|
| SUBJECTS REPORTING ANY ADVERSE EVENT  | 2256 (22.4)         | 2190 (21.8)           |
| NON-CARDIAC CHEST PAIN                | 389 (3.9)           | 372 (3.7)             |
| CARDIAC FAILURE                       | 116 (1.2)           | 109 (1.1)             |
| PNEUMONIA                             | 103 (1.0)           | 107 (1.1)             |
| ATRIAL FIBRILLATION                   | 65 (0.6)            | 90 (0.9)              |
| CARDIAC FAILURE CONGESTIVE            | 53 (0.5)            | 60 (0.6)              |
| SYNCOPE                               | 34 (0.3)            | 54 (0.5)              |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 52 (0.5)            | 49 (0.5)              |
| OSTEOARTHRITIS                        | 60 (0.6)            | 46 (0.5)              |
| URINARY TRACT INFECTION               | 23 (0.2)            | 38 (0.4)              |
| MUSCULOSKELETAL CHEST PAIN            | 22 (0.2)            | 33 (0.3)              |
| CHOLELITHIASIS                        | 32 (0.3)            | 30 (0.3)              |
| INGUINAL HERNIA                       | 23 (0.2)            | 29 (0.3)              |
| BENIGN PROSTATIC HYPERPLASIA          | 19 (0.2)            | 28 (0.3)              |
| CELLULITIS                            | 27 (0.3)            | 28 (0.3)              |
| PROSTATE CANCER                       | 37 (0.4)            | 28 (0.3)              |
| VENTRICULAR TACHYCARDIA               | 26 (0.3)            | 26 (0.3)              |
| ANAEMIA                               | 7 (0.1)             | 25 (0.2)              |
| CHOLECYSTITIS                         | 15 (0.1)            | 25 (0.2)              |
| GASTROENTERITIS                       | 25 (0.2)            | 25 (0.2)              |
| ATRIAL FLUTTER                        | 14 (0.1)            | 20 (0.2)              |
| BRONCHITIS                            | 17 (0.2)            | 20 (0.2)              |

a Death Date recorded by Adjudicator is used, if different from the one recorded by Investigator. b For subjects with partial death date, the death date is estimated This further supports the notion of the increased risk and poor prognosis of the PAD population.  With regard to specific causes of deaths in the PAD stratum the MAH has provided additional data which do not  show  any  particular  pattern  that  might  suggest  an  unfavourable  effect  of  vorapaxar  on  specific conditions. However, in most categories the numbers, and the respective differences between groups, are small to permit conclusions. The majority of deaths were due to 'cardiac disorders' and there was a small trend in favour of vorapaxar although overall 'cardiovascular' deaths were slightly more in the active group. SERIOUS ADVERSE EVENTS -Intended Label Population The  overall  incidence  of  non-bleeding  serious  adverse  events  (SAEs)  in  TRA  2ºP-TIMI  50  was  slightly lower in the vorapaxar group compared to placebo in the Intended Label Population (Table S.17). There was a slight imbalance in the incidence of atrial fibrillation and syncope between vorapaxar and placebo but there was no contributable cause for these differences. Table S.17. TRA 2 ° P - TIMI 50:  Summary of Serious Adverse Events: Other Adverse Events for at Least 20 Subjects During treatment By Descending Frequency For Subjects With No History of Stroke or TIA  Whose  Qualifying  Condition  Was  CAD  or  PAD:  As-Treated  Population  Event  Accrual  Period: Randomization to Last Visit SUBJECTS REPORTING ANY ADVERSE EVENT NON-CARDIAC CHEST PAIN CARDIAC FAILURE PNEUMONIA ATRIAL FIBRILLATION CARDIAC FAILURE CONGESTIVE SYNCOPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE OSTEOARTHRITIS URINARY TRACT INFECTION Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                  | Placebo (n=10049)   | Vorapaxar (n=10059)   |
|----------------------------------|---------------------|-----------------------|
| GASTRITIS                        | 16 (0.2)            | 20 (0.2)              |
| GASTROOESOPHAGEAL REFLUX DISEASE | 23 (0.2)            | 20 (0.2)              |
| RENAL FAILURE ACUTE              | 22 (0.2)            | 20 (0.2)              |
| HYPOTENSION                      | 21 (0.2)            | 19 (0.2)              |
| DEHYDRATION                      | 20 (0.2)            | 17 (0.2)              |
| INTERVERTEBRAL DISC PROTRUSION   | 28 (0.3)            | 16 (0.2)              |
| NEPHROLITHIASIS                  | 22 (0.2)            | 15 (0.1)              |
| SEPSIS                           | 21 (0.2)            | 10 (0.1)              |
| PULMONARY EMBOLISM               | 25 (0.2)            | 6 (0.1)               |

Note: Adverse Events are presented in decreasing frequency based upon the treatment group 'vorapaxar'. Cutoff is based on either treatment group overall.

|                                       | Placebo (n=1637)   | Placebo (n=1637)   | Vorapaxar n=1615   | Vorapaxar n=1615   |
|---------------------------------------|--------------------|--------------------|--------------------|--------------------|
| Adverse Event                         | n (%)              | n (%)              | n (%)              | n (%)              |
| SUBJECTS REPORTING ANY ADVERSE EVENT  | 484 longer         | (29.6)             | 488                | (30.2)             |
| NON-CARDIAC CHEST PAIN                | 24                 | (1.5)              | 34                 | (2.1)              |
| PNEUMONIA                             | 32                 | (2.0)              | 33                 | (2.0)              |
| CARDIAC FAILURE CONGESTIVE            | 16                 | (1.0)              | 24                 | (1.5)              |
| ATRIAL FIBRILLATION                   | 16                 | (1.0)              | 23                 | (1.4)              |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 17                 | (1.0)              | 23                 | (1.4)              |
| CARDIAC FAILURE                       | 30                 | (1.8)              | 22                 | (1.4)              |

-PAD stratum Table S.18. TRA 2 ° P - TIMI 50:  Summary of Serious Adverse Events: Other Adverse Events for at Least 20 Subjects During treatment By Descending Frequency For Subjects With No History of Stroke or TIA Whose Qualifying Condition Was PAD: As-Treated Population Event Accrual Period: Randomization to Last Visit Adverse Event SUBJECTS REPORTING ANY ADVERSE EVENT NON-CARDIAC CHEST PAIN PNEUMONIA CARDIAC FAILURE CONGESTIVE ATRIAL FIBRILLATION CHRONIC OBSTRUCTIVE PULMONARY DISEASE CARDIAC FAILURE Adverse Events are presented in decreasing frequency based upon the treatment group 'vorapaxar'. Cutoff is based on Either Treatment Group Overall. In general, there is little new information over the previously assessed TRA 2ºP-TIMI 50 data. In the Intended Label Population the rates of individual SAEs (other than bleeding) was low, with very few events like chest pain (non-cardiac) reaching an incidence &gt;1%. However, it is noted that PAD patients had an overall higher incidence of SAEs across both treatment groups. Still the numbers are small as they are the differences between vorapaxar and placebo. A  finding  in  the Intended  Label  Population, the  previous    Proposed    Label  Population  (only  post-MI patients) and the PAD stratum (where the relative rates are slightly higher) appears to be an slight imbalance in the reports of atrial fibrillation (reported as TEAE and SAE as well as the most frequent non-bleeding cause of discontinuation). Upon CHMP request, the MAH provided more information (on this  issue.  It  is  concluded  that  at  this  point  there  is  no  sufficient  evidence  to  suggest  a  causal relationship with vorapaxar therapy to justify the inclusion of this AE in the safety information (section 4.8) of the SmPC. Laboratory findings / Safety in special populations Medicinal product no longer authorised

TRA  2ºP-TIMI  50  laboratory  findings  and  safety  in  special  populations  were  assessed  during  the previous review and relevant information, as appropriate, is included in the SmPC.

## Safety related to drug-drug interactions and other interactions

There are no significant new data. Safety related to interactions was assessed during the initial MAA

<div style=\"page-break-after: always\"></div>

and relevant information on clinical important interactions is included in the SmPC.

## Discontinuation due to AES

In  the Intended  Label  Population ,  more  subjects  in  the  vorapaxar  group  (301  [3.0%])  discontinued treatment due to bleeding events compared to subjects in the placebo group (181 [1.8%]).

A  large  proportion  of  bleeding  events  leading  to  treatment  discontinuation  were  categorized  in  the gastrointestinal  System  Organ  Class  (SOC):100  [1.0%]  subjects  in  the  vorapaxar  group  and  vs.  66 [0.7%] subjects  in  the  placebo  group.    (Subjects  who  experienced  multiple  events  were  only  counted once in the respective SOC).  The most frequently reported single bleeding event resulting in treatment discontinuation in both treatment groups was epistaxis (47 [0.5%] in the vorapaxar group and 19 [0.2%] in  the  placebo  group).    However,  gastrointestinal  haemorrhage  is  the  most  common  bleeding  event causing discontinuation when relevant bleeding events are combined (melena, rectal haemorrhage, and GI haemorrhage).

For  other  (non-bleeding)  adverse  events  resulting  in  treatment  discontinuation  in  the Intended  Label Population , atrial fibrillation was the most frequently reported event. it should be noted that the protocol stipulated  that  administration  of  oral  anticoagulation  required  cessation  of  study  drug.    Additionally,  a higher observed incidence of anaemia leading to treatment discontinuation was noted in the vorapaxar group compared to placebo (0.3% for vorapaxar and 0.1% for placebo). CHMP comments Again there is little significant new information over the previously assessed TRA 2ºP-TIMI 50 data. In the Intended  Label  Population epistaxis  was  the  main  bleeding  event  leading  to  discontinuation  of vorapaxar.  It is noted that among non-bleeding events atrial fibrillation was the most common cause of discontinuation for vorapaxar therapy in the Intended Label Population (but also the PAD stratum ). As mentioned above, although the numbers are small this issue needs further investigation. Post marketing experience Vorapaxar was approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD) by the United States FDA in May 2014.  A positive Commission Decision was granted in the European Union on January 19, 2015 for the reduction of atherothrombotic events in patients with a history of MI.  Relevant published literature has been  cited  where  applicable  to  provide  context  and  background  around  antithrombotic  drugs,  other treatment options and typical populations which may be particularly useful when considering a new class of antithrombotic drugs. The MAH has provided additional safety data from post-marketing experience including post-marketing reports of bleeding from PAD patients treated with vorapaxar. However, the numbers are small and the data offer little  useful  information.  It  is  agreed  that  in  certain  serious  cases there  were  factors  that increased  the  general  risk  of  bleeding  (such  as  older  age,  peptic  ulcer,  recent  surgery)  which  are already described in the vorapaxar SmPC. Medicinal product no longer authorised

## 2.6.1. Discussion on clinical safety

The TRA 2ºP-TIMI 50 safety findings were evaluated during the initial MAA. In addition to the post-MI population,  data  from  the Overall population  of  the  trial  and  all  strata  were  also  analysed;  therefore,

<div style=\"page-break-after: always\"></div>

there is little new safety information in this submission over and above what was previously assessed. However, while in the previous review the focus was mainly on post-MI patients, this time safety data for patients  with  PAD  with  no  history  of  stroke  and  TIA  have  been  submitted  separately,  which  allows comparisons between populations.

In this application, as with efficacy, the MAH focuses on safety in the Intended Label Population , which comprises the CAD stratum (post-MI patients) enriched with the PAD stratum data. However, the latter group represents a small fraction of the Intended Label Population ; so it is not surprising that the safety findings are very similar to those in post-MI patients, as reviewed during the initial MAA.

Nevertheless, when PAD patients are examined separately (as PAD stratum, Clinical PAD and Aspirin-only PAD population ) there are some interesting differences and observations. For example, it appears that in general  patients  with  PAD  had  a  higher  incidence  of  bleedings,  serious  adverse  events  and  deaths compared to their post-MI counterparts. This concerned both vorapaxar and placebo groups, suggesting a population  at  an  overall  high  risk  and  poor  prognosis.  Whether  this  is  a  characteristic  related  to  the greater atherosclerotic burden of the disease or other factors it remains unknown. Clearly, the risk of bleeding is the major concern with vorapaxar and in TRA 2ºP-TIMI 50 this was the principal safety endpoint. Bleeding events were adjudicated by an independent clinical events committee and were graded according to GUSTO as well as TIMI criteria. Patients on vorapaxar were consistently at higher risk of bleedings across all examined populations and subgroups. In the PAD stratum the rate of GUSTO moderate or severe accrued event rate in the vorapaxar group was 6.8% compared to placebo at 4.9% (HR 1.38; 95% CI 1.03 to 1.85; p&lt; 0.033) a difference driven mainly by moderate events while GUSTO severe events were similar between groups. GUSTO moderate and TIMI minor/clinical significant bleedings were significantly more common with vorapaxar. There were very few cases of ICH and fatal bleeding, with similar numbers between vorapaxar and placebo. These findings are generally consistent to those previously seen in post-MI patients. In terms of the impact of concomitant antiplatelet treatment with aspirin and/or clopidogrel, it appears that  in  general  patients  receiving  aspirin  alone  had  a  lower  rate  of  bleeding  (according  to  GUSTO  and TIMI)  irrespective  of  whether  they  were  on  vorapaxar  or  placebo.  Patients  on  background  clopidogrel alone  (although  the  numbers  of  events  are  small)  appear  to  have  a  similar  risk  as  those  on  aspirin. However, further data submitted by the MAH showing bleeding events in patients receiving dual therapy with aspirin+clopidogrel raised further concerns. Although there are some limitations which do not permit drawing firm conclusions, the rates of bleeding in patients who received vorapaxar with both aspirin and clopidogrel are not reassuring. It is true that serious and life-threatening events are rare across all groups but  the  long-term  risks  of  an  intense  antiplatelet  therapy  should  be  carefully  considered  against  the possible expected benefits. Taking  also  into  account  the  overall  modest  efficacy  evidence,  it  is  not  possible  to  confirm  that  the benefit:risk  for  vorapaxar  as  part  of  a  triple  antiplatelet  therapy  with  aspirin  plus  clopidogrel  remains positive. Medicinal product no longer authorised

In this context and also in the light of the current clinical guidelines, which generally advise against dual antiplatelet  therapy  in  PAD,  a  recommendation  for  use  of  vorapaxar  in  combination  with  aspirin  plus clopidogrel is not justified. Therefore, the MAH updated the SmPC accordingly (sections 4.1 and 4.2) to indicate  that  vorapaxar  should  be  'co-administered  with  acetylsalicylic  acid  (ASA)  and/or,  where appropriate, clopidogrel…' .

An additional point that deserves further consideration is the cumulative risk of bleeding over long-term therapy. Unlike post-MI patients in whom treatment may be time-limited following the acute event (which applies also to the use of other concomitant antiplatelets like clopidogrel), in PAD, in the absence of an index event, vorapaxar (as well as concomitant aspirin and/or clopidogrel) may be a chronic therapy for

<div style=\"page-break-after: always\"></div>

many patients. Therefore, the cumulative risk of bleeding with vorapaxar over time in this group may be higher than in post-MI patients and this needs to be taken into account in the benefit:risk. The currently proposed  SmPC  (section  4.2)  suggests  a  re-evaluation  of  the  benefits  and  risks  to  continue  therapy beyond the first 24 months for post-MI patients but not for PAD patients.

With regard to other non-bleeding adverse events in the TRA 2ºP-TIMI 50, there were no particular new findings  but  a  consistency  was  noted  across  all  populations  (although  slightly  more  pronounced  in  the PAD stratum ) in the reports of atrial fibrillation with a higher frequency among vorapaxar treated patients and an imbalance in reports of thrombocytopenia. Which do not warrant any SmPC amendment at this time. Total mortality was slightly lower in the vorapaxar group.

2.6.2. Conclusions on clinical safety There  is  limited  new  safety  information  in  this  submission  over  and  above  the  TRA  2ºP-TIMI  50  data assessed during the initial MAA. Bleeding remains the main safety issue with vorapaxar. In consistence with previous analyses in post-MI patients,  the  data  suggest  that  risk  is  also  high  in  PAD  patients  receiving  vorapaxar,  although  the likelihood of severe bleeding including intracranial haemorrhages and fatal events is much smaller and no significantly  different  from  controls.  A  point  that  needs  careful  consideration  is  the  potential  impact  of background antiplatelet therapy with the combination of aspirin or clopidogrel. The current data suggest that  although  vorapaxar  may  be  taken  with  aspirin  or  clopidogrel  alone,  the  overall  long-term  risk  of bleeding  with  vorapaxar  as  part  of  a  triple  antiplatelet  therapy  may  be  excessively  high.Other  than bleeding, there were no major new issues or signals, although there are still outstanding points that the MAH will need to clarify and address to confirm that all safety aspects have been adequately investigated and ensure that all relevant safety information is included in the product information. 2.6.3. PSUR cycle The PSUR cycle remains unchanged. 2.7. Risk management plan The CHMP received the following PRAC Advice on the submitted Risk Management Plan: The PRAC considered that the risk management plan version 2.4 is acceptable. The PRAC endorsed PRAC Rapporteur assessment repor&gt; is attached. The MAH is reminded that, within 30 calendar days of the receipt of the Opinion, an updated version of Annex I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu. The CHMP endorsed this advice without changes. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Important identified risks   | • Medically important bleeding, including intracranial hemorrhage • Drug-drug interaction: strong inhibitor of CYP3A4 • Drug-drug interaction: strong inducer of CYP3A4                                                                                                   |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | • Increased risk of bleeding in patients with body weight < 60 kg • Ocular effects • Phospholipidosis                                                                                                                                                                     |
| Missing information          | • Pregnant and breastfeeding women • Pediatric population • Patients with severe hepatic dysfunction • Co-administration with oral anticoagulants (e.g. warfarin), prasugrel, or ticagrelor • Severe thrombocytopenia • Coadministration with NSAIDs (other than aspirin) |

| Study / Activity                                                                                                                                           | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                  | Status   | Date for Submission of Interim / Final Reports (target dates)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 3: Observational postauthorization safety study (PASS) to characterize normal conditions of use and safety following administration of vorapaxar. | Describe physician prescribing patterns in an outpatient setting during the post- licensure period with regards to key aspects of the product label in terms of appropriate patient selection (medical history, contraindications) and concomitant drug administration, and to estimate rates of hospitalization for bleeding events (e.g. intracranial hemorrhage (ICH), GI hemorrhage) in a real-world clinical setting. Evaluate the effectiveness of the risk minimization measures. Medicinal product | Intracranial haemorrhage, especially among patients with a history of stroke/TIA Medically important bleeding risks, excluding ICH Drug-drug interaction: strong inhibitor of CYP3A4 Patients with severe hepatic dysfunction Co-administration with oral anticoagulants (e.g. warfarin), prasugrel, or ticagrelor Off-label use no longer | Planned  | EU PASS: Progress reports will be submitted with each PSUR until completion of the study. Data on prescribing patterns will be submitted 2 years after EMA protocol approval and commercial launch in at least one participating PASS country. Additional reports with prescribing data will be submitted every two years thereafter until completion of the study. The timeline for the interim report with outcomes data and final study report will be included with the full protocol to the EMA at the time of EU commercial launch in at least one EU member state or within 3 months after approval of the indication extension to PAD patients. The final report with outcomes data and baseline data for all patients exposed to vorapaxar will be submitted once the required amount of person years of exposure has been accumulated. The timeline for this report will depend on sample size and the rate of marketing uptake, for which limited information is available at this time. The final report should be submitted no later than December 2020. |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

| Safety Concern                                                                                 | Routine Risk Minimization Measures                                                                                                                                                                                                                           | Additional Risk Minimization Measures   |
|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Important Identified Risks                                                                     | Important Identified Risks                                                                                                                                                                                                                                   | Important Identified Risks              |
| Medically important bleeding, including intracranial hemorrhage                                | SmPC: Section 4.3 Contraindications, Section 4.4 Special warnings and precautions for use, Section 4.5 Interaction with other medicinal products and other forms of interaction, Section 4.8 Undesirable effects, and Section 5.1 Pharmacodynamic properties | None                                    |
| Drug-drug interaction: strong inhibitor of CYP3A4                                              | SmPC: Section 4.5 Interaction with other medicinal products and other forms of interaction, and Section 5.2 Pharmacokinetic properties                                                                                                                       | None                                    |
| Drug-drug interaction: strong inducer of CYP3A4                                                | SmPC: Section 4.5 Interaction with other medicinal products and other forms of interaction, and Section 5.2 Pharmacokinetic properties                                                                                                                       | None                                    |
| Important Potential Risks authorised                                                           | Important Potential Risks authorised                                                                                                                                                                                                                         | Important Potential Risks authorised    |
| Increased risk of bleeding in patients with body weight < 60 kg                                | The risk of increased bleeding in patients with low body weight is described in the SmPC in 4.4 Special warnings and precautions for use General risk of bleeding. longer                                                                                    | None                                    |
| Ocular effects                                                                                 | Section 5.3 Preclinical safety data.                                                                                                                                                                                                                         | None                                    |
| Phospholipidosis                                                                               | Section 5.3 Preclinical safety data.                                                                                                                                                                                                                         | None                                    |
| Missing Information                                                                            | Missing Information                                                                                                                                                                                                                                          | Missing Information                     |
| Pregnant and Breastfeeding Women                                                               | Section 4.6 Fertility, pregnancy and breastfeeding women and Section 5.3 Pre-clinical safety data no                                                                                                                                                         | None                                    |
| Pediatric population                                                                           | Section 4.2 Posology and method of administration and Section 5.1 Pharmacodynamic properties                                                                                                                                                                 | None                                    |
| Patients with severe hepatic dysfunction                                                       | Section 4.2 Posology and method of administration, Section 4.3 Contraindications, Section 4.4 Special warnings and precautions for use, and Section 5.2 Pharmacokinetic properties product                                                                   | None                                    |
| Co-administration with oral anticoagulants (e.g. warfarin), prasugrel, or ticagrelor Medicinal | Section 4.2 Posology and method of administration, Section 4.4 Special warnings and precautions for use, and Section 4.5 Interaction with other medicinal products                                                                                           | None                                    |
| Severe thrombocytopenia                                                                        | No routine risk minimization measure proposed                                                                                                                                                                                                                | None                                    |
| Coadministration with NSAIDs (other than aspirin)                                              | Section 4.4 Special warnings and precautions for use, General risk of bleeding.                                                                                                                                                                              | None                                    |

## 2.8. Update of the Product information

As  a  consequence  of  this  new  indication,  sections  4.1,  4.2,  4.4,  4.8  and  5.1  of  the  SmPC  have  been updated. The Package Leaflet has been updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the contact details of local representative in Luxembourg in the Package Leaflet. Furthermore, the PI is brought in line with the QRD template version 9.1.

<div style=\"page-break-after: always\"></div>

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

Despite  improved  management  of  risk  factors  and  use  of  antiplatelets,  the  residual  CV  risk  among patients with PAD remains high, as the TRA 2ºP-TIMI 50 data also confirmed. This suggests a high unmet need for effective therapies that could help prevent future CV events and save lives. TRA 2ºP-TIMI 50 examined the incremental efficacy and safety of vorapaxar over standard therapy in a wide range of patients with atherosclerotic disease. After the exclusion of patients with history of stroke (and TIA) the results in the remaining patients with a recent history of MI or PAD, i.e. the 'Intended Label Population ' , showed that vorapaxar could significantly reduce the composite of CV deaths, MIs, stroke and urgent coronary revascularisation and key secondary endpoints by 17% and 20%, respectively relative to placebo.  All components of the composite endpoints showed a consistent trend in favour of vorapaxar, although MI  was the most frequent event that contributed most to the difference between treatments.  The  data  further  suggest  that  the  effect  of  vorapaxar  on  the  primary  and  key  secondary endpoints was maintained for the duration of the trial. In addition to lowering the risk of the first event within the composite endpoints exploratory analyses indicated that vorapaxar was also associated with a reduction in the incidence of total events. When the  TRA  2ºP-TIMI  50  efficacy  was  examined  separately  in  the PAD stratum, the  results  were generally consistent with the Intended Label Population with all components of the composite primary and key secondary endpoints showing a trend in favour of vorapaxar (an overall reduction of 13% and 12%, for the primary and key secondary endpoint respectively relative to placebo). In this case, the component contributing most to the differences between treatment groups was CV mortality (vorapaxar: 47 [2.9%] deaths vs placebo 58 [3.5%]), although again MI was the most common event. However, in the PAD stratum the differences between vorapaxar and placebo did not reach statistical significance. Additional analyses in the Clinical PAD and Aspirin-Only PAD populations were similar to the PAD stratum . Uncertainty in the knowledge about the beneficial effects As previously discussed, the strength of the efficacy evidence for vorapaxar in this application, depends to a large extent on the examined TRA 2ºP-TIMI 50 population; more specifically, whether the results in the Intended Label Population that includes mostly post-MI are adequate to draw conclusions also for PAD patients, or whether this should be based entirely on the findings in the PAD stratum . It  is  concluded  that the  results  showed  a  clear  consistency  across  the different  populations,  with  most individual  endpoints  in  the  primary  and  secondary  analyses  favouring  vorapaxar,  which  suggests  that there are patients who are likely to benefit from this treatment. However, in the PAD stratum alone the effects were not significantly different between vorapaxar and placebo. Medicinal product no longer authorised

The  MAH's  view  about  the  primary  role  of  the Intended  Label  Population in  this  evaluation,  based  on methodological and clinical arguments (in terms of the study design to maintain the scope and integrity of the trial and, in terms of clinical relevance to examine together patients with a common atherothrombotic background and risk factors) is understood but cannot be fully accepted. As in previous trials (CAPRIE and CHARISMA), TRA 2ºP-TIMI 50 also showed that although patients with various degrees of atherosclerotic disease share clinical features and often a common fate, they also have many important differences that challenge  the  notion  of  a  uniform  and  homogeneous  population.  This,  in  turn,  means  that  pooling

<div style=\"page-break-after: always\"></div>

together data from diverse atherosclerotic patient groups may not be as straightforward as presented. This  is  even  more  problematic  in  the Intended  Label  Population as,  due  to  the  relatively  small representation of PAD patients, their data are diluted in the much larger pool of patients from the CAD stratum (post-MI).

It can be agreed with the MAH that the number of patients might not be sufficient for a robust analysis as the PAD stratum alone was not powered to detect significant differences between treatments (as was also none of the other individual strata in TRA 2ºP-TIMI 50). The results in the larger Clinical PAD population which  included  apart  from  the  PAD  stratum  also  a  number  of  post-MI  patients  with  evidence  of  PAD, showing a reduction in the primary endpoint with vorapaxar that almost reached statistical significance appear  to  confort  this  hypothesis.  Whether  the  failure  of  the  primary  analysis  to  show  a  significant difference between treatment groups is due to the small number of observations or to the absence of a true effect is however difficult to confirm.

Nevertheless,  it  is  agreed  that  the  TRA  2ºP-TIMI  50  findings  show  a  clear  consistency  across  all populations with the findings in PAD patients showing a positive trend in favour of vorapaxar similar to their post-MI counterparts. The results in PAD stratum look similar to those previously seen in CAD but with wider CIs, suggesting that PAD patients may benefit to a similar degree as post-MI patients but the smaller  population  does  not  permit  a  more  robust  analysis.  A  calculation  of  the  treatment-stratum interaction  significance  levels  for  the  primary  and  key  secondary  endpoints  has  shown  no  significant heterogeneity. Further to the above, almost all PAD patients included in TRA 2ºP-TIMI 50 were symptomatic. The clinical guidelines  make  a  distinction  in  relation  to  symptoms,  recommending  antiplatelet  therapy  primarily  to symptomatic patients (higher level of evidence in both ESC and AHA guidelines), based on previous trial data suggesting that symptomatic patients may benefit more than asymptomatic ones. The efficacy of vorapaxar in asymptomatic patients has not been investigated and this is currently reflected in the SmPC which advises that vorapaxar should be used in patients with symptomatic PAD. Risks Unfavourable effects In line with the previous review of TRA 2ºP-TIMI 50 during the initial MAA, the safety findings across all populations showed once again a greater risk of bleeding in subjects receiving vorapaxar than placebo for all pre-specified bleeding endpoints. In  the Intended  Label  Population ,  the  risk  of  GUSTO  severe  or  moderate  bleeding  was  higher  in  the vorapaxar group compared to placebo (KM 3-yr rate 3.8% vs. 2.7%; HR 1.45; 95% CI 1.23 - 1.71; p &lt;0.001), but the difference was driven principally by GUSTO moderate bleeding. In the PAD stratum the GUSTO  severe  or  moderate  rate  was  generally  greater  in  both groups  than  in  the Intended  Label Population but the relative differences between vorapaxar and placebo were similar as before (6.8% vs 4.9% respectively; HR 1.38; 95% CI 1.03 to 1.85; p&lt; 0.033). Again the difference was driven mainly by moderate events while GUSTO severe events were similar between groups. There were very few cases of ICH  and  fatal  bleeding,  with  similar  numbers  between  vorapaxar  and  placebo.  These  findings  are generally consistent to those previously seen in post-MI patients. Medicinal product no longer authorised

The above suggest that as with their post-MI counterparts, patients with PAD also face an increased risk of bleeding when vorapaxar is added to their standard therapy and this needs to be considered in the benefit:risk;  although  life-threatening  or  fatal  events  are  rare.  Still  PAD  patients  on  vorapaxar  will  be likely to experience more often less serious bleedings like epistaxis, haematuria, GI haemorrhages and may also require a transfusion but the likelihood of hospitalisation or a procedure to manage the bleeding appears  to  be  similar  to  controls.  Still,  anaemia  was  consistently  more  common  with  vorapaxar  and

<div style=\"page-break-after: always\"></div>

appears to be related to bleeding. Serious events (other than bleeding) were generally rare with no major differences  between  treatment  groups.  There  were  no  concerns  about  overall  mortality  which  actually showed a trend in favour of vorapaxar.

Further to the bleeding risk, there was no indication of any new major safety issue in the PAD population over what is already known from the previous review, and most important information is already included in the SmPC.

## Uncertainty in the knowledge about the unfavourable effects

An issue that deserves careful consideration is the potential impact of background antiplatelet therapy on bleeding risk in the PAD population. The majority of PAD patients in TRA 2ºP-TIMI 50 were on aspirin but a  significant  proportion  (around  30%)  were  also  receiving  concomitantly  clopidogrel  whereas  some patients  were  on  clopidogrel  alone.  PAD  patients  receiving  vorapaxar  as  add-on  to  aspirin  alone (approximately 60% of the PAD stratum) appear to have had slightly less bleedings (although in most cases  vorapaxar  was  still  worse  than  placebo),  but  there  are  concerns  about  bleeding  events  when vorapaxar was given as add-on to both aspirin+clopidogrel as part of triple antiplatelet treatment. This is a critical point as current guidelines do not recommend DAPT in PAD patients. The TRA 2ºP-TIMI 50 data suggest a higher risk of bleeding in patients receiving vorapaxar with both aspirin and clopidogrel and such a combination is not recommended. An  additional  point  that  should  also  be  considered  is  the  cumulative  risk  of  bleeding  over  long-term therapy.  Unlike  post-MI  patients,  in  whom  treatment  may  be  time-limited  following  the  acute  event, vorapaxar therapy in PAD, in the absence of an index event, may be open ended. Taking into account also other possible concomitant antithrombotic therapies, the cumulative risk of bleeding with vorapaxar over time in the PAD group may be greater than in post-MI patients and this needs to be taken into account in the benefit:risk. The currently proposed SmPC (section 4.2) suggests a re-evaluation of the benefits and risks to continue therapy beyond the first 24 months in post-MI but not in PAD. Effects Table Effects  Table  for  vorapaxar  in  the  treatment  of  patients  with  PAD  (TRA  2ºP-TIMI  50; Intended  Label Population and PAD stratum with no history of stroke of TIA ) Effect Short Description Favourable Effects Intended Label population or PAD) CV outcome Composite of CV death, MI, stroke, UCR CV death Medicinal product no longer authorised

<!-- image -->

| Effect                                                                                                                      | Short Description                                                                                                           | Unit                                                                                                                        | Vorapaxar                                                                                                                   | Placebo                                                                                                                     | Strength of evidence/Uncertainties                                                                                          | References                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Favourable Effects                                                                                                          | Favourable Effects                                                                                                          | Favourable Effects                                                                                                          | Favourable Effects                                                                                                          | Favourable Effects                                                                                                          | Favourable Effects                                                                                                          | Favourable Effects                                                                                                          |
| Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) Medicinal | Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) Medicinal | Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) Medicinal | Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) Medicinal | Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) Medicinal | Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) Medicinal | Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) Medicinal |
| CV outcome                                                                                                                  | Composite of CV death, MI, stroke, UCR                                                                                      | N (%)                                                                                                                       | 896 (8.9%)                                                                                                                  | 1073 (10.6%)                                                                                                                | HR 0.83 (95% CI 0.76- 0.90). Consistent results across the three individual components                                      | P04737 study report                                                                                                         |
| CV outcome                                                                                                                  | Composite of CV death, MI, stroke, UCR                                                                                      | 3 year KM%                                                                                                                  | 10.1%                                                                                                                       | 11.8%                                                                                                                       | HR 0.83 (95% CI 0.76- 0.90). Consistent results across the three individual components                                      | P04737 study report                                                                                                         |
| CV outcome                                                                                                                  | CV death                                                                                                                    | N (%)                                                                                                                       | 129(1.3%)                                                                                                                   | 154(1.5%)                                                                                                                   |                                                                                                                             |                                                                                                                             |
| CV outcome                                                                                                                  | MI                                                                                                                          | N (%)                                                                                                                       | 450(4.5%)                                                                                                                   | 531(5.3%)                                                                                                                   |                                                                                                                             |                                                                                                                             |
| CV outcome                                                                                                                  | Stroke                                                                                                                      | N (%)                                                                                                                       | 91 (0.9%)                                                                                                                   | 123(1.2%)                                                                                                                   |                                                                                                                             |                                                                                                                             |
| CV outcome                                                                                                                  | UCR                                                                                                                         | N (%)                                                                                                                       | 226(2.2%)                                                                                                                   | 265(2.6%)                                                                                                                   |                                                                                                                             |                                                                                                                             |
| PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD)                                  | PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD)                                  | PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD)                                  | PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD)                                  | PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD)                                  | PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD)                                  | PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD)                                  |
| CV outcome                                                                                                                  | Composite of CV death, MI, stroke, UCR                                                                                      | N (%)                                                                                                                       | 177 (10.9%)                                                                                                                 | 206 (12.5%)                                                                                                                 | HR 0.87 (95% CI 0.71- 1.06).                                                                                                | P04737 study report                                                                                                         |
| CV outcome                                                                                                                  | Composite of CV death, MI, stroke, UCR                                                                                      | 3 year KM%                                                                                                                  | 11.1%                                                                                                                       | 12.8%                                                                                                                       | Consistent results across the three individual components                                                                   | P04737 study report                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Effect   | Short Description   | Unit   | Vorapaxar   | Placebo    | Strength of evidence/Uncertainties   | References   |
|----------|---------------------|--------|-------------|------------|--------------------------------------|--------------|
|          | CV death            | N (%)  | 47(2.9%)    | 58 (3.5% ) |                                      |              |
|          | MI                  | N (%)  | 76 (4.7%)   | 80 (4.8% ) |                                      |              |
|          | Stroke              | N (%)  | 31 (1.9%)   | 39 (2.4% ) |                                      |              |
|          | UCR                 | N (%)  | 23(1.4%)    | 29 (1.8% ) |                                      |              |

## Unfavourable Effects

| Bleedings   | GUSTO Severe or Moderate   | N (%) 3 year KM%   | 335(3.3%) 3.8%   | 233(2.3%) 2.7%   | HR 1.45 (95% CI 1.23 - 1.71).            | P04737 study report   |
|-------------|----------------------------|--------------------|------------------|------------------|------------------------------------------|-----------------------|
|             | GUSTO Severe               | N (%) 3 year KM%   | 115(1.1%) 1.3%   | 105(1.0%) 1.3%   | HR 1.09 (95% CI 0.84 - 1.43). authorised |                       |
|             | GUSTO moderate             | N (%) 3 year KM%   | 229(2.3%) 2.6%   | 138(1.4%) 1.6%   | HR 1.67 (95% CI 1.35 - 2.07).            |                       |
|             | ICH                        | N (%) 3 year KM%   | 49 (0.5%) 0.6%   | 39 (0.4%) 0.5%   | HR 1.25 (95% CI 0.82 - 1.91)             |                       |

| Bleedings   | GUSTO Severe or Moderate   | N (%) 3 year KM%         | 104(6.4%) 4.9%    | 77 (4.7%) 6.8%   | HR 1.38 (95% CI 1.03 - 1.85).   | P04737 study report   |
|-------------|----------------------------|--------------------------|-------------------|------------------|---------------------------------|-----------------------|
|             | GUSTO Severe               | N (%) 3 year KM%         | 30 (1.9%) 2.0% no | 32 (2.0%) 2.1%   | HR 0.94 (95% CI 0.57 - 1.54).   |                       |
|             | GUSTO moderate             | N (%) 3 year KM%         | 77 (4.8% 5.0%     | 50 (3.1%) 3.1%   | HR 1.58 (95% CI 1.11 - 2.25).   |                       |
|             | ICH                        | N (%) 3 year KM% product | 11 (0.7% 0.7%     | 9 (0.5%) 0.6%    | HR 1.24 (95% CI 0.51 - 2.98)    |                       |

Intended Label population ( s ubjects with no history of stroke or TIA whose qualifying condition was CAD or PAD) PAD stratum (subjects with no history of stroke or TIA whose qualifying condition was PAD) Benefit-Risk Balance Importance of favourable and unfavourable effects The earlier review of the pivotal trial established a positive benefit:risk for vorapaxar in the treatment of patients  with  history  of  MI  (but  with  no  previous  stroke  or  TIA)  based  on  a  statistically  and  clinically relevant reduction in the composite endpoint of CV death, MI, stroke and UCR that outweighed the risk of bleeding. In post-MI patients, compared with placebo, vorapaxar was found (based on calculations after adjustment for exposure) to prevent 80 (95% CI: 41, 120) CV deaths, MIs, strokes and urgent coronary revascularisations per 10,000 patient-years, while causing 6 severe bleeds. Medicinal product no longer authorised

The MAH now seeks to extend the indications to include also patents with PAD, based again on the results of TRA 2ºP-TIMI 50 but, this time, expanded to include also patients from the PAD stratum. In this, so called Intended Label Population , after adjusting for exposure, it was calculated that there were 330 CV  death  (excluding  fatal  bleed),  MI  (excluding  CV  death),  or  ischaemic  stroke  (excluding  CV  death) events in the placebo-treated group compared to 264 events in the vorapaxar treated group per 10,000 patient-years.  The risk difference between the two groups is -66 (95% CI -97, -36) i.e. there were 66 less events among the vorapaxar-treated subjects. This difference was mainly due to MIs (35 out of the

<div style=\"page-break-after: always\"></div>

66 events).

Conversely,  the  risk  of  irreversible  damage  from  bleeding  was  slightly  increased  in  vorapaxar  treated subjects  compared to placebo. There were 45 GUSTO severe bleeding events (including ICH  and  fatal events) per 10,000 patient-years in the vorapaxar group compared to 41 per 10,000 patient-years in the placebo group (risk difference: +4; 95% CI -8, 15). There was no risk difference between vorapaxar and placebo for fatal bleeding, including fatal ICH (0 [95% CI -5, 5) and for GUSTO severe non-fatal, non-ICH bleeding (0 [95% CI -8, 9]); for non-fatal ICH the risk difference was 2 (95% CI -4, 9). Taken together the above it was calculated that in the Intended Label Population the ratio of overall benefit (first event of CV death, MI, or ischemic stroke to overall risk i.e. all GUSTO severe bleeding) is 66:4, when vorapaxar is used on top of standard of care.

|                                                            | Subjects With Events (%)   | Subjects With Events (%)   | HR (95% CI) a,b    |
|------------------------------------------------------------|----------------------------|----------------------------|--------------------|
| Net Clinical Outcome Endpoints                             | Placebo (n =10049)         | Vorapaxar (n =10059)       |                    |
| CV death / MI / Stroke / UCR / GUSTO Severe GUSTO Moderate | / 1226/10049 12.2%         | 1112/10059 11.1%           | 0.90 (0.83 - 0.98) |
| CV death / MI / Stroke / GUSTO Severe                      | 914/10049 9.1%             | 753/10059 7.5%             | 0.82 (0.74 - 0.90) |
| All-Cause Death / MI / Stroke / GUSTO Severe               | 1052/10049 10.5%           | 905/10059 9.0%             | 0.85 (0.78 - 0.93) |

| Net Clinical Outcome Endpoints           | Subjects With Events (%)   | Subjects With Events (%)   | Subjects With Events (%)   | Subjects With Events (%)   | HR (95% CI) a,b    |
|------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|--------------------|
| ( CV death / MI / Stroke / GUSTO Severe) | Placebo                    | Placebo                    | Vorapaxar                  | Vorapaxar                  |                    |
| PAD with no history of stroke or TIA     | 200/1637                   | 12.2%                      | 170/1615                   | 10.5%                      | 0.85 (0.70 - 1.05) |
| Clinical PAD Population c                | 265/1992                   | 13.3%                      | 218/1931                   | 11.3%                      | 0.84 (0.70 - 1.01) |
| Aspirin Only PAD Population d            | 119/1044                   | 11.4%                      | 97/1030                    | 9.4%                       | 0.82 (0.62 - 1.07) |

The estimation of 'net clinical benefit' that included only the most robust endpoints CV death, MI, stroke, and  GUSTO  severe  bleeding  showed  a  significant  result  for  vorapaxar  in  reducing  the  rate  of  the  net clinical outcome by 18% (HR 0.82; 95% CI 0.74 - 0.90; Table B-R.1). A similar significant reduction was seen when the net outcome calculation included also UCR and GUSTO moderate bleedings, as per the definition of the 'net benefit' in the protocol (HR 90% ; 95% CI 0.74 - 0.90). Table B-R. 1 TRA 2 ° P - TIMI 50 Time-to-Event Analyses of the Net Clinical Outcome in the Intended Label Population: As-Treated Population ~ Event Accrual Period: Randomization to Last Visit a. Hazard ratio is vorapaxar group versus placebo group b. Hazard ratio was calculated based on Cox PH model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned   thienopyridine use) For the PAD stratum , the MAH did not provide any calculations for the adjusted risk difference between groups. However, an estimation of the rate of the net clinical outcome (including CV death/MI/stroke/GUSTO severe) was provided that favours vorapaxar (HR 0.85; 95% CI 0.70 - 1.05) but without reaching statistical significance (Table B-R.2). The net clinical outcome in Clinical PAD (HR 0.84; 95% CI 0.70 - 1.01) and Aspirin-Only PAD (HR 0.82; 95% CI 0.62 - 1.07) populations were consistent with the results in the PAD stratum. Table B-R.2 T RA  2 ° P -TIMI 50 Time-to-Event Analyses of the Net Clinical Outcome (CV death/MI/Stroke/ GUSTO Severe) in PAD: As-Treated Population ~ Event Accrual Period: Randomization to Last Visit Medicinal product no longer authorised

b. Hazard ratio was calculated based on Cox PH model with covariates treatment and stratification factors (qualifying atherosclerotic disease and planned   thienopyridine use)

c. Subjects With No History of Stroke or TIA Who Were NOT in the CVD Stratum AND Whose Qualifying Condition Was PAD OR (had ABI&lt;= 0.9 with Symptoms~) OR History of Peripheral Arterial Revascularization Symptoms [Fontaine Stage II, III, or IV])

d. Subjects with no history of stroke or TIA whose qualifying condition was PAD who were on aspirin at baseline, and did not plan thienopyridine use during the study.

## Benefit-risk balance

## Discussion on the Benefit-Risk Balance

<div style=\"page-break-after: always\"></div>

Patients with PAD are at high risk of future cardiovascular events. Unlike patients with a recent MI who have benefited from the introduction of newer antiplatelets in recent years, in PAD there has been little progress  in  this  area  of  CV  prevention,  with  most  patients  still  relying  on  aspirin  alone.  Undoubtedly, there is a high unmet need for additional therapies that could help prevent CV events and deaths. TRA 2ºP-TIMI  50  investigated  the  value  of  vorapaxar  in  this  role,  in  practice  also  testing  the  concept  of dual/triple  antiplatelet  in  PAD.  It  is  reminded  that  today  PAD  clinical  guidelines  do  not  routinely recommend dual antiplatelet  therapy  for  long-term  therapy,  mainly  due  to  the  negative  results  of  the CHARISMA trial.

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to include treatment of patients with symptomatic Peripheral Arterial Disease (PAD) and as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the contact details of local representative in Luxembourg in the Package Leaflet. Furthermore, the PI is brought in line with the QRD template version 9.1. Moreover, revised RMP version 2.4 has been agreed.

Vorapaxar  has  the  potential  to  contribute  to  the  secondary  prevention  in  patients  with  atherosclerotic disease and a positive benefit:risk was previously established in post-MI patients. The TRA 2ºP-TIMI 50 data also indicate a positive effect in the high risk symptomatic patients with PAD who were included in the  trial.  Although  the  results  in  the PAD stratum alone  did  not  reach  statistical  significance  the  clear consistency  across  endpoints  and  across  populations  provides  convincing  evidence  of  the  incremental benefits of vorapaxar over current therapies in the PAD population. On  the  other  hand,  it  is  clear  that  vorapaxar  increases  the  risk  of  bleeding.  Although  less  severe bleedings are still more common among patients receiving vorapaxar on top of their standard therapy life-threatening events, ICH and fatal cases are rare. Taken the above together it can be concluded that the expected benefits of vorapaxar co-administered with aspirin or , where appropriate, clopidogrel are likely to outweigh the potential risks. Considering also the high unmet need in this population, the overall benefit:risk balance is considered to be positive in patients with symptomatic PAD. 4. Recommendations Outcome Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change: Medicinal product no longer authorised

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).